CA2988637A1 - Aromatic sulfonamide derivatives - Google Patents

Abstract

Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:

AROMATIC SULFONAMIDE DERIVATIVES
FIELD OF APPLICATION OF THE INVENTION
The invention relates to substituted aromatic sulfonamides of formula (I) as described and defined herein, pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease. The present invention, as described and defined herein, relates to pharmaceutical compositions and combinations comprising an active ingredient which is an antagonist or a negative allosteric modulator of P2X4. The use of such compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as but not limited to diseases associated with pain, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, neuropathic pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis as such, cancer as such, and proliferative diseases as such like endometriosis, as a sole agent or in combination with other active ingredients.
BACKGROUND OF THE INVENTION
zo Chronic inflammatory pain such as in, but not limited to, conditions of endometriosis and adenomyosis, arises as a consequence of inflammatory responses mounted by the immune system following tissue damage and generally persists long after the initial injury has healed. Since a large percentage of patients with inflammatory diseases do not respond adequately to currently available analgesic drugs or suffer from intolerable side effects, investigation of alternative treatments for inflammatory conditions /
disorders is warranted.
Adenosine triphosphate ATP is widely recognized as important neurotransmitter implicated in various physiological and pathophysiological roles by acting through different subtypes of purinergic receptors (Burnstock 1993, Drug Dev Res 28:196-206;
Burnstock 2011, Prog Neurobiol 95:229-274). To date, seven members of the P2X family have been cloned, comprising P2X1-7 (Burnstock 2013, Front Cell Neurosci 7:227). The receptor is a ligand-gated ion channel that is expressed on a variety of cell types largely those known to be involved in inflammatory/ immune processes specifically including monocytes, macrophages, mast cells and microglia cells (Wang et al., 2004, BMC
Immunol 5:16; Brone et al., 2007 Immunol Lett 113:83-89). Activation of P2X4 by

2 extracellular ATP is known, amongst other things, to lead to release of pro-inflammatory cytokines and prostaglandins (PGE2) (Bo et al., 2003 Cell Tissue Res 313:159-165;
Ulmann et al., 2010, EMBO Journal 29:2290-2300; de Ribero Vaccari et al., 2012, J
Neurosci 32:3058-3066). Numerous lines of evidence in the literature using animal models implicate P2X4 receptor in nociception and pain. Mice lacking the P2X4 receptor do not develop pain hypersensitivity in response to numerous inflammatory challenges such as complete Freunds Adjuvant, carrageenan or formalin (Ulmann et al., 2010, EMBO
Journal 29:2290-2300). In addition, mice lacking the P2X4R do not develop mechanical allodynia after peripheral nerve injury, indicating an important role of P2X4 also in neuropathic pain conditions (Tsuda et al., 2009, Mol Pain 5:28; Ulmann et al., 2008, J
Neurocsci 28:11263-11268).
Besides the prominent role of P2X4 in acute and chronic pain-related diseases (Trang and Salter, 2012, Purinergic Signalling 8:621-628.), P2X4 is considered as a critically important mediator of inflammatory diseases such as, respiratory diseases (e.g. asthma, COPD), lung diseases including fibrosis, bone metabolism, cancer and atherosclerosis (Burnstock et al., 2012 Pharmacol Rev. 64:834-868).
EP 2 597 088 Al describes P2X4 receptor antagonists and in particular a diazepine derivative of formula (III) or a pharmacologically acceptable salt thereof.
Said document zo further disclosed the use of P2X4 receptor antagonist diazepine derivatives represented by the formula (I), (II), (Ill), or its pharmacologically acceptable salt, which shows P2X4 receptor antagonism, being effective as an agent for prevention or treatment of nociceptive, inflammatory, and neuropathic pain. In more detail, EP 2 597 088 Al describes P2X4 receptor antagonists being effective as a preventive or therapeutic agent for pain caused by various cancers, diabetic neuritis, viral diseases such as herpes, and osteoarthritis. The preventive or therapeutic agent according to EP 2 597 088 Al can also be used in combination with other agents such as opioid analgesic (e.g., morphine, fentanyl), sodium channel inhibitor (e.g., novocaine, lidocaine), or NSAIDs (e.g., aspirin, ibuprofen). The P2X4 receptor antagonist used for pain caused by cancers can be also used in combination with a carcinostatic such as a chemotherapic. Further P2X4 receptor antagonists and their use are disclosed in W02015005467 and W02015005468.
"Discovery and characterization of novel, potent and selective P2X4 receptor antagonists for the treatment of pain" was presented at the Society for Neuroscience Annual Meeting 2014 (Carrie A Bowen et al.; poster N. 241.1) Said poster describes the methods to identify novel, potent and selective small-molecule antagonists that inhibit P2X4 across

3 species, and how to evaluate selected compounds in experimental models of neuropatic and inflammatory pain. In particular a method for human, rat, mouse P2X4R
Flipr-based screening, a human P2X4R electrophysiology assay, a suitable mouse neuropathy model and a mouse inflammation model were described.
W01998025893 provides novel arylsulfonamides. These compounds have been found to inhibit phospholipase A2 activity, in particular cPLA2 (cytosolic phospholipase A2).
Additionally, the compounds inhibit the release of cytokines in stimulated cells. Still further, the compounds have been found to inhibit neurodegeneration in a mammalian neuronal cell population.
W02009138758 desribes novel pharmaceutically-useful bis-aryl compounds, which compounds are useful as inhibitors of the production of leukotrienes, such as leukotriene 04. The compounds are of potential utility in the treatment of respiratory and/or inflammatory diseases. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to synthetic routes for their production.
W02009136889 describes substituted isoindoles, which are vascular endothelial growth factor receptor (VEGFR) inhibitors, pharmaceutical compositions containing the same, and methods of using the same as anti-tumor agents for treatment of cancer (e.g., breast, colorectal, lung, prostate, and ovarian).
W02013192517 provides compounds useful for inhibiting fungal or parasitic growth, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. .
The compounds are useful as inhibitors of glycosylphosphatidylinositol (GPI)-anchor biosynthesis, in particular, as inhibitors of fungal Gwtl activity.
There is no reference in the state of the art about substituted aromatic sulfonamides of general formula (I) as described and defined herein and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, particularly to the use of substituted aromatic sulfonamides of general formula (I) for the treatment or prophylaxis of diseases associated with pain, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, neuropathic pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as

4 PCT/EP201 6/06 284 1 well as endometriosis as such, cancer as such, and proliferative diseases as such like endometriosis, as a sole agent or in combination with other active ingredients.
Therefore, the inhibitors of P2X4 of the current invention represent valuable compounds that should complement therapeutic options either as single agents or in combination with other drugs.
DESCRIPTION OF THE INVENTION
The present invention relates to a compound of formula (I) I I
0=S¨N H2 5b 0 R (12)1R2 R5a (I) in which:
A represents CR5 or N;
R1 represents a group selected from:
R6b R7a R7a R7a R6a Rec R7b_i_ N
R6 ' or wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents Ca-C6-cycloalkyl, C3-C6-cycloalkyl-Cl-C4-alkyl, 4-to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-C1-C4-alkyl, phenyl, phenyl-C1-C4-alkyl, heteroaryl or heteroaryl-C1-C4-alkyl, wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring or substituted with one to five deuterium atoms and optionally one to two times with R11 being, independently from each other, the same or different, or R2 represents branched (C1-C4-alkyl)-C1-C4-alkyl;
R3 represents hydrogen, deuterium, fluoro or methyl;
R4 represents hydrogen, deuterium or fluoro:
R5, R5a and R5b are the same or different and represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy;
R6, R6a, R6b and R6c are the same or different and represent, independently from each other, respectively R6 hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)- or F3C-S-;
R6a hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (Ci-C4-alkyl)-S02-;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, R9F10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (Ci-C4-alkyl)-S02-; or R6a and R6b adjacent to each other together represent a group selected from -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-Co-;
R6c hydrogen or halogen;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, hydroxy, halogen, C1-C4-alkyl or C1-C4-haloalkyl;

R8 represents, independently from each respective occurence, Cl-Cs-alkyl, Cl-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or Cl-C4-haloalkyl;
R9 and R1 are the same or different and represent, independently from each other, hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, Cl-C4-haloalkyl, (Cl-C4-alkoxy)-(C2-C4-alkyl), phenyl or heteroaryl, wherein said phenyl and heteroaryl groups are optionally substitutedone to three times, independently from each other, with hydrogen, halogen, CI-Ca-alkyl, C1-C4-haloalkyl, Cl-C4-alkoxy or 0l-C4-haloalkoxy, R9a and Rwa together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from 0, NH, NR a in which Ra represents a C1-06-alkyl- or C1-C6-haloalkyl- group or S and being optionally substituted, one to three times, independently from each other, with halogen or 01-C4-alkyl ;
Ril represents, independently from each other, halogen, hydroxy, nitro, cyano, Cl-C4-alkyl, C2-C4-alkenyl, C1-04-haloalkyl, C1-04-hydroxyalkyl, 01-C4-alkoxy, C1-C4-haloalkoxy, HO-(02-C4-alkoxy)-, (01-04-alkoxy)-(02-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(0)-NH-, R8-0(0)-, R8-0-0(0)-, R9R10N-0(0)- or (01-C4-alkyl )-S02-;
R11a represents a group selected from 03-C6-cycloalkyl, morpholino, R9aRioaN_;
R9aRl aN-0(0)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl, or represents:
CN\
(0¨*
0,\( , 0 0 CI
CN¨* CN¨* 0 N ¨* or N N¨*

wherein * indicates the point of attachment of said group with the rest of the molecule.; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisonner.
In a second aspect, the invention relates in particular to compounds of formula (la), 0= ¨NH2 0, 2 (la) wherein R1 represents a group selected from:
R6b R7a R7a R7a R6a 410 R6b R7b_i_ R7b R6 or wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, 4-to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-C1-C4-alkyl, phenyl, phenyl-C1-C4-alkyl, heteroaryl or heteroaryl-C1-C4-alkyl, wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring or substituted with one to five deuterium atoms and optionally one to two times with R11 or R11a being, independently from each other, the same or different;or R2 represents branched (Ci-C4-alkyl)-Ci-C4-alkyl;
R3 represents hydrogen, deuterium, fluoro or methyl;
R4 represents hydrogen, deuterium or fluoro;
R6, R6a, R6') and R6c are the same or different and represent, independently from each other, respectively R6 hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)- or F3C-S-;
R6a hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (C1-C4-alkyl)-S02-;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (C1-C4-alkyl)-S02-; or R6a and IR' adjacent to each other together represent a group selected from -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-0-;
R6c hydrogen or halogen;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, hydroxy, halogen, C1-C4-alkyl or C1-C4-haloalkyl;
R8 represents, independently from each respective occurence, C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl;
R9 and Rw are the same or different and represent, independently from each other, hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, (C1-C4-alkoxy)-(C2-C4-alkyl), phenyl or heteroaryl, wherein said phenyl and heteroaryl groups are optionally substituted one to three times, independently from each other, with hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy, R9a and Rwa together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from 0, NH, NRa in which Ra represents a C1-C6-alkyl- or C1-C6-haloalkyl- group, or S and being optionally substituted, one to three times, independently from each other, with halogen or C1-C4-alkyl and;
R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Cl-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (Ci-C4-alkyl)-S02-;
R11a represents a group selected from C3-C6-cycloalkyl, morpholino, R9aR10aN_;
RsaRloaN_c (t..))-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents:
r\N¨* 0 CN)¨*
, 0_1( H' CI
or 0 1\-71¨*

wherein * indicates the point of attachment of said group with the rest of the molecule; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
In a third aspect, the invention relates in particular to compounds of formula (lb) 01¨NH2 R. 0 R3 Fe H
R5a (lb) wherein R1 represents a group selected from:
R6b R7a R7a R7a R6a = R6c R7b_17N R7b-1¨

R6 ' N or wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, 4-to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-Cl-C4-alkyl, phenyl, phenyl-C1-C4-alkyl, heteroaryl or heteroaryl-Cl-C4-alkyl, wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring or substituted with one to five deuterium atoms and optionally one to two times with R11 being, independently from each other, the same or different;
or R2 represents branched (C1-C4-alkyl)-C1-C4-alkyl;
R3 represents hydrogen, fluoro or methyl;
R4 represents hydrogen or fluoro;
R5a and R5b are the same or different and represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy;
Re, Rea, Re') and R6c are the same or different and represent, independently from each other, respectively R6 hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, 01-04-haloalkoxy, HO-(C2-04-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)- or F3C-S-;

Rea hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, Ca-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Cl-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (Ci-C4-alkyl)-S02-;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (C1-C4-alkyl)-S02-; or R6a and Reb adjacent to each other together represent a group selected from -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-0-;
R6c hydrogen or halogen;
R7a and R76 are the same or different and represent, independently from each other, hydrogen, hydroxy, halogen, C1-C4-alkyl or C1-C4-haloalkyl;
R8 represents, independently from each respective occurence, C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl;
R9 and R1 are the same or different and represent, independently from each other, hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, (Ci-C4-alkoxy)-(C2-C4-alkyl), phenyl or heteroaryl, wherein said phenyl and heteroaryl groups are optionally substituted one to three times, independently from each other, with hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy, R9a and Rwa together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from 0, NH, NR a in which Ra represents a C1-C6-alkyl- or C1-C6-haloalkyl- group, or S and being optionally substituted, one to three times, independently from each other, with halogen or C1-C4-alkyl;
R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, H0-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(0)-NH-, Fe-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (C1-C4-alkyl)-S02-;

R11a represents a group selected from Ca-C6-cycloalkyl, morpholino, R9aR10aN_;

R9aR 1 aN-C(0)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents:
qN¨* Q1¨*
t>1 ¨*C 0 130¨*
0 , , 0 0 cH3 ci /---\
CN ¨* Q1¨* 0q1¨* or wherein * indicates the point of attachment of said group with the rest of the molecule; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
In a fourth aspect, the invention refers more in particular to compounds of formula (la) as described supra, wherein:
R1 represents a group selected from:
R6b R7a R7a R7a N
R6a CO Rec R7bH.... 713 7Ni Rlb , R -y , R6 , N or * * * *
wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents Ca-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-C1-C4-alkyl, phenyl, phenyl-C1-C4-alkyl, heteroaryl or heteroaryl-C1-C4-alkyl, wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R" being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring or substituted with one to five deuterium atoms and optionally one to two times with R11 being, independently from each other, the same or different;
represents hydrogen, fluoro or methyl;
R4 represents hydrogen or fluoro;
R6, msa, R6b and R6c are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, C1-C4-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or F3C-S-;
R6a hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or R9R10N-C(0)-;
11 hydrogen, fluoro, chloro or bromo; or R6a and R6b adjacent to each other together represent a group selected from ¨0-CH2-CH2-, ¨0-CH2-0- or ¨0-CH2-CH2-0-;
Fec hydrogen or halogen;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, chloro, methyl, difluoromethyl or trifluoromethyl;
represents methyl;
R9 and R1 are the same or different and represent, independently from each other, hydrogen, methyl, cyclopropyl or 2-methoxy-ethyl;
R9a and Rwa together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from 0, NH, NCH3 or S and being optionally substituted, one to three times, independently from each other, with halogen or methyl;
R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, Ci-C4-haloalkyl, Ci-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Cl-C4-alkoxy)-(C2-C4-alkoxy)-, (Ci-C4-haloalkyl)-S-, R9R10N_, R8_c(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R1 N-C(0)-or (Ci-C4-alkyl)-S02-;
R11a represents a group selected from C3-C6-cycloalkyl, morpholino, WaRloaN_;
R9aRl aN-C(0)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents a group selected from:
qN_* r"\N¨*

Cl =
CN¨* QN-* 0 N¨* or N N¨*

wherein * indicates the point of attachment of said group with the rest of the molecule; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
Furthermore, according to a particular aspect of the present invention, compounds of formula (la) as described supra, are those wherein:
R1 represents a group selected from:
6b R6a Rec R6 ' wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents C4-C6-cycloalkyl, C3-C6-cycloalkyl-methyl, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-methyl, phenyl, phenyl-Ci-C2-alkyl, heteroaryl, heteroaryl-methyl wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R1la and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring;
R3 represents hydrogen or methyl;
R4 represents a hydrogen;
R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, CI-Ca-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or F3C-S-;
R6a hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or R9R10N_c(o)_;
R6b hydrogen, fluoro, chloro or bromo; or R6a and R6b adjacent to each other together represent a group selected from ¨0-C Ha-C H2-, ¨0-C H2-0- or ¨0-CH2-CH2-0-;
Rec hydrogen or halogen;
R9 and R1 are the same or different and represent, independently from each other, hydrogen, methyl, cyclopropyl or 2-methoxy-ethyl;
R9a and Rwa together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from 0, NH, NR a in which Ra represents a C1-C6-alkyl- or Cl-C6-haloalkyl- group, or S and being optionally substituted, one to three times, independently from each other, with halogen or methyl;
R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, Cl-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, Cl-C4-hydroxyalkyl, C1-C4-alkoxy, Cl-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-04-alkoxy)-(C2-C4-alkoxy)-, (Ci-C4-haloalkyl)-S-, R9R10N-, R8-C(0)-NH-, Fe-C(0)-, R8-0-C(0)-, R9R19N-C(0)- or (Cl-C4-alkyl)-S02-;

R11a represents a group selected from Ca-C6-cycloalkyl, morpholino, R9aR10aN_;
R9aR10aN-C(0)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents a group selected from:
c* r\N¨*
Cl , 0 ...\( , 01 ¨*
H' ' or wherein * indicates the point of attachment of said group with the rest of the molecule; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
In particular the invention refers further to compounds of formula (I), (la) and (lb) as described supra, wherein:
R1 represents a group selected from:
R6b R6a *R6c R6 ' *
wherein * indicates the point of attachment of said group with the rest of the molecule;
R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)- ;
R6a hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (C1-C4-alkyl)-S02-;
R61 hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (Cl-C4-alkyl)-S02-;
R6c represents hydrogen.
According to a further alternative the invention refers to compounds of formula (I), (la) and (lb) as described supra, in which:
R1 represents a group selected from:
R6b R6a .Fec R6 ' *
wherein * indicates the point of attachment of said group with the rest of the molecule; and R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, C1-C4-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or F3C-S-;
R6a hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy;
Reb hydrogen, halogen, hydroxy, nitro, cyano, Cr-Ca-alkyl, C3-C6-cycloalkyl, Cl-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (C1-C4-alkyl)-S02-R6c represents hydrogen.
In particular the invention refers further to compounds of formula (I), (la) and (lb) as described supra, wherein:
R1 represents a group selected from:

R6b R6a =R6c R6 ' *
wherein * indicates the point of attachment of said group with the rest of the molecule; and R6, Rea and R6b are the same or different and represent, independently from each other, respectively Re fluoro, chloro, bromo, cyano, C1-C4-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy or F3C-S-;
Rea hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9RioN_C(0)-s or (C1-C4-alkyl)-S02-R represents hydrogen.
In particular the invention refers further to compounds of formula (I), (la) and (lb) as described supra, wherein:
R1 represents a group selected from:
R6b R6a .
R6c R6 ' *
wherein * indicates the point of attachment of said group with the rest of the molecule; and Re represents hydrogen or halogen and Rea and R6b adjacent to each other together represent a group selected from ¨0-CH2-CH2- or ¨0-CH2-CH2-0-Rec represents hydrogen.
In particular the invention refers further to compounds of formula (I), (la) and (lb) as described supra, wherein:
R1 represents a group selected from:

R7a Fea R7a N
R7b¨ R7b_01 R7I:L.0 N / or /
, * * *
wherein * indicates the point of attachment of said group with the rest of the molecule;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, fluor , chloro, C1-C4-alkyl, difluoromethyl or trifluoromethyl.
According to a further aspect of the present invention compounds of formula (I), (la) and (lb) as described supra are those in which:
R2 represents a group selected from:
* * CH3 R" R11 * ito toR11 R" *
le 1 , R11 , Ri R11 ' wherein * indicates the point of attachment of said group with the rest of the molecule and in which, R11 represents independently from each other, hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)-or (Ci-C4-alkyl)-S02-.
In a further aspect of the present invention, compounds of formula (I), (la) and (lb) as described supra are those in which:
R2 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule and in which, * * CF-I3 * 0 le *I 0 ' R11 , R11 ' * R11 ' R11 represents independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)-or (Ci-C4-alkyl)-S02-.
According to a more particular aspect of the present invention compounds of formula (I), (la) and (lb) as described supra are those in which:
R2 represents a group selected from:
* * CH3 *
R1la R"a * Rlla Rlla R11 , 10 led *
ICI
R11 , R11 ' R11 ' wherein * indicates the point of attachment of said group with the rest of the molecule and in which R" and R11a are respectively R" represents, hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, (Ci-C4-haloalkyl)-S-, R9R10N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R10N-C(0)- or (Ci-C4-alkyl)-S02-;
R11a represents a group selected from hydrogen, C3-C6-cycloalkyl, morpholino, RsaRloaN.; R9aR10 kv aN_c,, _ )-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents:
r--\ 0---.N_* --_õ cS_* C-* 0¨*
, 0i , H' ' 0 0 CH3 ' CI
,--\
o:¨* or 41 r\--//--\N
¨*
, 0 0 .
In particular the invention refers further to compounds of formula (I), (la) and (lb) as described supra, wherein:
R2 represents a group selected from:

R12a R12a ril , R12b N Ri2b , feR12 , * * * *
1;12a 612a R 6R12a N N N
N
Ri2b , N R12b , R12 'R12 , wherein * indicates the point of attachment of said group with the rest of the molecule R12 represents hydrogen, halogen, C1-C4-alkyl, C3-C6-cycloalkyl, methoxy, difluoromethyl or trifluoromethyl;
R12a and R12b represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C3-C6-cycloalkyl, methoxy, difluoromethyl or trifluoromethyl.
According to a further aspect of the present invention the compounds of formula (I), (la) and (lb) as described supra, comprise the following groups in which:
R2 represents a group selected from:
*
c--3 p *0 * *
, , , A , , * * * * *
* * *
,13 (C) ===T:T) * * * *
- 1 . N-N N-11 II or /
n`o 41H
0 , CH3 , Cl-I3 ' Cl-I3 wherein * indicates the point of attachment of said group with the rest of the molecule;

R13 represents hydrogen, halogen, cyano or Cl-C4-alkyl.
More particularly, compounds of formula (I), (la) and (lb) according to the present invention as described supra, have the following groups in which:
R5, R5a and R5b are the same or different and represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or Ci-C4-haloalkoxy.
In particular the invention refers further to compounds of formula (I), (la) and (lb) as described supra, wherein:
represents Cl-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl.
According to a further aspect of the present invention compounds of formula (I), (la) and (lb) as described supra are those in which:
R9 represents, independently from each other, Cl-C4-alkyl or C3-C6-cycloalkyl;
Rlo represents, independently from each other, hydrogen or C1-C4-alkyl.
In particular the invention refers further to compounds of formula (I), (la) and (lb) as described supra, wherein:
R9a and Rwa together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom selected from 0, NMe or NH;
In accordance with a further aspect, the invention relates to compounds of formula (la) in which:
R1 represents a group selected from:
R6b R6a R6c R6 ' wherein * indicates the point of attachment of said group with the rest of the molecule; and R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or F3C-S-;

Rea hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, Ca-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R19N-, R9-C(0)-NH-, R9-C(0)-, R9-0-C(0)-, R9R19N-C(0)- or (C1-C4-alkyl)-S02-R6c represents hydrogen;
R2 represents a group selected from:
11 * * CH3 R
R"
* 0 toR11 R11 R" *
it.
R11 , R11 , R11 , wherein * indicates the point of attachment of said group with the rest of the molecule and in which, R11 represent independently from each other,hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (Ci-C4-alkoxy)-(C2-C4-alkoxy)-, (Ci-C4-haloalkyl)-S-, R9R19N-, R9-C(0)-NH-, R9-C(0)-, R9-0-C(0)-, R9R19N-C(0)- or (Ci-C4-alkyl)-S02-.
R3 represents hydrogen or methyl;
R4 represents hydrogen R9 represents C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl;
R9 represents, independently from each other, C1-C4-alkyl or C3-C6-cycloalkyl;
Rlo represents, independently from each other, hydrogen or C1-C4-alkyl;
In accordance with a further aspect, the invention relates to compounds of formula (la) in which:
R1 represents a group selected from:
R6b R6a .R6c R6 ' *

wherein * indicates the point of attachment of said group with the rest of the molecule; and R6, R6a and Reb are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, C1-C4-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or F3C-S-;
R6a hydrogen, fluor , chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, Cl-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R19N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R19N-C(0)- or (Ci-C4-alkyl)-S02-R& represents hydrogen;
R2 represents a group selected from:
* * *) *) *) *
13 I'd 0 ' 0 wherein * indicates the point of attachment of said group with the rest of the molecule and in which, R13 represents hydrogen, halogen, cyano or C1-C4-alkyl.
R3 represents hydrogen or methyl;
R4 represents hydrogen R8 represents C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl;
R9 represents, independently from each other, C1-C4-alkyl or C3-C6-cycloalkyl;
R10 represents, independently from each other, hydrogen or C1-C4-alkyl;
Furthermore, a particular form of embodiment according to the present invention comprises compounds of formula (la) in which:
R1 represents a group selected from:

R6b R6a .R6c R6 ' *
wherein * indicates the point of attachment of said group with the rest of the molecule; and R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, CI-Cs-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or F3C-S-;
Rea hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy;
Reb hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, Ca-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9W0N-, Re.-C(0)-NH-, W.-C(0)-, R8-0-C(0)-, R9W0N-C(0)- or (Ci-C4-alkyl)-S02-R6c represents hydrogen;
R2 represents a group selected from:
R12a R12a * * *
N
N ( j Ri2b ' N Ri2b , N"µR12 ' 1 RN12a R
6 12a N 'N

N R12b , 12 ' N =R12 , R12b ' R.12b ' R
wherein * indicates the point of attachment of said group with the rest of the molecule R12 represents hydrogen, halogen, C1-C4-alkyl, C3-C6-cycloalkyl, methoxy, difluoromethyl or trifluoromethyl;
W2a and R12b represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C3-C6-cycloalkyl, methoxy, difluoromethyl or trifluoromethyl:.
R3 represents hydrogen or methyl;

R4 represents hydrogen R8 represents C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, Ca-C6-cycloalkyl or C1-C4-haloalkyl;
R9 represents, independently from each other, C1-C4-alkyl or C3-C6-cycloalkyl;
Rlo represents, independently from each other, hydrogen or C1-C4-alkyl;
or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
In particular the invention refers further to compounds of formula (la) as described supra, wherein:
R1 represents a group selected from:
R7a R7a R7a R7b_01 R7b_CI
R7b_ N / or /
, * * *
wherein * indicates the point of attachment of said group with the rest of the molecule;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, fluoro, chloro, C1-C4-alkyl, difluoromethyl or trifluoromethyl;
R2 represents a group selected from:
R11 . . CH3 * *11 *
R11 , t.Rii ' wherein * indicates the point of attachment of said group with the rest of the molecule and in which, R" represents, independently from each other, hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (Ci-C4-haloalkyl)-S-, R9R19N-, R8-C(0)-NH-, R8-C(0)-, R8-0-C(0)-, R9R19N-C(0)- or (Ci-C4-alkyl)-S02-.
R3 represents hydrogen or methyl;

R4 represents hydrogen R9 represents C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, Ca-C6-cycloalkyl or C1-C4-haloalkyl;
R9 represents, independently from each other, C1-C4-alkyl or C3-C6-cycloalkyl;
R19 represents, independently from each other, hydrogen or C1-C4-alkyl;
or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
In a further aspect of the invention compounds of formula (I) as described above are selected from the group consisting of:
001 N44-(3-chloro-5-cyanophenoxy)-3-sulfamoylpheny11-2-(2-chlorophenyl)acetamide 002 2-(2-chloropheny1)-N-443-(dimethylamino)phenoxyl-3-sulfamoylphenylacetamide 003 2-(2-chloropheny1)-N-4-[(2-chloropyridin-4-yl)oxyl-3-sulfamoylphenylacetamide 004 2-(2-chloropheny1)-N44-(3-isopropylphenoxy)-3-sulfamoylphenyllacetamide 005 2-(2-chloropheny1)-N-3-sulfamoy1-443-(trifluoromethyl)phenoxy]phenylacetamide 006 2-(2-chloropheny1)-N-3-sulfamoy1-443-(trifluoromethoxy)phenoxy]phenylacetamide 007 N44-(3-acetylphenoxy)-3-sulfamoylpheny11-2-(2-chlorophenyl)acetamide 008 N-(4-(1,3-benzodioxo1-5-yloxy)-3-sulfamoylpheny1]-2-(2-chlorophenyl)acetamide 009 N44-(3-acetamidophenoxy)-3-sulfamoylpheny11-2-(2-chlorophenyl)acetamide 010 2-(2-chloropheny1)-N-[4-(2-fluorophenoxy)-3-sUlfamoylphenyl]acetamide 011 2-(2-chloropheny1)-N44-(3-fluorophenoxy)-3,:sulfamoylphenyllacetamide 012 2-(2-chloropheny1)-N44-(4-fluorophenoxy)-3-sulfamoylphenyllacetamide 013 2-(2-chloropheny1)-444-(pYridin-2-yloxy)-3-sulfamoylphenyljacetamide 014 2-(2-chlorophenyI)-N-(4-phenoxy-3-sulfamoylphenyl)acetamide 015 2-(2-chloropheny1)-444-(3-cyanophenoxy)-3-sulfamoylphenyllacetamide 016 2-(2-chlorophenyI)-N-4-[3-(methylsulfonyl)phenoxy]-3-sulfamoylphenylacetamide 017 .3-(4-[(2-chlorophenyl)acetyl]amino-2-sulfamoylphenoxy)benzarnide 018 .2-(2-chloropheny1)-N44-(3-methylphenoxy)-3-sulfamoylphenyl]acetamide 019 .2-(2-chloropheny1)-N44-(pyrimidin-5-yloxy)-3-sulfamoylphenyl]acetamide 020 .2-(2-chloropheny1)-N-3-sulfamoy1-443-(4H-1,2,4-triazol-4-yl)phenoxy]phenylacetamide 021 µ2-(2-chloropheny1)-N-3-sulfamoy1-443-(1H-tetrazol-5-yl)phenoxy]phenylacetamide 022 .2-(2-chloropheny1)-N44-(3-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 023 .2-(2-chloropheny1)-N44-(4-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 024 .2-(2-chlorophenyI)-N-4-[3-(difluoromethoxy)phenoxy]-3-sulfamoylphenylacetamide 025 .2-(2-chloropheny1)-N44-(3,4-dicyanophenoxy)-3-sulfamoylphenyl]acetamide 026 .2-(2-chloropheny1)-N-4-[3-(morpholin-4-Aphenoxy]-3-sulfamoylphenylacetamide 027 .2-(2-chloropheny1)-N-[4-(3-4-[(2-chlorophenyl)acetyl]piperazin-1-ylphenoxy)-3-sulfamoylphenyl]acetamide 028 .2-(2-chloropheny1)-N44-(pyridin-3-yloxy)-3-sulfamoylphenyl]acetamide 029 .2-(2-chlorophenyI)-N-4-[(5-chloropyridin-3-yl)oxy]-3-sulfamoylphenylacetamide 030 .2-(2-chloropheny1)-N44-(4-cyanophenoxy)-3-sulfamoylphenyl]acetamide 031 .2-(2-chlorophenyI)-N-4-[3-(difluoromethyl)phenoxy]-3-sulfamoylphenylacetamide 032 .2-(2-chloropheny1)-N44-(2-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 033 .2-(2-chloropheny1)-N44-(3,5-dicyanophenoxy)-3-sulfamoylphenyl]acetamide 034 .2-(2-chloropheny1)-N44-(5-cyano-2-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 035 .2-(2-chloropheny1)-N-4-[(2,5-dichloropyridin-3-0)oxy]-3-sulfamoylphenylacetamide 036 .2-(2-chloropheny1)-N-4-[(5,6-dichloropyridin-3-yl)oxy]-3-sulfamoylphenylacetannide 037 3-(44(2-chlorophenyl)acetyllamino-2-sulfamoylphenoxy)-N-cyclopropylbenzamide 038 2-(2-chloropheny1)-N-4-[(3-chloropyridin-2-y1)oxy]-3-sulfamoylphenylacetamide 039 2-(2-chloropheny1)-N-4-[(4-chloropyridin-2-yl)oxy]-3-sulfamoylphenylacetamide 040 2-(2-chloropheny1)-N-4-[(6-chloropyridin-2-y1)oxy]-3-sulfamoylphenylacetamide 041 2-(2-chloropheny1)-N-443-(1-methy1-4,5-dihydro-1H-imidazol-2-Aphenoxy]-3-sulfamoylphenylacetamide 042 2-(2-chloropheny1)-N-444-(1A-imidazol-1-yl)phenoxyl-3-sulfamoylphenylacetamide 043 2-(2-chloropheny1)-N-444-(2-oxopyrrolidin-1-yl)phenoxyl-3-sulfamoylphenylacetamide 044 2-(2-chloropheny1)-N-444-(morpholin-4-yl)phenoxyl-3-sulfamoylphenylacetamide 045 2-(2-chloropheny1)-N44-(5-cyano-2-methylphenoxy)-3-sulfamoylphenyllacetamide 046 2-(2-chloropheny1)-N44-(3-cyano-2-methylphenoxy)-3-sulfamoylphenyllacetamide 047 2-(2-chloropheny1)-N44-(3-cyano-4-fluorophenoxy)-3-sulfamoylphenyllacetamide 048 N-4-[(5-chloro-2-cyanopyridin-3-yl)oxy]-3-sulfamoylphenyl-2-(2-chlorophenyl)acetamide 049 2-(2-chloropheny1)-N-4-[3-(piperidin-1-yl)phenoxy]-3-sulfamoylphenylacetamide 050 2-(2-chloropheny1)-N-443-(2-oxopyrrolidin-1-yl)phenoxy]-3-sulfamoylphenylacetamide 051 2-(2-chloropheny1)-N-443-(2-oxo-1,3-oxazolidin-3-yl)phenoxy1-3-sulfamoylphenylacetamide 052 2-(2-Chloropheny1)-N-443-(morpholin-4-ylcarbonyl)phenoxyl-3-sulfamoylphenylacetamide 053 2-(2-chloropheny1)-N-4-[(4-methyltetrahydro-2H-pyran-4-yl)methoxy]-3-sulfamoylphenylacetamide 054 2-(2-chloropheny1)-N-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-sulfamoylphenylacetamide 055 2-(2-chloropheny1)-N-4-[(4-cyanotetrahydro-2H-pyran-4-yl)methoxy]-3-sulfamoylphenylacetamide 056 2-(2-chloropheny1)-N-(3-sulfamoy1-442-(trifluoromethyppyrimidin-5-ylloxyphenyl)acetamide 057 2-(2-chloropheny1)-N-4-[(2-isopropylpyrimidin-5-y1)oxy]-3-sulfamoylphenylacetamide 058 2-(2-chloropheny1)-N-4-[(2-cyclopropy1-4-methylpyrimidin-5-yl)oxy]-3-sulfamoylphenylacetamide 059 N44-(3-bromophenoxy)-3-sulfamoylpheny11-2-(2-chlorophenyl)acetamide 060 N44-(4-bromophenoxy)-3-sulfamoylpheny11-2-(2-chlorophenyl)acetamide 061 2-(2-chloropheny1)-N-443-(2-methy1-1,3-thiazol-4-y1)phenoxy]-3-sulfamoylphenylacetamide 062 2-(2-chloropheny1)-N-4-[4-(5-oxopyrrolidin-2-yl)phenoxy]-3-sulfamoylphenylacetamide 063 2-(2-chloropheny1)-N-444-(2-oxo-1,3-oxazolidin-3-yl)phenoxy]-3-sulfamoylphenylacetamide 064 2-(2-chloropheny1)-N-3-sulfa moy1-444-(1,3-thiazol-2-yl)phenoxy]phenylacetamide 065 N44-(2-chlorophenoxy)-3-sulfamoylpheny11-2-(2-chlorophenyl)acetamide 066 N44-(4-chlorophenoxy)-3-sulfarnoylpheny11-2-(2-chlorophenyl)acetarnide 067 2-(2-chloropheny1)-N-443-(piperidin-1-ylcarbonyl)phenoxy]-3-sulfamoylphenylacetamide 068 2-(2-chloropheny1)-N-3-sulfamoy1-444-(tetrahydrofuran-3-yl)phenoxylphenylacetamide 069 2-(2-chloropheny1)-N44-(3-cyano-5-fluorophenoxy)-3-sulfamoylphenyllacetamide 070 N44-(2-methoxyphenoxy)-3-sulfamoylpheny11-2-phenylacetamide 071-- N44-(2-methoxyphenoxy)-3-sulfamoylpheny11-244-(trifluoromethyl)phenyllacetamide 072 N-3-sulfamoy1-442-(trifluoromethoxy)phenoxylpheny1-244-(trifluoromethyl)phenyllacetamide 073 N44-(2-chlorophenoXy)-3-sulfamoylpheny11-244-(trifluoromethyl)phenyllacetamide 074 2-phenyl-N-3-sulfamoy1-442-(trifluoromethoxy)phenoxylphenylacetamide 075 2-(2-chlorophenyI)-N-4-[(2-oxo-1 ,2-dihydropyridin-3-yl)oxy]-3-sulfamoylphenylacetamide 076 N44-(2-chlorophenoxy)-3-sulfamoylphenylj-2-phenylacetamide =
-077 N44-(4-chlorophenoxy)-3-sulfamoylpheny11-2-phenylacetamide 078 N-4-[(5-chloropyridin-3-0)oxy]-3-sulfamoylpheny1-2-phenylacetamide 079 2-(2-chloropheny1)-N-4-[(2-chloropyrimidin-5-yl)oxy]-3-sulfamoylphenylacetamide 080 2-(2-chloropheny1)-N-4-[(5-fluoropyridin-3-y0oxy)-3-sulfamoylphenylacetamide 081 2-(2-chloropheny1)-N-4-[(6-chloropyridin-3-y1)oxy]-3-sulfamoylphenylacetamide 082 N42-chloro-4-(3-chlorophenoxy)-5-sulfamoylpheny11-2-(2-chlorophenyl)acetamide 083 N42-chloro-4-(3-chlorophenoxy)-5-sulfamoylpheny11-2-(2-Chloro-3-fluorophenyl)acetamide 084 N44-(3:chlorophenoxy)-3-sulfamoylpheny11-2-(3-fluorophenyl)acetamide¨

. 085 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(4-fluorophenyl)acetamide 086 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-242-(trifluoromethyl)phenyllacetamide 087 N144-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2-isopropylphenyl)acetamide 088 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2-ethoxyphenyl)acetamide 089 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-242-(difluoromethyl)phenyljacetamide 090 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-2-[(trifluoromethyl)sulfanyl]phenylacetamide 091 2-(2-bromopheny1)-1144-(3-chlorophenoxy)-3-sulfamoylphenyljacetamide 092 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(4-methylpyridin-3-yl)acetamide 093 N14-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-(2-chloropyridin-3-yl)acetamide 094 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2-chloropheny1)-2,2-difluoroacetamide .õ .

095 2-(2-chloro-4-methylpheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 096 2-(2-chloro-6-methylpheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 097 2-(2-chloro-5-methylpheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 098 2-(2-chloro-3-fluoropheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 099 2-(2-chloro-5-fluoropheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 100 2-(2-chloro-6-fluoropheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 101 2-(2-chloro-6-methoxypheny1)-N14-(3-chlorophenoxy)-3-sulfamoylphenyllacetamide 102 2-(2-chloro-5-methoxypheny1)-N44-(3-chlorophenoxy)-3-sulfamoylphenyllacetamide 103 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-(2,3-dichlorophenyl)acetamide 104 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-(2,6-dichlorophenyl)acetamide 105 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny11-242-(trifluoromethoxy)phenyllacetamide 106 N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2,2-difluoro-2-phenylacetamide 107 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-242-chloro-3-(trifluoromethyl)phenyllacetamide 108 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-[2-chloro-6-(trifluoromethyl)phenyl]acetamide 109 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-242-chloro-5-(trifluoromethyl)phenyllacetamide 110 N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2,4-dichlorophenyl)acetamide 111 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-(4,6-dichloropyridin-3-yl)acetamide 112 N-[4-(3-Chlorophenoxy)-3-sulfamoylpheny11-2-(3-chloropyridin-2-yl)acetamide 113 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-242-(difluoromethoxy)phenyllacetamide 114 N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2,5-dichlorophenyl)acetamide 115 2-[6-chloro-2,3-difluoro-4-(trifluoromethyl)phenyl]-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 116 N44-(3-chlorophenoxy)-3-sulfamoylphenylj-2-[4-(trifluoromethyl)phenyl]acetamide 117 2-(5-bromo-2-chloropheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 118 2-(4-bromo-2-chloro-5-methylpheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 119 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-(3-chloropyridin-4-yl)acetamide '120 2-(2-chloro-6-fluoro-3-methylpheny1)-N-14-(3-chlorophenoxy)-3-sulfamoylphenyllacetamide 121 2-(6-chloro-2-fluoro-3-methylpheny1)-N14-(3-chlorophenoxy)-3--sulfamoylphenyllacetamide 122 2-(2-chloro-3,6-difluoropheny1)-414-(3-chlorophenoxy)-3-sulfamoylphenyllacetamide 123 2-(2-chloro-4,5-difluoropheny1)-N44-(3-chlorophenoxy)-3-sulfamoylphenyllacetamide 124 N14-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2,3-dichloro-6-fluorophenyl)acetamide 125 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2,3,6-trichlorophenyl)acetamide 126 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-(2,6-dichloro-4-methylphenyl)acetamide 127 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-242,3-dichloro-6-(trifluoromethyl)phenyllacetamide 128 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2,6-dichloro-3-methylphenyl)acetamide 129 N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2,6-dichloro-3-cyclopropylphenyl)acetamide 130 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-[2,6-dichloro-3-(trifluoromethyl)phenyl]acetamide 131 2-(3-bromo-2,6-dichloropheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 132 2-(3-bromo-2-chloro-6-methylpheny1)-N44-(3-chlorophenoxy)-3-sulfamoylphenyljacetamide -133 2-(3-bromo-6-chloro-2-methylpheny1)-N44-(3-chlorophenoxy)-3-sulfamoylphenyljacetamide 134 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2[2-chloro-5-(1,1,2,2- .---tetrafluoroethoxy)phenyllacetamide 135 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-[2-chloro-4-(trifluoromethyl)phenyl]acetamide 136 2-(2-chloropheny1)-N-(4-[3:(methylsulfonyl)benzyl]oxy-3-sulfamoylphenyl)acetamide 137 2-(2-chloropheny1)-N-4-[(2-fluorobenzyl)oxy]-3-sulfamoylphenylacetamide 138' "2-(2-chloropheny1)-N-41(4-cyanobenzyl)oxyl-3-sulfamoylphenylacetamide 139 N-4-[(3-chlorobenzyl)oxy]-3-sulfamoylpheny1-2-(2-chlorophenyl)acetamide 140 2-(2-chloropheny1)-N-41(3-methoxybenzyl)oxy]-3-sulfamoylphenylacetamide 141 N-[4-(benzyloxy)-3-sulfamoylpheny1]-2-(2-chlorophenyl)acetamide 142 2-(2-chloropheny1)-N-44(3-cyanobenzyl)oxy1-3-sulfamoylphenylacetamide 143 2-(2-chloropheny1)-N-41(4-fluorobenzyl)oxyl-3-sulfamoylphenylacetamide 144' N-4-[(2-chlorobenzyl)oxy]-3-sulfamoylpheny1-2-(2-chlorophenyl)acetamide 145 2-(2-chlorophenyI)-N-4-[(2-cyanobenzyl)oxy]-3-sulfamoylphenylacetamide 146 fv-[4-(benzyloxy)-3-sUlfamoylpheny1]-2:phenylacetamide 147 2-(2-chloropheny1)-N-(444-(methylsulfonyl)benzylloxy-3-sulfamoylphenyl)acetamide 148A 2-(2-chloropheny1)-N-[4-(1-phenylethoxy)-3-sulfamoylphenyl]acetamide 148B 2-(2-chloropheny1)-N44-(1-phenylethoxy)-3-sulfamoylphenyljacetamide 149 2-(2-chloropheny1)-N-[4-(pyridin-3-ylmethoxy)-3-sulfamoylphenyl]acetamide 150 2-(2-chloropheny1)-N-[4-(pyridin-2-ylmethoxy)-3-sulfamoylphenyl]acetamide 151 2-(2-chloropheny1)-N-14-(pyridin-4-ylmethoxy)-3-sulfamoylphenyllacetamide 152 N-[4-(pyridin-2-ylmethoxy)-3-sulfamoylpheny1]-2-[4-(trifluoromethyl)phenyl]acetamide 153 2-(2-chloropheny1)-N-(4-(pyrimidin-4-ylmethoxy)-3-sulfamoylphenyllacetamide 154 2-(2-chlorophenY1)-N-K-(pyrimidin-2-ylmethoxy)-3-sulfamoylphenyllacetamide 155 2-(2-chloropheny1)-N44-(2-phenylethoxy)-3-sulfamoylphenyllacetamide 156 2-(2-chlorophenyI)-N-4-[2-(3-chlorophenyl)ethoxy]-3-sulfamoylphenylacetamide 157 2-(2-chloropheny1)-N44-(cyclobutylmethoxy)-3-sulfamoylphenyllacetamide -158- 2-(2-61oropheny1)-N-K-(oxetan-2-ylmethoxy)-3-sulfamoylphenyllacetamide 159 2-(2-chloropheny1)-N44-(oxetan-3-ylmethoxy)-3-sulfamoylphenyllacetamide 160 2-(2-chloropheny1)-N-14-(cyclopentylmethoxy)-3-sulfamoylphenyllacetamide 161 2-(2-chloropheny1)-N-[3-sulfamoy1-4-(tetrahydrofuran-2-ylmethoxy)phenyl]acetamide 162 2-(2-chloropheny1)-N43-sulfamoy1-4-(tetrahydrofuran-3-ylmethoxy)phenyllacetamide 163 2-(2-chloro-5-fluoropheny1)-N43-sulfamoy1-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyllacetamide 164 2-(2-chlorophenyl)-N-[3-sulfamoy1-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide 165 2-(2-chloropheny1)-N-[3-sulfamoy1-4-(tetrahydro-2H-pyran-3:¨
ylmethoxy)phenyl]acetamide 166 2-(2-chloro-6-fluoropheny1)-1143-sulfamoy1-4-(tetrahydro-2H-pyran-4: -ylmethoxy)phenyljacetamide 167 2-(2-chloro-3-fluOropheny1)-N-(3-sulfamoy1-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyllacetamide 168 2-(2-chloropheny1)-N-5-sulfamoy1-643-(trifluoromethyl)phenoxylpyridin-3-ylacetamide 169 2-phenyl-N-5-suffamoy1-643-(trifluoromethyl)phenoxylpyridin-3-ylacetamide 170 N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoylpheny1]-2-phenylacetamide 171 N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoylpheny1]-2-(2-methylphenyl)acetamide 172 N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoylphenyI]-2-(3-methylphenyl)acetamide 173 2-(2-chloropheny1)-N-443-(3-oxomorpholin-4-yl)phenoxyl-3-sulfamoylphenylacetamide 174 2-(2-chlonSpheny1)-N-4-[4-(3-oxomorpholin-4-yl)phenoxy]-3-sulfamoylphenylacetamide 175 2-(2-chloropheny1)-N-414-(2-oxopiperidin-1-y1)phenoxy]-3-sulfamoylphenylacetamide .176 2-(2-chloropheny1)-N-4:13-(2-oxopipendin-1-yl)phenoxyj-3-sulfamoylphenylacetamide 177- 2-(2-chloropheny1)-N-443-(prop-1-en-2-Aphenoxyl-3-sulfamoylphenylacetamide 178 2-(2-chloropheny1)-N-412-(prop-1-en-2-yl)phenoxyl-3-sulfamoylphenylacetamide 179 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(4-methylphenyl)acetiade 180 N-[4-(3-chlorophenoxy)-3.-sulfamoylpheny1]-2-(4-chlorophenyl)acetamide 181 N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(pyridin-3-yl)acetamide 182- N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2-methylphenyOacetamidW
183 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(3-methylphenyl)acetamide 184 N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenyipropanamide 185 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(pyridin-2-yl)acetamide 186 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-(3-chlorophenyOacetamide 187 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2-chlorophenyl)acetamide ¨188' N-14-(3-chlorophenoxy)-3-sulfamoylphenylj-2-(Pyridin-4-yl)acetamide 189 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(6-methylpyridin-2-yOacetamide 190 N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(4-methoxyphenyl)aCetamide 191 N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(3-methoxyphenyl)acetamide 192 N44:(3-chlorophenoxy)-3-sulfamoylphenyli-2-(2-methoxyphenyl)acetamide 193 N144-(3-chlorophenoxy)-3-SulfamoYlpheny11-2-(5-methylpyridin-2-yl)acetamide 194 (2S)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylpropanamide 195 (2R)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylpropanamide 196 N-(4-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2-chlorophenyl)propanamide 197 2-(244-(3-chlorophenoxy)-3-sulfamoylphenyliamino-2-oxoethyl)-N-(2-methoxyethyl)-N-methylbenzamide 198 2-(244-(3-chlorophenoxy)-3-sulfamoylphenyljamino-2-oxoethylyN,N- ¨
dimethylbenzamide 199 N-K-(cyclohexyloxy)-3-sulfamoylpheny11-2-phenylacetamide 200 2-(2-chloropheny1)-N44-(cyclohexyloxy)-3-sulfamoylphenyllacetamide 201 3-(214-(3-chlorophenoxy)-3-sulfamoylphenyllamino-2-oxoethyl)-N-(2-methoxyethyl)benzamide 202 3-(244-(3-chlorophenoxy)-3-sulfamoylphenyljamino-2-oxoethyl)-N,N-dimethylbenzamide 203 3-(244-(3-chlorophenoxy)-3-sulfamoylphenyllamino-2-oxoethyl)-N-methylbenzamide 204 N-[4-(cyclobutyloxy)-3-sulfamoylphenyI]-2-phenylacetamide 205 2-(2-chloropheny1)-N-K-(cyclobutyloxy)-3-sulfamoylphenyllacetamide 206 2-phenYI-N43-sulfamoy1-4-(tetrahydro-2H-pyran-4-yloxy)phenyljacetaMide 207 2-(2-chloropheny1)-N-[3-sulfamoy1-4-(tetrahydro-2H-pyran-4-yloxy)phenyl]acetamide 208 3-(244-(3-chlorophenoxy)-3-sulfamoylphenyllamino-2-oxoethyl)-N-(2-methoxyethyl)-N-methylbenzamide 209 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(5-chloropyridin-2-yl)acetamide 210 N-K-(3-chlorophenoxy)-3-sulfamoylpheny11-2-[3-(2-methoxyethoxy)phenyllacetamide 211 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-242-(2-methoxyethoxy)phenyllacetamide 212 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-243-(2-hydroxyethoxy)phenyllacetamide _ 213 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2[2-(2-hydroxyethoxy)phenyllacetamide 214 N44-(3-chlorophenoxy)-3-sulfamoylpheny11-2-(2-fluoiOptienyl)acetamide 215 N-14-(oxetan-3-yloxy)-3-sulfamoylpheny1]-2-phenylacetamide 216 2-(2-chloropheny1)-N-K-(oxetan-3-yloxy)-3-sulfamoylphenyljacetamide 217 N[4-(cyclopentyloxy)-3-sulfamoylpheny11-2-phenylacetamide 218 2-(2-chloropheny1)4144-(cyclopentyloxy)-3-sulfamoylphenyllacetamide 219 N-4-[(1-methylpiperidin-3-yl)oxy]-3-sulfamoylphenyl-2-phenylacetamide 220 2-(2-chloropheny1)-N-4-[(1-methylpiperidin-3-y1)oxy]-3-sulfamoylphenylacetamide 221 N-4-[(1-methylpyrrolidin-3-yl)oxy]-3-sulfamoylphenyl-2-phenylacetamide 222 2-(2-chloropheny1)-N-4-[(1-methylpyrrolidin-3-Y1)oxy]:3-sulfamoylphenylacetamide 223 N44-(4-chlorophenoxy)-3-sulfamoylpheny11-2-(4-fluorophenyl)acetamide 224 N-KL(3-chlorophenoxy)-3-sulfamoylpheny11-2-(4-cyanophenyl)acetamide 225 N-E4-(3-chlorophenoxy)-3-sulfamoylphenylj-2-(2-cyanophenyl)acetamide 226 N44-(3-chlorophenoxy)-3"-sulfamoylpheny-(3-cyanophenyl)acetamide 227 N44-(4-chlorophenoxy)-3-sulfamoYlpheny11-244-(trifluoromethyl)phenyljacetamide 228 N-E4-(4-chlorophenoxy)-3-sulfamoylpheny11-2-(4-chlorophenyl)acetamide 229 N44-(4-chlorophenoxy)-3-sulfamoylpheny11-2-(4-methoxyphenyl)acetamide 230 N44-(4-chlorophenoxy)-3-sulfamoylpheny11-2-(2-fluorophenyl)acetamide 231 2-(2-chloro-4-fluoropheny1)-N44-(4-chlorophemixy)-3:
sulfamoylphenyljacetamide 232 2-(2-chloropheny1)-N-4-[(1,1-dioxidotetrahydrothiophen-3-y1)oxy]-3-sulfamoylphenylacetamide õ
233 2-(2-chloropheny1)-N-4-[(1-methyl-1H-pyrazol-4-yl)oxy]-3-_ sulfamoylphenylacetamide 234 N44-(4-chlorophenoxy)-3-sulfamoylpheny11-244-(difluoromethyl)phenyllacetamide 235 2-(2-chloro-4-methoxypheny1)-N44-(4-chlorophenoxy)-3-sulfamoylphenyllacetamide 236 2-(2-chloropheny1)-N-4-[(1-methy1-1H-pyrazol-3-y1)oxy]-3-sulfamoylphenylacetamide 237 2-(2-chloropheny1)-N-4-[(1-methy1-1H-pyrazol-5-y1)oxy]-3-sulfamoylphenylacetamide 238 2-(2-chloropheny1)-N-4-[(1-methylpiperidin-4-yl)oxy]-3-sulfamoylphenylacetamide 239 2-(2-chloropheny1)-N-(445-methy1-2-(pyridin-3-y1)-1,3-thiazol-4-ylloxy-3-sulfamoylphenyl)acetamide 240 N-[4-(3-chlorophenoxy)-2-methy1-5-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide 241 2-(2-chloropheny1)-N-{44(1-oxidotetrahydrothiophen-3-yl)oxy]-3-sulfamoylphenyl}acetamide 242 N44-(4-chlorophenoxy)-3-sulfamoylpheny11-242,6-dichloro-4-(trifluoromethyl)phenyllacetamide 243 1144-(4-chlorophenoxy)-3-sulfamoylpheny11-2-(2,5-dichloro-4-cyanophenyl)acetamide 244 N-[4-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-phenylacetamide 245 N-K-(cyclopropylmethoxy)-3-sulfamoylpheny11-2-phenylacetamide 246 N44-(3,5-dimethylphenoxy)-3-sulfamoylpheny11-2-phenylacetamide 247 N-[4-(2,4-difluorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide 248 N14-(4-fluorophenoxy)-3-sulfamoylpheny11-2-phenylacetamide 249 N-K-(3-fluorophenoxy)-3-sulfamoylpheny11-2-phenylacetamide 250 1144-(3-methoxyphenoxy)-3-sulfamoylphenylj-2-phenylacetamide 251 N44-(2-fluoro-5-methylphenoxy)-3-sulfamoylpheny11-2-phenylacetamide 252 2-phenyl-N-3-sulfarnoy1-444-(trifluoromethoxy)phenoxylphenylacetamide-253 2-phenyl-N-3-sulfamoy1-4-[3-(trifluoromethyl)phenoxy]phenylacetamide '254 N-[4-(3,5-diMethoxyphenoxy)-3-sulfamoylpheny1]:2-Phenylacetamide 255 N44-(3-cyanophenoxy)-3-sulfamoylpheny1]-2-phenylacetamide _ 256 N44-(3-chlorophenoxy)-3-sulfamoylphenylj-2-(4-hydroxyphenyl)aceiamide 257 2-(2-chloro-6-methoxy-4-methylpheny1)-N-K-(3-chlorophenoxy)-3-sulfamoylphenyllacetamide 258 2-(2-chloro-6-fluoropheny1)-1144-(3-chlorophenoxy)-3-sulfamoylphenylipropanamide 259 2-(2-chloro-4,6-difluoropheny1)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 260 N-K-(3-Chlorophenoxy)-3-sulfamoylpheny11-2-(2,6-dichlorophenyl)propanamide 261 2-(2-chloropheny1)-N-41(2H5)phenyloxyl-3-sulfamoylphenylacetamide 262 2-(2-chloropheny1)-N-(4-{K-chloro(2H4)phenylloxy)-3-sulfamoylphenyl)acetamide 263 2-(2-chloropheny1)-N-(44[2-chloro(2H4)phenyl]oxy)-3-sulfamoylphenyl)acetamide 264 2-(2-chloropheny1)-N-444-(2-hydroxypropan-2-yl)phenoxy]-3-sulfamoylphenylacetamide 265 2-(2-chloropheny1)-N-4-[(2,2-dimethyltetrahydro-2H-pyran-4-y1)methoxy]-3-sulfamoylphenylacetamide 266 2-(2-chloropheny1)-N-{4-[(1R,5S,60-3-oxabicyclo[3.1.0jhe-6-ylmethoxy]-3-sulfamoylphenyl}acetamide 267 2-(2-chloropheny1)-N-4-[(4-chlorotetrahydro-2H-pyran-4-y1)methoxy]-3-sulfamoylphenylacetamide 268 2-(2-chloropheny1)-N44-(1,4-dioxan-2-ylmethoxy)-3-sulfamoylphenyllacetamide 269 2-(2-chloropheny1)-N-3-sulfamoy1-4-[(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-y1)oxy]phenylacetamide 270 N44-(3-chlorophenoxy)-3-methy1-5-sulfa.moylphenylj-2-(2-chlorophenyl)acetamide 271 N44-(3-chlorophenoxy)-3-methyl-5-sulfamoylpheny11-2-phenylacetamide 272 methyl 2-(4[(2-chlorophenyl)acetyljamino-2-sulfamoylphenoxy)benzoate 273 methyl 4-(4[(2-chlorophenyl)acetyllamino-2-sulfamoylphenoxy)benzoate 274 2-(2-chloropheny1)-N-443-(2-hydroxypropan-2-yl)phenoxy]-3-sulfamoylphenylacetamide 275 2-(2-chiorophenyl)-N-442-(2-hydroxypropan-2-y1)phenoxyl-3-sulfamoylphenylacetamide 276 N44-(4-chlorophenoxy)-3-sulfamoylpheny11-2-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide 277 2-(7-chloro-2,3-dihydro-1,4-benzodioxin-6-yI)-N-[4-(3-chloropherToXy)-3-sulfamoylphenyl]acetamide -278 2-(5-chlOro-2,3-dihydr6-i-benzofuran-4-y1)-N44-(3-chlorophenoxy)-3-sulfamoylphenyllacetamide 279 2-(2-fluoropheny1)-N43-sulfamoy1-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyllacetamide 280 N43-sulfamoy1-4-(tetrahydro-2H-pyran-4-ylmethoxy)pheny11-212-(trifluoromethyl)phenyllacetamide 281 242-(difluoromethyl)phenyll-N43-sulfamoy1-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyllacetamide 282 2-(2-chloro-4-fluoropheny1)-N43-sulfamoy1-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide 283 2-(2-Chloropheny1)-N-(3-sulfamoy1-4-{[6-(trifluoromethyppyridin-3-yl]oxyl-ipheny1)-acetamide 284 .2-(2-Chloropheny1)-N-(44[5-chloro-4-(trifluoromethyppyridin-2-yl]oxy}-3-sulfamoyl-phenypacetamide 285 .N44-(3-chlorophenoxy)-3-sulfamoylpheny1]-2-pheny1(2H2)acetamide 286 .N-{4-[(6-Chloro-5-fluoropyridin-3-yl)oxy]-3-sulfamoylpheny11-2-(2-chloropheny1)-acetamide 287 .2-(2-ChlorophenyI)-N-{4-[(4,4-difluoro-1-hydroxycyclohexyl)methoxy]-3-sulfamoyl-phenyllacetamide 288 .2-(2-Chloropheny1)-N-{4-[(1-hydroxycyclohexyl)methoxy]-3-sulfamoylphenyll-acetamide 289 .N44-(3-Chlorophenoxy)-3-fluoro-5-sulfamoylpheny1]-2-(2-fluorophenypacetamide 290 .N44-(3-chlorophenoxy)-3-fluoro-5-sulfamoylpheny1]-2-[2-(difluoromethyl)-phenyl]acetamide 291 .N44-(3-chlorophenoxy)-3-fluoro-5-sulfamoylpheny1]-2-(2-chlorophenypacetamide 292 2-(2-chloro-5-fluoropheny1)-N44-(3-chlorophenoxy)-3-fluoro-5-sulfamoyl-phenyl]acetamide 293 .N46-(3-Chlorophenoxy)-5-sulfamoylpyridin-3-y1]-2-(2-fluorophenypacetamide 294 .N46-(3-Chlorophenoxy)-5-sulfamoylpyridin-3-y1]-242-(trifluoromethyl)phenylFacetamide 295 .N46-(3-Chlorophenoxy)-5-sulfamoylpyridin-3-y1]-242-(difluoromethyl)phenylFacetamide 296 .2-(2-Chloro-5-fluorophenyI)-N-[6-(3-chlorophenoxy)-5-sulfamoylpyridin-3-yl]-acetamide or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
One aspect of the invention are compounds of formula (I), (la), (lb) as described in the examples, as characterized by their names in the title and their structures as well as the subcombinations of all residues specifically disclosed in the compounds of the examples.

Another aspect of the present invention are intermediates according to formula 0, ii - S' N HW
R5b OH

RyL w R R5a whereby R', R3, R4, R5, R5a and R5b are defined according to the description and claims and W corresponds to either a hydrogen atom or a protecting group (e.g., N-(dimethylamino)methylene or 2,4-dimethoxybenzyl). The intermediates according to formula 9 are used for the synthesis of the compounds of formula (I), more in particular of compounds of formula 6, and compounds of formula (la).
Furthermore the present invention refers to intermediates according to formula 13 or 14 0 ii 'S---Nliv R5b0, 2 R
I
N
Y
R5a 13:Y = -N=CAr2 14:Y = -NH2 whereby R2õ R5a and R5b are defined according to the description and claims, Ar stands for aryl and W corresponds to either a hydrogen atom or a protecting group (e.g., N-(dimethylamino)methylene or 2,4-dimethoxybenzyl). The intermediates according to formula 13 or 14 are used for the synthesis of the compounds of formula (I), more in particular of compounds of formula 15, and compounds of formula (lb).
Specific intermediates for the synthesis of compounds of formula (I) according to present invention are:

002 N-(2,4-DimethoxybenzyI)-2-fluoro-5-nitrobenzenesulfonamide 003 2,4-Dichloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide 004 N-(2,4-DimethoxybenzyI)-2,3-difluoro-5-nitrobenzenesulfonamide 008 2-(2-ChlorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide 009 2-(2-Chloro-3-fluorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide 010 2-(2-Chloro-6-fluorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide 011 5-Bromo-2-hydroxypyridine-3-sulfonamide 013 5-Amino-243-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide 057 N-(2,4-Dimethoxybenzy1)-2-fluoro-4-methy1-5-nitrobenzenesulfonamide 068 N-(2,4-Dimethoxybenzy1)-2-fluoro-3-methy1-5-nitrobenzenesulfonamide Another aspect of the invention relates to the use of any of the intermediates described herein for preparing a compound of formula (1) as defined herein or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.
Preferred intermediates are the Intermediate Examples as disclosed below.
A further aspect of the invention are compounds of formula (1), (la) and (lb) which are present as their salts.
It is to be understood that the present invention relates to any sub-combination within any embodiment or aspect of the present invention of compounds of general formula (1), (la) and (lb) supra.
More particularly still, the present invention covers compounds of general formula (1), (la) and (lb) which are disclosed in the Example section of this text, infra.
In accordance with another aspect, the present invention covers methods of preparing compounds of the present invention, said methods comprising the steps as described in zo the Experimental Section herein.
Another embodiment of the invention are compounds according to the claims as disclosed in the Claims section wherein the definitions are limited according to the preferred or more preferred definitions as disclosed below or specifically disclosed residues of the exemplified compounds and subcombinations thereof.
Definitions Constituents which are optionally substituted as stated herein, may be substituted, unless otherwise noted, one or more times, independently from one another at any possible position. When any variable occurs more than one time in any constituent, each definition is independent. For example, when R1, R2, R3, Ra, R5, Rs, R7, R5, R9, R10, R11, R12, and/or Y occur more than one time in any compound of formula (I) each definition of R1, R2, R3, R4, R5, R6, R7, Rs, R9, Rlo, 1-µ R12, X and Y is independent.
Should a constituent be composed of more than one part, e.g. Ci-C4-alkoxy-Ci-C4-alkyl-, the position of a possible substituent can be at any of these parts at any suitable position.
A hyphen at the beginning of the constituent marks the point of attachment to the rest of the molecule. Should a ring be substituted the substitutent could be at any suitable position of the ring, also on a ring nitrogen atom if suitable.
Furthermore, a constituent composed of more than one part and comprising several chemical residues, e.g. Cl-C4-alkoxy-C1-C4-alkyl or phenyl-Ci-C4-alkyl, should be read from left to right with the point of attachment to the rest of the molecule on the last part (in the example mentioned previously on the C1-C4-alkvl residue) The term "comprising" when used in the specification includes "consisting of'.
If it is referred to "as mentioned above" or "mentioned above" within the description it is referred to any of the disclosures made within the specification in any of the preceding pages.
"suitable" within the sense of the invention means chemically possible to be made by methods within the knowledge of a skilled person.
The terms as mentioned in the present text have preferably the following meanings:
The term "halogen", "halogen atom", "halo-" or "Hal-" is to be understood as meaning a fluorine, chlorine, bromine or iodine atom, preferably a fluorine or chlorine atom.
The term "Ci-C4-alkyl" is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group having 1, 2, 3 or 4 carbon atoms, e.g.
a methyl, ethyl, propyl, butyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl group, particularly 1, 2 or 3 carbon atoms ("Ci-C3-alkyl"), e.g. a methyl, ethyl, n-propyl- or iso-propyl group.

The term "Ci-C4-haloalkyl" is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group in which the term "C1-C4-alkyl" is defined supra, and in which one or more hydrogen atoms is replaced by a halogen atom,

5 in identically or differently, i.e. one halogen atom being independent from another.
Particularly, said halogen atom is F. Said C1-C4-haloalkyl group is, for example, -CF3, -CHF2, -CH2F, -CF2CF3, or-CH2CF3.
The term "C1-C4-alkoxy" is to be understood as preferably meaning a linear or branched, 10 saturated, monovalent, hydrocarbon group of formula ¨0-alkyl, in which the term "alkyl" is defined supra, e.g. a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy or sec-butoxy group, or an isomer thereof.
The term "Ci-C4-haloalkoxy" is to be understood as preferably meaning a linear or 15 branched, saturated, monovalent C1-C4-alkoxy group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a halogen atom.
Particularly, said halogen atom is F. Said C1-04-haloalkoxy group is, for example, ¨0CF3, -OCHF2, -OCH2F, -0CF2CF3, or -OCH2CF3.
zo The term "C1-04-hydroxyalkyl" is to be understood as meaning a linear or branched, saturated, monovalent hydrocarbon group in which the term "Ci-C4-alkyl" is defined supra, and in which one or more hydrogen atoms is replaced by a hydroxy group, e.g. a hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 2,3-dihydroxypropyl, 1,3-dihydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 25 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl group.
The term "C1-04-alkoxy-C1-04-alkyl" is to be understood as preferably meaning a linear or branched, saturated, monovalent alkyl group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a Ci-C4-alkoxy group, as 30 defined supra, e.g. methoxyalkyl, ethoxyalkyl, propyloxyalkyl, iso-propoxyalkyl, butoxyalkyl, iso-butoxyalkyl, tert-butoxyalkyl or sec-butoxyalkyl group, in which the term "C1-C4-alkyl" is defined supra, or an isomer thereof.
The term "C3-C6-cycloalkyl" is to be understood as meaning a saturated, monovalent, 35 mono-, or bicyclic hydrocarbon ring which contains 3, 4, 5 or 6 carbon atoms ("03-06-cycloalkyl"). Said C3-C6-cycloalkyl group is for example, a monocyclic hydrocarbon ring, e.g. a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, or a bicyclic hydrocarbon ring.
The term "4- to 6-membered heterocycloalkyl" or "4- to 6-membered heterocyclic ring", is to be understood as meaning a saturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 3, 4 or 5 carbon atoms, and one or more heteroatom-containing groups selected from C(=0), 0, S, S(=0), S(=0)2, NH, NRa, in which Ra represents a Cl-C6-alkyl-or C1-C6-haloalkyl- group; it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom.
Particularly, said heterocycloalkyl can contain 4 or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "5- to 6-membered heterocycloalkyl").
Particularly, without being limited thereto, said heterocycloalkyl can be a 4-membered ring, such as an azetidinyl, oxetanyl, or a 5-membered ring, such as tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, or a 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or zo trithianyl, for example. Optionally, said heterocycloalkyl can be benzo fused.
The term "heteroaryl" is understood as preferably meaning a monovalent, monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms (a "5- to 14-membered heteroaryl" group), particularly 5, 6, 9 or 10 ring atoms, and which contains at least one heteroatom which may be identical or different, said heteroatom being such as oxygen, nitrogen or sulfur. In addition said ring system can be benzocondensed. Particularly, heteroaryl is selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl, and benzo derivatives thereof, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl; or pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and benzo derivatives thereof, such as, for example, quinolinyl, quinazolinyl, isoquinolinyl; or azocinyl, indolizinyl, purinyl, and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthpyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, xanthenyl or oxepinyl.

In general, and unless otherwise mentioned, the heteroarylic radical include all the possible isomeric forms thereof, e.g. the positional isomers thereof. Thus, for some illustrative non-restricting example, the term pyridyl includes pyridin-2-yl, pyridin-3-y1 and pyridin-4-y1; or the term thienyl includes thien-2-y1 and thien-3-yl.
Preferably, the heteroaryl group is a pyridyl group.
As mentioned supra, said nitrogen atom-containing ring can be partially unsaturated, i.e. it can contain one or more double bonds, such as, without being limited thereto, a 2,5-dihydro-1H-pyrrolyl, 4H41,3,41thiadiazinyl, 4,5-dihydrooxazolyl, or 4H41,41thiazinyl ring, for example, or, it may be benzo-fused, such as, without being limited thereto, a dihydroisoquinolinyl ring, for example.
The term "C1-C4", as used throughout this text, e.g. in the context of the definition of "C1-C4-alkyl", "C1-C4-haloalkyr, "C1-C4-alkoxy", or "C1-C4-haloalkoxy" is to be understood as meaning an alkyl group having a finite number of carbon atoms of 1 to 4, i.e.
1, 2, 3 or 4 carbon atoms. It is to be understood further that said term "Ci-C4" is to be interpreted as any sub-range comprised therein, e.g. Cl-C4, C2-C4, C3-C4, Cl-C2, Cl-C3 , particularly Cl-C2 , C1-C3 , C1-C4, in the case of "Ci-C6-haloalkyl" or "C1-C4-haloalkoxy"
even more particularly Ci-C2.
Further, as used herein, the term "C3-C6", as used throughout this text, e.g.
in the context of the definition of "Ca-C6-cycloalkyl", is to be understood as meaning a cycloalkyl group having a finite number of carbon atoms of 3 to 6, i.e. 3, 4, 5 or 6 carbon atoms. It is to be understood further that said term "Ca-Cs" is to be interpreted as any sub-range comprised therein, e.g. Ca-Cs, C4-05, C3-05, C3-C4, C4-C6, Cs-C6; particularly Ca-C6.
The R9R10N-C(0)- group include, for example, -C(0)NH2, -C(0)N(H)CH3, -C(0)N(CH3)2, -C(0)N(H)CH2CH3, -C(0)N(CH3)CH2CH3 or -C(0)N(CH2CH3)2.
The R9R19N- group includes, for example, -NH2, -N(H)CH3, -N(CH3)2, -N(H)CH2CH3 and .._, -N(CH3)CH2CH3. In the case of R9aR10aINwhen R9a and Ri a together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from 0, NH, NRa in which Ra represents a C1-C6-alkyl- or Cl-C6-haloalkyl- group, particularly a CH3, or S and being optionally substituted, one to three times, independently from each other, with halogen or C1-C4-alkyl, particularly a CH3.

The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
Ring system substituent means a substituent attached to an aromatic or nonaromatic ring system which, for example, replaces an available hydrogen on the ring system.
As used herein, the term "one or more", e.g. in the definition of the substituents of the compounds of the general formulae of the present invention, is understood as meaning "one, two, three, four or five, particularly one, two, three or four, more particularly one, two or three, even more particularly one or two".
The invention also includes all suitable isotopic variations of a compound of the invention.
zo An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually or predominantly found in nature.
Examples of isotopes that can be incorporated into a compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), 3H (tritium), 11C, 13C, 14C, 15N, 170, 180, 3210, 33p, 33s, 34s, 35S, 36S, 18F, 38CI, 82Br, 1231, 1241, 1251, 1291 and 1311, respectively.
Certain isotopic variations of a compound of the invention, for example, those in which one or more radioactive isotopes such as 3H or 14C are incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of a compound of the invention can generally be prepared by conventional procedures known by a person skilled in the art such as by the illustrative methods or by the preparations described in the examples hereafter using appropriate isotopic variations of suitable reagents.

Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like.
By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The compounds of this invention may contain one or more asymmetric centre, depending upon the location and nature of the various substituents desired. Asymmetric carbon atoms may be present in the (R) or (S) configuration, resulting in racemic mixtures in the case of a single asymmetric centre, and diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the present invention.
zo Preferred compounds are those which produce the more desirable biological activity.
Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.
The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid.
Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC
columns), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable.
Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active 5 starting materials.
In order to limit different types of isomers from each other reference is made to IUPAC
Rules Section E (Pure Appl Chem 45, 11-30, 1976).
10 The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g.
R- or S- isomers, or E- or Z-isomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention may be achieved by any suitable state of the art method, such as chromatography, especially 15 chiral chromatography, for example.
Further, the compounds of the present invention may exist as tautomers. For example, any compound of the present invention which contains a pyrazole moiety as a heteroaryl group for example can exist as a 1H tautomer, or a 2H tautomer, or even a mixture in any zo amount of the two tautomers, or a triazole moiety for example can exist as a 1H tautomer, a 2H tautomer, or a 4H tautomer, or even a mixture in any amount of said 1H, 2H and 4H
tautomers, namely:
-NH
N
N
N=i 1H-tautomer 2H-tautomer 4H-tautomer.
The present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio.
Further, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides.

The present invention also relates to useful forms of the compounds as disclosed herein, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and co-precipitates.
The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example as structural element of the crystal lattice of the compounds. The amount of polar solvents, in particular water, may exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc.
solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates.
Further, the compounds of the present invention can exist in free form, e.g.
as a free base, or as a free acid, or as a zwitterion, or can exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, customarily used in pharmacy.
The term "pharmaceutically acceptable salt" refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M.
Berge, etal. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1-19.
zo A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyI)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, persulfuric, 3-phenylpropionic, picric, pivalic, 2-hydroxyethanesulfonate, itaconic, sulfamic, trifluoromethanesulfonic, dodecylsulfuric, ethansulfonic, benzenesulfonic, para-toluenesulfonic, methansulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, hemisulfuric, or thiocyanic acid, for example.

Further, another suitably pharmaceutically acceptable salt of a compound of the present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, dicyclohexylamine, 1,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-aminomethane, aminopropandiol, sovak-base, 1-amino-2,3,4-butantriol. Additionally, basic nitrogen containing groups may be quaternised with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
Those skilled in the art will further recognise that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.
In the present text, in particular in the Experimental Section, for the synthesis of intermediates and of examples of the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form, as obtained by the respective preparation and/or purification process, is, in most cases, unknown.
Unless specified otherwise, suffixes to chemical names or structural formulae such as "hydrochloride", "trifluoroacetate", "sodium salt", or "x HCI", "x CF3000H", "x Na+", for example, are to be understood as not a stoichiometric specification, but solely as a salt form.
This applies analogously to cases in which synthesis intermediates or example compounds or salts thereof have been obtained, by the preparation and/or purification processes described, as solvates, such as hydrates with (if defined) unknown stoichiometric composition.

The salts include water-insoluble and, particularly, water-soluble salts.
Furthermore, derivatives of the compounds of formula (I) and the salts thereof which are converted into a compound of formula (I) or a salt thereof in a biological system (bioprecursors or pro-drugs) are covered by the invention. Said biological system is e.g. a mammalian organism, particularly a human subject. The bioprecursor is, for example, converted into the compound of formula (I) or a salt thereof by metabolic processes.
Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorphs, or as a mixture of more than one polymorphs, in any ratio.
In the context of the properties of the compounds of the present invention the term "pharmacokinetic profile" means one single parameter or a combination thereof including permeability, bioavailability, exposure, and pharmacodynamic parameters such as duration, or magnitude of pharmacological effect, as measured in a suitable experiment.
Compounds with improved pharmacokinetic profiles can, for example, be used in lower doses to achieve the same effect, may achieve a longer duration of action, or a may zo achieve a combination of both effects.
The term "combination" in the present invention is used as known to persons skilled in the art and may be present as a fixed combination, a non-fixed combination or kit-of-parts.
A "fixed combination" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present together in one unit dosage or in a single entity. One example of a "fixed combination" is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in admixture for simultaneous administration, such as in a formulation. Another example of a "fixed combination" is a pharmaceutical combination wherein the said first active ingredient and the said second active ingredient are present in one unit without being in admixture.
A non-fixed combination or "kit-of-parts" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present in more than one unit. One example of a non-fixed combination or kit-of-parts is a combination wherein the said first active ingredient and the said second active ingredient are present separately. The components of the non-fixed combination or kit-of-parts may be administered separately, sequentially, simultaneously, concurrently or chronologically staggered. Any such combination of a compound of formula (1) of the present invention with an anti-cancer agent as defined below is an embodiment of the invention.
The term "(chemotherapeutic) anti-cancer agents", includes but is not limited to 131I-chTNT, abarelix, abiraterone, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, aminoglutethimide, amrubicin, amsacrine, anastrozole, arglabin, arsenic trioxide, asparaginase, azacitidine, basiliximab, belotecan, bendamustine, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, bortezomib, buserelin, busulfan, cabazitaxel, calcium folinate, calcium levofolinate, capecitabine, carboplatin, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, cetuximab, chlorambucil, chlormadinone, chlormethine, cisplatin, cladribine, clodronic acid, clofarabine, copanlisib , crisantaspase, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, deslorelin, dibrospidium chloride, docetaxel, doxifluridine, doxorubicin, doxorubicin + estrone, eculizumab, edrecolomab, elliptinium acetate, eltrombopag, zo endostatin, enocitabine, epirubicin, epitiostanol, epoetin alfa, epoetin beta, eptaplatin, eribulin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, fadrozole, filgrastim, fludarabine, fluorouracil, flutamide, formestane, fotemustine, fulvestrant, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, glutoxim, goserelin, histamine dihydrochloride, histrelin, hydroxycarbamide, 1-125 seeds, ibandronic acid, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, interferon alfa, interferon beta, interferon gamma, ipilimumab, irinotecan, ixabepilone, lanreotide, lapatinib, lenalidomide, lenograstim, lentinan, letrozole, leuprorelin, levamisole, lisuride, lobaplatin, lomustine, lonidamine, masoprocol, medroxyprogesterone, megestrol, melphalan, mepitiostane, mercaptopurine, methotrexate, methoxsalen, Methyl aminolevulinate, methyltestosterone, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, nedaplatin, nelarabine, nilotinib, nilutamide, nimotuzumab, nimustine, nitracrine, ofatumumab, omeprazole, oprelvekin, oxaliplatin, p53 gene therapy, paclitaxel, palifermin, palladium-103 seed, pamidronic acid, panitumumab, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pegfilgrastim, peginterferon alfa-2b, pemetrexed, pentazocine, pentostatin, peplomycin, perfosfamide, picibanil, pirarubicin, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polysaccharide-K, porfimer sodium, pralatrexate, prednimustine, procarbazine, quinagolide, radium-223 chloride, raloxifene, raltitrexed, ranimustine, razoxane, refametinib , regorafenib, risedronic acid, rituximab, romidepsin, romiplostim, roniciclib , sargramostim, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sorafenib, 5 streptozocin, sunitinib, talaporfin, tamibarotene, tamoxifen, tasonermin, teceleukin, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, tioguanine, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trastuzumab, treosulfan, tretinoin, trilostane, triptorelin, trofosfamide, tryptophan, ubenimex, valrubicin, vandetanib, 10 vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, zorubicin.
It has now been found, and this constitutes the basis of the present invention, that said 15 compounds of the present invention have surprising and advantageous properties.
In particular, compounds according to the present invention have surprisingly been found to effectively be active as an antagonist or a negative allosteric modulator of P2X4.
An allosteric modulator is a substance which indirectly influences (modulates) the effects zo of an agonist or inverse agonist at a target protein, for example a receptor. Allosteric modulators bind to a site distinct from that of the orthosteric agonist binding site. Usually they induce a conformational change within the protein structure. A negative modulator (NAM) reduces the effects of the orthosteric ligand, but is inactive in the absence of the orthosteric ligand.
Commercial utility and medical indications As mentioned supra, the compounds of the present invention have surprisingly been found to to effectively be active as an antagonist or a negative allosteric modulator of P2X4.
A compound according to the invention is used for the manufacture of a medicament.
A further aspect of the invention is the use of the compounds according to formula (I), (la) or (lb) for the treatment or prophylaxis of a disease comprising administering an effective amount of a compound of formula (I), (la) or (lb).

In accordance with an aspect of the present invention therefore the invention relates to a compound of general formula (I) (la) or (lb), or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer particularly a pharmaceutically acceptable salt thereof, or a mixture of same, as described and defined herein, for use in the treatment or prophylaxis of a disease, especially for use in the treatment of a disease.
Preferably, the use of the compounds according to the present invention is in the treatment or prophylaxis of pain syndromes, especially the treatment, wherein the pain io syndromes is related to endometriosis as well as for the treatment of endometriosis as such.
Another aspect is the use of a compound of formula (I), (la) or (lb) is for the treatment of genitourinary, gastrointestinal, proliferative or pain-related disease, condition or disorder;
cancer; fibrotic diseases including lung fibrosis, heart fibrosis, kidney fibrosis and fibrosis of other organs; gynaecological diseases including dysmenorrhea, dyspareunia, endometriosis and adenomyosis; endometriosis-associated pain; endometriosis-associated symptoms, wherein said symptoms are in particular endometriosis-associated proliferation, dysmenorrhea, dyspareunia, dysuria, or dyschezia; endometriosis-associated proliferation; pelvic hypersensitivity; urethritis; prostatitis;
prostatodynia;
cystitis; idiopathic bladder hypersensitivity; gastrointestinal disorders including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, gastroesophageal reflux, gastrointestinal distension, Crohn's disease and the like; atherosclerosis; lipid disorders;
and pain-associated diseases selected from the group consisting of hyperalgesia, allodynia, functional bowel disorders (such as irritable bowel syndrome), arthritis (such as osteoarthritis and rheumatoid arthritis), burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer, traumatic nerve-injury, post-traumatic injuries (including fractures and sport injuries), trigeminal neuralgia, small fiber neuropathy, diabetic neuropathy, chronic arthritis and related neuralgias, HIV
and HIV treatment-induced neuropathy, pruritus; impaired wound healing and disease of the skeleton like degeneration of the joints, ankylosing spondylitis (Burnstock et al., 2012 Pharmacol Rev. 64:834-868).
According to a particular aspect of the invention as reported above a compound of formula (I), (la) or (lb) is for the treatment of pain syndromes (Trang and Salter, 2012, Purinergic Signalling 8:621-628; Burnstock , 2013 Eur J Pharmacol 716:24-40) including acute, chronic, inflammatory and neuropathic pain, preferably inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, endometriosis-associated pain, pain associated with fibrotic diseases, central pain, pain due to burning mouth syndrome, pain due to burns, pain due to migraine, cluster headaches, pain due to nerve injury, pain due to neuritis, neuralgias, pain due to poisoning, pain due to ischemic injury, pain due to interstitial cystitis, cancer pain, pain due to viral, parasitic or bacterial infections, pain due to traumatic nerve-injury, pain due to post-traumatic injuries (including fractures and sport injuries), pain due to trigeminal neuralgia, pain associated with small fiber neuropathy, pain associated with diabetic neuropathy, chronic lower back pain, phantom limb pain, pelvic pain syndrome, chronic pelvic pain, neuroma pain, complex regional pain syndrome, pain associated with gastrointestinal distension, chronic arthritic pain and related neuralgias, and pain associated with cancer, pain associated with chemotherapy, HIV and HIV treatment-induced neuropathy; and pain associated with diseases or disorders selected from the group consisting of hyperalgesia, allodynia, functional bowel disorders (such as irritable bowel syndrome) and arthritis (such as osteoarthritis and rheumatoid arthritis).
According to a further aspect of the invention as reported above a compound of formula (I), (la) or (lb) is for the treatment of amyotrophic lateral sclerosis Furthermore, a compound of formula (I), (la) or (lb) according ito the present invention is for use in the treatment of a gynecological disease, preferably dysmenorrhea, dyspareunia or endometriosis, adenomyosis, endometriosis-associated pain, or other endometriosis-associated symptoms, wherein said symptoms are in particular endometriosis-associated proliferation, dysmenorrhea, dyspareunia, dysuria, or dyschezia.
Pharmaceutical compositions of the compounds of the invention This invention also relates to pharmaceutical compositions containing one or more compounds of the present invention. These compositions can be utilised to achieve the desired pharmacological effect by administration to a patient in need thereof.
A patient, for the purpose of this invention, is a mammal, including a human, in need of treatment for the particular condition or disease.

Therefore, the present invention includes pharmaceutical compositions that are comprised of a pharmaceutically acceptable carrier or auxiliary and a pharmaceutically effective amount of a compound, or salt thereof, of the present invention.
Another aspect of the invention is a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of formula (I) and a pharmaceutically acceptable auxiliary for the treatment of a disease mentioned supra, especially for the treatment of haematological tumours, solid tumours and/or metastases thereof.
A pharmaceutically acceptable carrier or auxiliary is preferably a carrier that is non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient. Carriers and auxiliaries are all kinds of additives assisting to the composition to be suitable for administration.
A pharmaceutically effective amount of compound is preferably that amount which produces a result or exerts the intended influence on the particular condition being treated.
The compounds of the present invention can be administered with pharmaceutically-acceptable carriers or auxiliaries well known in the art using any effective conventional dosage unit forms, including immediate, slow and timed release preparations, orally, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, zo and the like.
For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions. The solid unit dosage forms can be a capsule that can be of the ordinary hard- or soft-shelled gelatine type containing auxiliaries, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and corn starch.
In another embodiment, the compounds of this invention may be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with binders such as acacia, corn starch or gelatine, disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, gum tragacanth, acacia, lubricants intended to improve the flow of tablet granulation and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example talc, stearic acid, or magnesium, calcium or zinc stearate, dyes, colouring agents, and flavouring agents such as peppermint, oil of wintergreen, or cherry flavouring, intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient.
Suitable excipients for use in oral liquid dosage forms include dicalcium phosphate and diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance tablets, pills or capsules may be coated with shellac, sugar or both.
Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.
Additional excipients, for example those sweetening, flavouring and colouring agents described above, may also be present.
The pharmaceutical compositions of this invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil such as liquid paraffin or a mixture of zo vegetable oils. Suitable emulsifying agents may be (1) naturally occurring gums such as gum acacia and gum tragacanth, (2) naturally occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived form fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil such as, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent such as, for example, beeswax, hard paraffin, or cetyl alcohol. The suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate ; one or more colouring agents; one or more flavouring agents; and one or more sweetening agents such as sucrose or saccharin.

Syrups and elixirs may be formulated with sweetening agents such as, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, and preservative, such as methyl and propyl parabens and flavouring and colouring agents.
5 The compounds of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intraocularly, intrasynovially, intramuscularly, or interperitoneally, as injectable dosages of the compound in preferably a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol io such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethy1-1,1-dioxolane-4-methanol, ethers such as poly(ethylene glycol) 400, an oil, a fatty acid, a fatty acid ester or, a fatty acid glyceride, or an acetylated fatty acid glyceride, with or without the addition of a pharmaceutically acceptable surfactant such as a soap or a detergent, suspending agent 15 such as pectin, carbomers, methycellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agent and other pharmaceutical adjuvants.
Illustrative of oils which can be used in the parenteral formulations of this invention are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, petrolatum and mineral oil.
zo Suitable fatty acids include oleic acid, stearic acid, isostearic acid and myristic acid.
Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate. Suitable soaps include fatty acid alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example, alkyl, 25 aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates ; non-ionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and poly(oxyethylene-oxypropylene)s or ethylene oxide or propylene oxide copolymers; and amphoteric detergents, for example, alkyl-beta-aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.
30 The parenteral compositions of this invention will typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimise or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) preferably of from about 12 to about 17. The quantity of surfactant in such formulation preferably ranges from about 5% to about 15% by weight.
The surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.
Illustrative of surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
The pharmaceutical compositions may be in the form of sterile injectable aqueous suspensions. Such suspensions may be formulated according to known methods using io suitable dispersing or wetting agents and suspending agents such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia ; dispersing or wetting agents which may be a naturally occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadeca-ethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived form a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of an ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorbitan monooleate.
zo The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Diluents and solvents that may be employed are, for example, water, Ringer's solution, isotonic sodium chloride solutions and isotonic glucose solutions. In addition, sterile fixed oils are conventionally employed as solvents or suspending media. For this purpose, any bland, fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectables.
A composition of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are, for example, cocoa butter and polyethylene glycol.
Controlled release formulations for parenteral administration include liposomal, polymeric microsphere and polymeric gel formulations that are known in the art.

It may be desirable or necessary to introduce the pharmaceutical composition to the patient via a mechanical delivery device. The construction and use of mechanical delivery devices for the delivery of pharmaceutical agents is well known in the art.
Direct techniques for administration, for example, administering a drug directly to the brain usually involve placement of a drug delivery catheter into the patient's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of agents to specific anatomical regions of the body, is described in US Patent No. 5,011,472, issued April 30, 1991.
The compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired. Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized.
Such ingredients and procedures include those described in the following references, each of which is incorporated herein by reference: Powell, M.F. et al., "Compendium of Excipients for Parenteral Formulations" PDA Journal of Pharmaceutical Science &
Technology 1998, 52(5), 238-311 ; Strickley, R.G "Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1" PDA Journal of Pharmaceutical Science & Technology 1999, 53(6), 324-349 ; and Nema, S. et al., "Excipients and Their Use in Injectable Products" PDA Journal of Pharmaceutical zo Science & Technology 1997, 51(4), 166-171.
Commonly used pharmaceutical ingredients that can be used as appropriate to formulate the composition for its intended route of administration include:
acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid) ;
alkalinizing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine) ;
adsorbents (examples include but are not limited to powdered cellulose and activated charcoa)1 ;
aerosol propellants (examples include but are not limited to carbon dioxide, CCI2F2, F2CIC-CCIF2 and CCIF3) air displacement agents - examples include but are not limited to nitrogen and argon ;
antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate) ;
antimicrobial preservatives (examples include but are not limited to benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate and thimerosal) ;
antioxidants (examples include but are not limited to ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorus acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium io formaldehyde sulfoxylate, sodium metabisulfite) ;
binding materials (examples include but are not limited to block polymers, natural and synthetic rubber, polyacrylates, polyurethanes, silicones, polysiloxanes and styrene-butadiene copolymers) ;
buffering agents (examples include but are not limited to potassium metaphosphate, dipotassium phosphate, sodium acetate, sodium citrate anhydrous and sodium citrate dihydrate);
carrying agents (examples include but are not limited to acacia syrup, aromatic syrup, aromatic elixir, cherry syrup, cocoa syrup, orange syrup, syrup, corn oil, mineral oil, peanut oil, sesame oil, bacteriostatic sodium chloride injection and bacteriostatic water for zo injection);
chelatinq agents (examples include but are not limited to edetate disodium and edetic acid);
colourants (examples include but are not limited to FD&C Red No. 3, FD&C Red No. 20, FD&C Yellow No. 6, FD&C Blue No. 2, D&C Green No. 5, D&C Orange No. 5, D&C Red No. 8, caramel and ferric oxide red) ;
clarifying agents (examples include but are not limited to bentonite) ;
emulsifying agents (examples include but are not limited to acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyoxyethylene monostearate) ;

encapsulating agents (examples include but are not limited to gelatin and cellulose acetate phthalate), flavourants (examples include but are not limited to anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin) ;
humectants (examples include but are not limited to glycerol, propylene glycol and sorbitol) ;
leviqatinq agents (examples include but are not limited to mineral oil and glycerin) ;
oils (examples include but are not limited to arachis oil, mineral oil, olive oil, peanut oil, sesame oil and vegetable oil) ;
ointment bases (examples include but are not limited to lanolin, hydrophilic ointment, polyethylene glycol ointment, petrolatum, hydrophilic petrolatum, white ointment, yellow ointment, and rose water ointment) ;
penetration enhancers (transdermal delivery) (examples include but are not limited to monohydroxy or polyhydroxy alcohols, mono-or polyvalent alcohols, saturated or unsaturated fatty alcohols, saturated or unsaturated fatty esters, saturated or unsaturated dicarboxylic acids, essential oils, phosphatidyl derivatives, cephalin, terpenes, amides, ethers, ketones and ureas), plasticizers (examples include but are not limited to diethyl phthalate and glycerol) ;
solvents (examples include but are not limited to ethanol, corn oil, cottonseed oil, glycerol, zo isopropanol, mineral oil, oleic acid, peanut oil, purified water, water for injection, sterile water for injection and sterile water for irrigation) ;
stiffening agents (examples include but are not limited to cetyl alcohol, cetyl esters wax, microcrystalline wax, paraffin, stearyl alcohol, white wax and yellow wax) ;
suppository bases (examples include but are not limited to cocoa butter and polyethylene glycols (mixtures)) ;
surfactants (examples include but are not limited to benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbate 80, sodium lauryl sulfate and sorbitan mono-palmitate) ;

suspending agents (examples include but are not limited to agar, bentonite, carbomers, carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, kaolin, methylcellulose, tragacanth and veegum) ;
sweetening agents (examples include but are not limited to aspartame, dextrose, glycerol, 5 mannitol, propylene glycol, saccharin sodium, sorbitol and sucrose) ;
tablet anti-adherents (examples include but are not limited to magnesium stearate and talc) ;
tablet binders (examples include but are not limited to acacia, alginic acid, carboxymethylcellulose sodium, compressible sugar, ethylcellulose, gelatin, liquid 10 glucose, methylcellulose, non-crosslinked polyvinyl pyrrolidone, and pregelatinized starch) ;
tablet and capsule diluents (examples include but are not limited to dibasic calcium phosphate, kaolin, lactose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sodium carbonate, sodium phosphate, sorbitol and 15 starch) ;
tablet coating agents (examples include but are not limited to liquid glucose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, cellulose acetate phthalate and shellac) ;
tablet direct compression excipients (examples include but are not limited to dibasic zo calcium phosphate) ;
tablet disintegrants (examples include but are not limited to alginic acid, carboxymethylcellulose calcium, microcrystalline cellulose, polacrillin potassium, cross-linked polyvinylpyrrolidone, sodium alginate, sodium starch glycollate and starch) ;
tablet glidants (examples include but are not limited to colloidal silica, corn starch and 25 talc) ;
tablet lubricants (examples include but are not limited to calcium stearate, magnesium stearate, mineral oil, stearic acid and zinc stearate) ;
tablet/capsule opaquants (examples include but are not limited to titanium dioxide) ;

tablet polishing agents (examples include but are not limited to carnuba wax and white wax) ;
thickening agents (examples include but are not limited to beeswax, cetyl alcohol and paraffin) ;
tonicity agents (examples include but are not limited to dextrose and sodium chloride) ;
viscosity increasing agents (examples include but are not limited to alginic acid, bentonite, carbomers, carboxymethylcellulose sodium, methylcellulose, polyvinyl pyrrolidone, sodium alginate and tragacanth) ; and wetting agents (examples include but are not limited to heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, and polyoxyethylene stea rate).
Pharmaceutical compositions according to the present invention can be illustrated as follows:
Sterile i.v. solution: A 5 mg/ml solution of the desired compound of this invention can be made using sterile, injectable water, and the pH is adjusted if necessary. The solution is diluted for administration to 1 ¨ 2 mg/ml with sterile 5% dextrose and is administered as an i.v. infusion over about 60 minutes.
Lyophilised powder for i.v. administration: A sterile preparation can be prepared with (i) 100- 1000 mg of the desired compound of this invention as a lyophilised powder, (ii) 32-327 mg/ml sodium citrate, and (iii) 300 ¨ 3000 mg Dextran 40. The formulation is reconstituted with sterile, injectable saline or dextrose 5% to a concentration of 10 to 20 mg/ml, which is further diluted with saline or dextrose 5% to 0.2 ¨ 0.4 mg/ml, and is administered either IV bolus or by IV infusion over 15 ¨ 60 minutes.
Intramuscular suspension: The following solution or suspension can be prepared, for intramuscular injection:
50 mg/ml of the desired, water-insoluble compound of this invention 5 mg/ml sodium carboxymethylcellulose 4 mg/ml TVVEEN 80 9 mg/ml sodium chloride 9 mg/ml benzyl alcohol Hard Shell Capsules: A large number of unit capsules are prepared by filling standard two-piece hard galantine capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.
Soft Gelatin Capsules: A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried. The active ingredient can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.
io Tablets: A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg. of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg. of starch, and 98.8 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption.
Immediate Release Tablets/Capsules: These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication. The active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners.
These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction zo techniques. The drug compounds may be compressed with viscoelastic and thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.
Dose and administration Based upon standard laboratory techniques known to evaluate compounds useful for the treatment of pain syndromes, and particularly in endometriosis, by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication. The amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
The total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day. Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing. In addition, "drug holidays" in which a patient is not dosed with a drug for a certain period of time, may be beneficial to the overall balance between pharmacological effect and tolerability. A unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg. The average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
zo Of course the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.
Combination Therapies The term "combination" in the present invention is used as known to persons skilled in the art and may be present as a fixed combination, a non-fixed combination or kit-of-parts.
A "fixed combination" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present together in one unit dosage or in a single entity. One example of a "fixed combination" is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in admixture for simultaneous administration, such as in a formulation. Another example of a 'fixed combination" is a pharmaceutical combination wherein the said first active ingredient and the said second active ingredient are present in one unit without being in admixture.
A non-fixed combination or "kit-of-parts" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present in more than one unit. One example of a non-fixed combination or kit-of-parts is a combination wherein the said first io active ingredient and the said second active ingredient are present separately. The components of the non-fixed combination or kit-of-parts may be administered separately, sequentially, simultaneously, concurrently or chronologically staggered.
The compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects. The present invention relates also to such combinations.
Those combined pharmaceutical agents can be other agents having antiproliferative, antinociceptive and/or antiinflammatory effects such as for example for the treatment of haematological tumours, solid tumours and/or metastases thereof and/or agents for the zo treatment of different pain syndromes and/or undesired side effects.The present invention relates also to such combinations.
Other anti-hyper-proliferative agents suitable for use with the composition of the invention include but are not limited to those compounds acknowledged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition), editor Molinoff et al., publ. by McGraw-Hill, pages 1225-1287, (1996), which is hereby incorporated by reference, especially (chemotherapeutic) anti-cancer agents as defined supra.
Furhtermore, the compounds of this invention can be combined with known hormonal therapeutical agents.
In particular, the compounds of the present invention can be administered in combination or as comedication with hormonal contraceptives. Hormonal contraceptives are for example Combined Oral Contraceptives (COCs) or Progestin-Only-Pills (POPs) or hormone-containing devices.

COCs include but are not limited to birth control pills or a birth control method that includes a combination of an estrogen (estradiol) and a progestogen (progestin). The estrogenic part is in most of the COCs ethinyl estradiol. Some COCs contain estradiol or estradiol valerate.
5 Said COCs contain the progestins norethynodrel, norethindrone, norethindrone acetate, ethynodiol acetate, norgestrel, levonorgestrel, norgestimate, desogestrel, gestodene, drospirenone, dienogest, or nomegestrol acetate.
Birth control pills include for example but are not limited to Yasmin, Yaz, both containing ethinyl estradiol and drospirenone; Microgynon or Miranova containing levonorgestrel and 10 ethinyl estradiol; Marvelon containing ethinyl estradiol and desogestrel; Valette containing ethinyl estradiol and dienogest; Belara and Enriqa containing ethinyl estradiol and chlormadinonacetate; Qlaira containing estradiol valerate and dienogest as active ingredients; and Zoely containing estradiol and normegestrol.
POPs are contraceptive pills that contain only synthetic progestogens (progestins) and do 15 not contain estrogen. They are colloquially known as mini pills.
POPs include but are not limited to Cerazette containing desogestrel; and Micronor containing norethindrone.
Other Progeston-Only forms are intrauterine devices (IUDs), for example Mirena containing levonorgestrel or injectables, for example Depo-Provera containing zo medroxyprogesterone acetate.
A preferred embodiment of the present invention is the administration of a compound of general formula (I) in combination with a COO or a POP or other Progestin-Only forms as mentioned above.
25 Another preferred embodiment of the present invention is the administration of a compound of general formula (la) in combination with a COO or a POP or other Progestin-Only forms as mentioned above.
Methods of testing for a particular pharmacological or pharmaceutical property are well 30 known to persons skilled in the art.
The example testing experiments described herein serve to illustrate the present invention and the invention is not limited to the examples given.

As will be appreciated by persons skilled in the art, the invention is not limited to the particular embodiments described herein, but covers all modifications of said embodiments that are within the spirit and scope of the invention as defined by the appended claims.
The following examples illustrate the invention in greater detail, without restricting it.
Further compounds according to the invention, of which the preparation is not explicitly described, can be prepared in an analogous way.
The compounds, which are mentioned in the examples and the salts thereof represent preferred embodiments of the invention as well as a claim covering all subcombinations of the residues of the compound of formula (I) as disclosed by the specific examples.
The term "according to" within the experimental section is used in the sense that the procedure referred to is to be used "analogously to".
SYNTHESIS OF COMPOUNDS
The following schemes and general procedures illustrate general synthetic routes to the compounds of general formula (I) of the invention and are not intended to be limiting. It is zo obvious to the person skilled in the art that the order of transformations as exemplified in schemes 1 to 2 can be modified in various ways. The order of transformations exemplified in schemes 1 to 2 is therefore not intended to be limiting. In addition, interconversion of substituents, for example of residues R1, Rz, R3, R4, R5, R5a and R5b can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups, cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to the person skilled in the art. These transformations include those which introduce a functionality which allows for further interconversion of substituents.
Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999).
All reagents used for the preparation of the compounds of the invention are commercially available, known in the literature or can be prepared as described.

0..', O.
s¨ci ----NHW ""*NHW
R5 0 Cl, F NH2-W R5 Cl, F R2OH R5b 0 (--)R2 ---...
02N Rs 02N (.1 Rs 02N R5 R52 R5a R5a SNar j 2 0 // C) //
*--NHW Acylation/ ---NHW
Reduction R5b 0 0.R2 peptide coupling 0. R5b 0R
, 2 Rly.

N Rs R5a R3 R4 H R5a 4 1-7.. 5: W = PG ...¨

Deprotection

6: W= H
C) ,,C) 0.,/,0 O., ii Ss-NHW '-'11HW Acylation/ `S¨NHW
R5b Alkylation OH Reduction R5b OH peptide R5b OH
0 ______________________________________________________________ 02N 1.1 R5 H2N R IR N

R3 R4 H R5a R5a R5a AlkylationE 7 Scheme 1: General procedures for the preparation of compounds of general formula (I) corresponding to formula 6; R1, R2, R3, R4, R5, R5a and R5b are as defined in the description and claims of this invention, W corresponds to either a hydrogen atom or a protecting group PG (e.g., N-(dimethylamino)methylene, 2,4-dimethoxybenzyl).
Compounds of general formula 6 can by synthesized as depicted in Scheme 1.
Starting from the sulfonyl chloride the corresponding sulfonamides 2 can be obtained by reaction of ammonia or any amine in polar aprotic solvents such as dimethylformamide and acetonitrile. Subsequent nucleophilic aromatic substitution (SNar) reaction with alcohols or phenols in the presence of a base, e.g. cesium carbonate or sodium hydride, in dimethylformamide or acetonitrile yield intermediates of general formula 3.
Subsequent reduction under hydrogenation conditions, in polar solvents such as ethanol or tetrahydrofurane in the presence of for example Pd-, Pt- or Sn- based catalysts yield the aniline derivatives with general formula 4. Subsequent acylation to the corresponding amides for example by reaction with acyl chlorides or by standard peptide bond formation using all known procedures, such as reaction of the corresponding carboxylic acid in the presence of a coupling reagent e.g. HATU, and for W equals a protecting group subsequent deprotection with e.g. trifluoroacetic acid (TFA), results in compounds of general formula 6.
Alternatively starting from intermediate 7, which can be derived from intermediate 2 through reaction with hydroxide in various solvents such as DMF, alkylation with any alkylation reagent such as bromides in the presence of a base or reaction with the corresponding boronic acids in the presence of a suitable catalyst, e.g.
copper(I1)acetate (see for example Tetrahedron Letters, 1998, 39, 2937-2940.), leads to 3 and according to the procedures described above to final compounds with general formula 6. In addition intermediate 7 can be converted to the corresponding aniline derivatives 8 and by acylation and alkylations procedures, followed by deprotection (for W = PG) be converted to compounds 6.
NH2 1) Diazotisation/
0 , r ,0 /2 sulfur-source R5byCl 2) Ammonia NS"-NH
R2OH 5b 0 ____________________________ R5b2C1 __________________________________________________________________ .. R.,)r ,R2 BrI N I
==,,,i,õõ, R5a Br Br N
R5a R5a IBuchwald Amination 0, //0 o `s:N1-102, R1 Acylation I N'S ¨NW
_____________________________________________________ R,,1C) 5b ........ , 2 R
)NN
R3'1a H Y
R- R5a R5a 13:Y = -N=CAr2 14:Y = -NH2 Scheme 2: General procedure for the preparation of compounds of general formula (1) corresponding to formula 15; R1, R2, R3, R4, R5a and R5b are as defined in the description and claims of this invention, W corresponds to either hydrogen or a protecting group (e.g., N-(dimethylamino)methylene, 2,4-dimethoxybenzyl) and Ar is aryl.
Diazotisation of 5-bromo-2-chloropyridin-3-amine using for example sodium nitrite in aqueous acid solution and subsequent transformation to the corresponding sulfonamide using a sulfonyl chloride source such as thionyl chloride in water followed by amination results in intermediate 11 (see for example J. Med. Chem., 2014, 57, 5, 2091-2106).
Reaction with any nucleophiles undergoing aromatic nucleophilic substitution e.g.
aromatic and aliphatic alcohols in the presence of base result in intermediate 12. Using protection and deprotection strategies, Buchwald amination in the presence of suitable catalysts (see for example W02011120026A1) lead to intermediates 14 which can be converted to the final compounds of general formula 15 by acylation to the corresponding amides for example by reaction with acyl chlorides or by standard peptide bond formation using all known procedures, such as reaction of the corresponding carboxylic acid in the presence of a coupling reagent e.g. HATU.
The compounds according to the invention are isolated and purified in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such zo as chromatography on a suitable support material. Furthermore, reverse phase preparative HPLC of compounds of the present invention which possess a sufficiently basic or acidic functionality, may result in the formation of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example. Salts of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays.
Additionally, the drying process during the isolation of compounds of the present invention may not fully remove traces of cosolvents, especially such as formic acid or trifluoroacetic acid, to give solvates or inclusion complexes. The person skilled in the art will recognise which solvates or inclusion complexes are acceptable to be used in subsequent biological assays. It is to be understood that the specific form (e.g. salt, free base, solvate, inclusion complex) of a compound of the present invention as isolated as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity.

Salts of the compounds of formula (I) according to the invention can be obtained by dissolving the free compound in a suitable solvent (for example a ketone such as acetone, methylethylketone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low 5 molecular weight aliphatic alcohol such as methanol, ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added. The acid or base can be employed in salt preparation, depending on whether a mono-or polybasic acid or base is concerned and depending on which salt is desired, in an equimolar quantitative ratio or one differing therefrom. The salts are obtained by filtering, 10 reprecipitating, precipitating with a non-solvent for the salt or by evaporating the solvent.
Salts obtained can be converted into the free compounds which, in turn, can be converted into salts. In this manner, pharmaceutically unacceptable salts, which can be obtained, for example, as process products in the manufacturing on an industrial scale, can be converted into pharmaceutically acceptable salts by processes known to the person 15 skilled in the art. Especially preferred are hydrochlorides and the process used in the example section.
Pure diastereomers and pure enantiomers of the compounds and salts according to the invention can be obtained e.g. by asymmetric synthesis, by using chiral starting zo compounds in synthesis and by splitting up enantiomeric and diasteriomeric mixtures obtained in synthesis.
Enantiomeric and diastereomeric mixtures can be split up into the pure enantiomers and pure diastereomers by methods known to a person skilled in the art.
Preferably, 25 diastereomeric mixtures are separated by crystallization, in particular fractional crystallization, or chromatography. Enantiomeric mixtures can be separated e.g. by forming diastereomers with a chiral auxilliary agent, resolving the diastereomers obtained and removing the chiral auxilliary agent. As chiral auxilliary agents, for example, chiral acids can be used to separate enantiomeric bases such as e.g. mandelic acid and chiral 30 bases can be used to separate enantiomeric acids by formation of diastereomeric salts.
Furthermore, diastereomeric derivatives such as diastereomeric esters can be formed from enantiomeric mixtures of alcohols or enantiomeric mixtures of acids, respectively, using chiral acids or chiral alcohols, respectively, as chiral auxilliary agents. Additionally, diastereomeric complexes or diastereomeric clathrates may be used for separating 35 enantiomeric mixtures. Alternatively, enantiomeric mixtures can be split up using chiral separating columns in chromatography. Another suitable method for the isolation of enantiomers is the enzymatic separation.
One preferred aspect of the invention is the process for the preparation of the compounds of claims 1-6 according to the examples, as well as the intermediates used for their preparation.
Optionally, compounds of the formula (I) can be converted into their salts, or, optionally, salts of the compounds of the formula (I) can be converted into the free compounds.
Corresponding processes are customary for the skilled person.
EXPERIMENTAL PART
Abbreviations The following table lists the abbreviations used in this paragraph and in the Intermediate Examples and Examples section as far as they are not explained within the text body.
Abbreviation Meaning AcOH acetic acid (ethanoic acid) aq. aqueous avg average boc t-butoxycarbonyl br broad Cl chemical ionisation doublet -DAD diode array detector DBU 1 ,8-Diazabicyclo(5.4.0)undec-7-ene DCM dichloromethane dd double-doublet DIPEA diisopropylethylamine DMF N, N-dimethylformamide DMSO dimethyl sulfoxide ELSD Evaporative Light Scattering Detector Et0Ac ethyl acetate Et0H ethanol eq. equivalent ESI electrospray (ES) ionisation HATU 11bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate HPLC high performance liquid chromatography LC-MS liquid chromatography mass spectrometry multiplet MeCN acetonitrile Me0H methanol MS mass spectrometry MTBE methyl tert-butylether NMR nuclear magnetic resonance spectroscopy: chemical shifts (6) are given in ppm. The chemical shifts were corrected by setting the DMSO signal to 2.50 ppm unless otherwise stated.
PDA Photo Diode Array PoraPakTM; a HPLC column obtainable from Waters quartet quant. quantitative r.t. or rt room temperature Rt retention time (as measured either with HPLC or UPLC) in minutes singlet SM starting material SQD Single-Quadrupol-Detector triplet td dublett of a triplet triplett of a dublet TEA triethylamine THF tetrahydrofuran UPLC ultra performance liquid chromatography Other abbreviations have their meanings customary per se to the skilled person.
The various aspects of the invention described in this application are illustrated by the following examples which are not meant to limit the invention in any way.

Specific Experimental Descriptions NMR peak forms in the following specific experimental descriptions are stated as they appear in the spectra, possible higher order effects have not been considered.
Reactions employing microwave irradiation may be run with a Biotage Initator microwave oven optionally equipped with a robotic unit. The reported reaction times employing microwave heating are intended to be understood as fixed reaction times after reaching the indicated reaction temperature. The compounds and intermediates produced according to the methods of the invention may require purification. Purification of organic compounds is well known to the person skilled in the art and there may be several ways of purifying the same compound. In some cases, no purification may be necessary. In some cases, the compounds may be purified by crystallization. In some cases, impurities may be stirred out using a suitable solvent. In some cases, the compounds may be purified by chromatography, particularly flash column chromatography, using for example prepacked silica gel cartridges, e.g. from Separtis such as Isolute Flash silica gel or Isolute Flash NH2 silica gel in combination with a Isolera autopurifier (Biotage) and eluents such as gradients of e.g. hexane/ethyl acetate or DCM/methanol. In some cases, the compounds may be purified by preparative HPLC using for example a Waters autopurifier equipped zo with a diode array detector and/or on-line electrospray ionization mass spectrometer in combination with a suitable prepacked reverse phase column and eluents such as gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia. In some cases, purification methods as described above can provide those compounds of the present invention which possess a sufficiently basic or acidic functionality in the form of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example. A salt of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays. It is to be understood that the specific form (e.g. salt, free base etc) of a compound of the present invention as isolated as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity.

The percentage yields reported in the following examples are based on the starting component that was used in the lowest molar amount. Most reaction conditions were not optimized for yield. Air and moisture sensitive liquids and solutions were transferred via syringe or cannula, and introduced into reaction vessels through rubber septa.
Commercial grade reagents and solvents were used without further purification.
The term "concentrated in vacuo" refers to use of a Buchi rotary evaporator at a minimum pressure of approximately 15 mm of Hg. All temperatures are reported uncorrected in degrees Celsius ( C).
In order that this invention may be better understood, the following examples are set forth.
These examples are for the purpose of illustration only, and are not to be construed as limiting the scope of the invention in any manner. All publications mentioned herein are incorporated by reference in their entirety.
Analytical LC-MS and UPLC-MS conditions LC-MS and UPLC-MS data given in the subsequent specific experimental descriptions refer (unless otherwise noted) to the following conditions:
Method A
zo Instrument: Waters Acquity UPLC-MS SingleQuad; Column: Acquity UPLC BEH
C18 1.7 pm, 50x2.1mm; eluent A: water + 0.1 vol % formic acid (99%), eluent B:
acetonitrile;
gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 ml/min; temperature:
60 C;
DAD scan: 210-400 nm.
Method B
Instrument: Waters Acquity UPLC-MS SingleQuad; Column: Acquity UPLC BEH C18 1.7 pm, 50x2.1mm; eluent A: water + 0.2 vol % aqueous ammonia (32%), eluent B:
acetonitrile; gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 ml/min;

temperature: 60 C; DAD scan: 210-400 nm.
Method C
Instrument: Waters Acquity UPLC-MS SingleQuad; Column: Acquity UPLC BEH C18 1.7 pm, 50x2.1mm; eluent A: water + 0.1 vol % formic acid (99%), eluent B:
acetonitrile;

gradient: 0-1.7 min 1-45% B, 1.7-1.72 min 45-99% B, 1.72-2.0 min 99% B; flow 0.8 ml/min; temperature: 60 C; DAD scan: 210-400 nm.
Method D
5 Instrument: Waters Acquity UPLC-MS SingleQuad; Column: Acquity UPLC BEH
C18 1.7 50x2.1mm; eluent A: water + 0.1 vol % formic acid (99%), eluent B:
acetonitrile; gradient:
0-4.5 min 1-99% B, 4.5-5.0 min 99% B; flow 0.8 ml/min; temperature: 60 C; DAD
scan:
210-400 nm.
10 Method E (chiral HPLC) Instrument: Agilent HPLC 1260; Saule: Chiralpak IA 3p 100x4,6mm; eluent A:
hexan +
0.1% vol. diethylamine (99%), eluent B: ethanol; isocratic: 60%A + 40%B; flow 1.0 mL/min; temperature: 25 C; injection: 5 pl; DAD @ 254 nm 15 Method F
Instrument: Waters Acquity UPLC-MS SingleQuad; Column: Acquity UPLC BEH C18 1.7 pm, 50x2.1mm; eluent A: water + 0.1 vol % trifluoroacetic acid (99%), eluent B:
acetonitrile; gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 ml/min;

temperature: 60 C; DAD scan: 210-400 nm.
Method G
Instrument: Waters Acquity UPLC-MS SingleQuad; Column: Acquity UPLC BEH C18 1.7 pm, 50x2.1mm; eluent A: water + 0.2 vol % aqueous ammonia (32%), eluent B:
acetonitrile; gradient: 0-4.5 min 5-95% B, 4.5-5.0 min 95% B; flow 0.8 ml/min;
temperature: 50 C; DAD scan: 210-400 nm.
Method H
Instrument: Waters Acquity UPLCMS SingleQuad; Column: Acquity UPLC BEH C18 1.7 pm, 50x2.1mm; eluent A: water + 0.1 vol % formic acid (99%), eluent B:
methanol;
gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 ml/min; temperature:
60 C;
DAD scan: 210-400 nm.

Method I
Instrument: Waters Acquity UPLCMS SingleQuad; Column: Acquity UPLC BEH C18 1.7 pm, 50x2.1mm; eluent A: water + 0.1 vol % trifluoroacetic acid, eluent B:
acetonitrile;
gradient: 0-4.5 min 5-95% B, 4.5-5.0 min 95% B; flow 0.8 ml/min; temperature:
50 C;
DAD scan: 210-400 nm.
Method J
Instrument: Agilent 1290 UHPLCMS Tot column: BEH C 18 (Waters) 1.7 pm, 50x2.1mm;
eluent A: water + 0.05 Vol-% formic acid (99%), eluent B: acetonitrile + 0.05%
formic acid;
io gradient: 0-1.7 min 98-10% A, 1.7-2.0 min 10% A, 2.0-2.5 min 10-98% A, flow 1.2 ml/min;
temperature: 60 C; DAD scan: 210-400 nm.
Flash column chromatography conditions "Purification by (flash) column chromatography" as stated in the subsequent specific experimental descriptions refers to the use of a Biotage Isolera purification system. For technical specifications see "Biotage product catalogue" on www.biotage.com.
Determination of optical rotation conditions Optical rotations were measured using a JASCO P2000 Polarimeter at 589 nm zo wavelength, temperature 20 C, integration time 10 s and path length 100 mm. The solvent and concentration are specified in the examples.

General Experimental Procedures CH
i 3 CH

0 0,CH3 VI 0 0 0,CH3 CWI,,NEI (-.WINEI
S S
Rsb F
0, +fA CI or R5b0, 2 N I
_õ...

0,N.rA
ii II
0 R5a 0 R5a A B
General Procedure GP1.1 (nucleophilic aromatic substitution with cesium carbonate) Sulfonamide A (1.29 mmol) was dissolved in acetonitrile (10 mL) and cesium carbonate (1.29 mmol, 1.0 eq) and the corresponding alcohol (1.29 mmol, 1.0 eq) were added.
Stirring was continued at 85 - 100 C until TLC showed consumption of starting material.
The solvent was removed under reduced pressure, followed by addition of water and dichloromethane. Afterwards, the phases were separated, the organic phase was dried and it was concentrated in vacuo. The crude was either used without further purification or purified as indicated in the examples.
General Procedure GP1.2 (nucleophilic aromatic substitution with sodium hydride) Sulfonamide A (1.29 mmol) was dissolved in dimethylformamide (20 mL) and the corresponding alcohol (1.94 mmol, 1.5 eq) was added followed by the addition of sodium hydride (9.05 mmol, 1.5 eq). Stirring was continued for aliphatic alcohols at room temperature and for phenols at 110 C until TLC showed consumption of starting material.
The reaction mixture was cooled to 0 C and water and ethyl acetate was carefully added.
zo Afterwards, the phases were separated and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were dried and concentrated in vacuo.
The crude was either used without further purification or purified as indicated in the examples.

General Procedure GP1.3 (nucleophilic aromatic substitution with potassium carbonate) Sulfonamide A (1.29 mmol) was dissolved in dimethylformamide (20 mL) and the corresponding alcohol (1.94 mmol, 1.5 eq) was added followed by the addition of potassium carbonate (9.05 mmol, 1.5 eq). Stirring was continued at 100 C until TLC
showed consumption of starting material. The reaction mixture was cooled to 0 C and water and ethyl acetate was carefully added. Afterwards, the phases were separated and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were dried and concentrated in vacuo. The crude was either used without further io purification or purified as indicated in the examples.
CH

0,CH3 1011,NH
R5b0, R2 R" O.R2 0 R5a Rd General Procedure GP2.1 (reduction with hydrogen on Pd/C) Nitro compound B (0.85 mmol) was dissolved in tetrahydrofuran (25 mL) and Pd/C
(0.09 Mind, 0.1 eq) was added. The flask was evacuated three times and flushed with hydrogen (1 bar) and stirring was continued at room temperature. After completion of the reaction, the mixture was filtered and concentrated in vacuo. The crude was used without further purification.
zo General Procedure GP2.2 (reduction with tinn(I1)chloride dehydrate) Nitro compound B (1.29 mmol) was dissolved in dioxane (6 mL) and tinn(I1)chloride dihydrate (6.46 mmol, 5.0 eq) was added and the reaction mixture was stirred for 2h at 70 C. After cooling to room temperature the reaction mixture was filtered and concentrated in vacuo. The filtrate was either used without further purification or purified as indicated in the examples.

General Procedure GP2.3 (reduction with iron) Nitro compound B (2.6 mmol) was dissolved in tetrahydrofuran/methanol (40 mL
1/1 v/v) and added to a solution of ammonium chloride (13 mmol, 5.0 eq) and iron powder (13 mmol, 5.0 eq) in water (40 mL). The reaction mixture was heated for 2h at 80 -90 C. After cooling to room temperature the reaction mixture was filtered via Celite, washed with methanol and the filtrate was concentrated in vacuo. The crude was dissolved in ethyl acetate and the organic phase was washed with water. The aqueous phase was extracted three times with ethyl acetate, the combined organic phases were dried and concentrated in vacuo. The crude was used without further purification.
CH CH

0 0,CH3 I

A
R5a R3 R4 H
R5a General procedure GP3.1 (acylation with HATU ) Amino compound C (0.17 mmol) was dissolved in dimethylformamide (5 mL) followed by the addition of the corresponding acid (0.2 mmol), N,N-diisopropylethylamine (0.15 mL, 0.8 mmol) and HATU (131 mg, 0.33 mmol). The reaction mixture was either stirred overnight at room temperature or heated at 50 C until TLC showed consumption of starting material. After cooling to r.t. ethyl acetate and water were added to the reaction zo mixture and phases were separated. The aqueous phase was extracted three times with ethyl acetate and the combined organic phase was dried and the solvent was removed under reduced pressure. The crude was used without further purification.

General procedure GP3.2 (acylation with HATU) Substituted aniline C (1.29 mmol) was dissolved in dimethylformamide (6 mL) followed by the addition of the corresponding acid (1.42 mmol, 1.1 eq), N,N-diisopropylethylamine (6.46 mmol, 5.0 eq) and HATU (2.07 mmol, 1.6 eq). The reaction mixture was either 5 stirred overnight at room temperature or heated at 50 C until TLC showed consumption of starting material. After cooling to room temperature the reaction mixture was concentrated in vacuo. Ethyl acetate and water were added, the organic phase was dried and concentrated in vacuo. The crude was used without further purification.
10 General procedure GP3.3 (acylation with HATU) Substituted aniline C (0.25 mmol), the corresponding acid (0.50 mmol, 2.0 eq), HATU
(0.50 mmol, 2.0 eq) and N-methylmorpholine (1.0 mmol, 2.0 eq) were dissolved in NMP
(2.83 mL, containing 2.5 % DMAP) and were stirred for 2h at room temperature, followed bei stirring overnight at 60 C. The reaction mixture was concentrated in vacuo and the 15 crude was used without further purification.
General procedure GP3.4 (acylation with acid chlorides) Amino compound C (0.17 mmol) was dissolved in dimethylformamide (5 mL) followed by the addition of the corresponding acid chloride (0.6 mmol), potassium carbonate (0.5 zo mmol). The reaction mixture was stirred at room at 100 C until TLC
showed consumption of starting material. After cooling to r.t. dichloromethane and water were added to the reaction mixture and phases were separated. The aqueous phase was extracted three times with ethyl acetate and the combined organic phase was dried and the solvent was removed under reduced pressure. The crude was used without further purification.
H3C1 C''CCFI3 0.,11NH
R5brO.R2 OR I Lj...R2 RNA RNõA

R

General procedure GP4 (deprotection of 2,4-dimethoxybenzyl sulfonamides) Crude amide D (1.29 mmol) was dissolved in dichloromethane (5-10 mL), trifluoroacetic acid (64.5 mmol, 50 eq) was added and the reaction mixture was stirred at room temperature until TLC showed consumption of starting material. The reaction mixture was concentrated in vacuo, ethyl acetate and water were added to the crude and the organic phase was dried and the solvent was removed under reduced pressure. The resulting residue was purified as indicated in the examples. Purification without aqueous extraction was also possible but made the HPLC purification more difficult.
General procedure GP5 (alkylation of hydroxyarylsulfonamides) 0.II'SNH, 0,NH, ' 'S ' Rst) OH
_ R
.. 510, 2 FR1LN i A
,.
RIA)LNA
i H i H
,1 R: R4 R5a R R R5 F G
Substituted phenol F (0.20 mmol) was dissolved in dimethyl formannide (3 - 5 mL), cooled in an ice bath and treated with sodium hydride (55% purity, 0.24 mmol, 1.2 eq). After stirring for 20 min the corresponding alkyl or benzyl halide (0.30 mmol, 1.5 eq) was added and the reaction mixture was allowed to warm up and was stirred at room temperature (if not indicated otherwise) until TLC showed consumption of starting material.
Water and ethyl acetate were added, the organic phase was washed twice with water, dried and concentrated in vacuo. The crude was purified as indicated in the examples to yield pure zo final compound.

Synthesis of Intermediates Intermediate 001 2-Chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide O..

OH
0-.11õN
Cl O., ON

To a solution of 2-chloro-5-nitrobenzenesulfonamide (10.8 g, 42.2 mmol) in dichloromethane (108 mL) was added sodium bicarbonate (7.09 g, 84.4 mmol) and 1-(2,4-dimethoxyphenyl)methanamine (7.05 g, 42.2 mmol). The mixture was stirred overnight.
The reaction mixture was concentrated in vacuo, followed by addition of water (75 mL) and ethyl acetate (75 mL). After stirring for 10 min the resulting precipitate was separated by filtration and it was dried at 40 C overnight in vacuo to yield 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (14.1 g, 36.5 mmol, 86 % yield).
LC-MS (Method A): Rt = 1.17 min MS (ESIneg): m/z = 385 (M-H) 11-I-NMR (400MHz, DMSO-d6) 8 [ppm]: 3.56 (s, 3H), 3.61 (s, 3H), 4.08 (s, 2H), 6.10 (d, 1H), 6.26 (dd, 1H), 7.04 (d, 1H), 7.79 (d, 1H), 8.19 (d, 1H), 8.28 (dd, 1H), 8.45 (s, 1H).
Intermediate 002 N-(2,4-DimethoxybenzyI)-2-fluoro-5-nitrobenzenesulfonamide 0,CH.
OH

C)N.

To a solution of 1-(2,4-dimethoxyphenyl)methanamine (0.669 g, 4.00 mmol) in dichloromethane (40 mL) was added under ice cooling N-ethyl-N-isopropylpropan-amine (1.29 g, 10.0 mmol). Over 25 min a solution of 2-fluoro-5-nitrobenzenesulfonyl chloride (0.958 g, 4.00 mmol) in dichloromethane (10 mL) was slowly added.
Stirring was continued under ice cooling for 2h, followed by stirring at room temperature overnight. It was washed with water, dried over sodium sulfate and concentrated in vacuo.
Column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) gave N-(2,4-dimethoxybenzyI)-2-fluoro-5-nitrobenzenesulfonamide (400 mg, 1.08 mmol, 27 % yield, purity 70 %).
LC-MS (Method A): Rt = 1.12 min MS (ESIneg): m/z = 369 (M-H) Intermediate 003 2,4-Dichloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide OH 40 O., CHON
Ci 0,N=
0 Cl To a suspension of 2,4-dichloro-5-nitrobenzenesulfonyl chloride (900 mg, 3.10 mmol) and sodium bicarbonate (521 mg, 6.20 mmol) in dichloromethane (10 mL) was added at 0 C a solution of 1-(2,4-dimethoxyphenyl)methanamine (518 mg, 3.10 mmol) in dichloromethane (10 mL). The reaction was stirred overnight at room temperature, water was added and the organic phase was separated and dried over sodium sulfate. Concentration in vacuo gave crude 2,4-dichloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1.30 g, quant.) which was used without further purification in the next steps.
LC-MS (Method A): Rt = 1.26 min MS (neg): m/z = 419 (M-H) Intermediate 004 N-(2,4-DimethoxybenzyI)-2,3-difluoro-5-nitrobenzenesulfonamide 0, 11, CH3 OH
ON
F (-2$CH3 0,N, IS

To a solution of 2,3-difluoro-5-nitrobenzenesulfonyl chloride (5.0 g, 19.3 mmol) in dichloromethane (50 mL) was added sodium bicarbonate (3.25 g, 38.6 mmol) and 1-(2,4-dimethoxyphenyl)methanamine (3.23 g, 19.3 mmol). The mixture was washed with water and extracted with ethyl acetate, the organic phases were dried over sodium sulfate and concentrated in vacuo. Crystallization from n-hexane/ethyl acetate gave N-(2,4-dimethoxybenzyI)-2,3-difluoro-5-nitrobenzenesulfonamide (3.25 g, 8.37 mmol, 43 '3/0 yield, 99% purity).
LC-MS (Method A): Rt = 1.48 min MS (neg): m/z = 387 (M-I-1) Intermediate 005 2-(3-Chlorophenoxy)-N-(2,4-dimethoxybenzyI)-3-fluoro-5-nitrobenzenesulfonamide CH

0 0,oH3 0,N, 1101 Cesium carbonate (2.73 g, 8.38 mmol) and 3-chlorophenol (1.08 g, 8.38 mmol) were added at 0 C to a solution of N-(2,4-DimethoxybenzyI)-2,3-difluoro-5-nitrobenzenesulfonamide (3.25 g, 8.38 mmol) in acetonitrile (50 mL), followed by stirring at room temperature until TLC showed consumption of starting material. The mixture was washed with water and extracted with ethyl acetate, the organic phases were dried over sodium sulfate and concentrated in vacuo to give crude 2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzy1)-3-fluoro-5-nitrobenzenesulfonamide in quantitative yield (4.16 g, 8.38 mmol).

LC-MS (Method A): Rt = 1.60 min MS (neg): m/z = 495 (M-H).
Intermediate 006 5 5-Amino-2-(3-chlorophenoxy)-3-fluorobenzenesulfonamide 0 a CI
To a solution of crude 2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyI)-3-fluoro-5-nitrobenzenesulfonamide (4.16 g, 8.38 mmol) in dioxane (150 mL) was slowly added tin(I1)chloride dihydrate (10.2 g, 45.1 mmol). After stirring at room temperature overnight, 10 the mixture was washed with water and extracted with ethyl acetate, the organic phases were dried over sodium sulfate and concentrated in vacuo. Chromatography on a Biotage Isolera system (silica gel, gradient n-hexane/ethyl acetate gradient) led to 5-amino-2-(3-chlorophenoxy)-3-fluorobenzenesulfonamide of around 70% purity which was used without further purification in the following acylation step.
15 LC-MS (Method A): Rt = 1.12 min MS (pos): m/z = 317 (M+H)+
Intermediate 007 5-Amino-2-hydroxybenzenesulfonamide ."S
OH

To a solution of 2-hydroxy-5-nitrobenzenesulfonamide (10.9 g, 50.0 mmol) in methanol (250 mL) was added under argon aqueous 2M-HCI (25 mL, 50 mmol) and 10% Pd/C
(1.5 g). After stirring under an atmosphere of hydrogen for 20 h, the catalyst was removed by filtration over a PTFE-membrane and the filtrate was concentrated in vacuo affording crude 5-amino-2-hydroxybenzenesulfonamide hydrochloride that was used in the next steps without further purification (11.2 g, 0.499 mmol, 99 % yield, 95%
purity).
LC-MS (Method C): Rt = 0.20 min MS (ESIneg): m/z = 187 (M-H) 1H-NMR (400MHz, deuterium oxide) 5 [ppm]: 7.23 (d, 1H), 7.57 (dd, 1H), 7.83 (d, 1H).
Intermediate 008 2-(2-ChlorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide O,NH'S 2 = o OH
CI
To a suspension of 5-amino-2-hydroxybenzenesulfonamide hydrochloride (2.25 g, 10.0 mmol) in tetrahydrofuran (75 mL) was added (2-chlorophenyl)acetic acid (1.88 g, 11 mmol), N,N-diisopropylethylamine (6.46 g, 50 mmol) and HATU (4.18 g, 11 mmol).
The reaction mixture was stirred overnight at room temperature. Then it was concentrated in vacuo, followed by extraction from ethyl acetate/water. The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo. Column chromatography on a Biotage lsolera system (silica gel, gradient dichloromethane to dichloromethane/methanol 80/20) led to 2-(2-chlorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide (1.60 g, 4.70 mmol, 47 % yield, 90% purity).
LC-MS (Method A): Rt = 0.85 min MS (ESIpos): m/z = 341 (M+H)*
1H NMR (400MHz, DMSO-d6) 8 [ppm]: 3.78 (s, 2H), 6.85 - 6.95 (m, 3H), 7.25 -

7.33 (m, 2H), 7.36 - 7.46 (m, 2H), 7.59 (dd, 1H), 7.93 (d, 1H), 10.17 (s, 1H), 10.39 (s, 1H).
Intermediate 009 2-(2-Chloro-3-fluorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide 00) CI
To a suspension of 5-amino-2-hydroxybenzenesulfonamide hydrochloride (0.450 g, 2.00 mmol) in tetrahydrofuran (20 mL) was added (2-chloro-3-fluorophenyl)acetic acid (0.415 g, 2.20 mmol), N,N-diisopropylethylamine (1.29 g, 10.0 mmol) and HATU (0.837 g, 2.20 mmol). The reaction mixture was stirred overnight at room temperature, followed by concentration in vacuo and extraction from ethyl acetate/water. The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo. As LC-MS
showed mostly bisacylated product the residue was redissolved in tetrahydrofuran and treated for 24 h with aqueous 1M-NaOH (15 mL). After removing tetrahydrofuran in vacuo, it was neutralized with diluted hydrochloric acid, followed by extraction with ethyl acetate.
The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo. Purification by preparative HPLC (Chromatorex 0-18 10pm, 125x30mm, acetonitrile/water + 0.1% formic acid) led to 2-(2-chloro-3-fluorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide (240 mg, 0.669 mmol, 331% yield, 99% purity).
LC-MS (Method A): Rt = 0.86 min MS (ESIpos): m/z = 359 (M+H)+
11-I-NMR (400MHz, DMS0-(16) zi [ppm]: 3.86 (s, 2H), 6.90 - 7.00 (m, 3H), 7.24 -7.41 (m, 3H), 7.60 (dd, 1H), 7.94 (d, 1H), 10.24 (s, 1H), 10.45 (s, 1H).
Intermediate 010 2-(2-Chloro-6-fluorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide 0,I1,-NH
'S 2 CI
To a suspension of 5-amino-2-hydroxybenzenesulfonamide hydrochloride (1.24 g, 5.50 mmol) in tetrahydrofuran (55 mL) was added (2-chloro-6-fluorophenyl)acetic acid (1.14 g, 6.05 mmol), N,N-diisopropylethylamine (3.55 g, 27.5 mmol) and HATU (2.3 g, 6.05 mmol).
The reaction mixture was stirred over a weekend at room temperature, followed by concentration in vacuo and extraction from ethyl acetate/water. The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo. As LC-MS
showed mostly bisacylated product the residue was redissolved in tetrahydrofuran and treated for 24 h with aqueous 1M-NaOH (30 mL). After removing tetrahydrofuran in vacuo, it was neutralized with diluted hydrochloric acid, followed by extraction with ethyl acetate.
The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo. Purification by preparative HPLC (Chromatorex 0-18 10pm, 125x30mm, acetonitrile/water + 0.1% formic acid) led to 2-(2-chloro-6-fluorophenyI)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide (55 mg, 0.153 mmol, 3 % yield, 99% purity).
LC-MS (Method A): Rt = 0.85 min MS (ESIpos): m/z = 359 (M+H)*
1H-NMR (400MHz, DMSO-d6) 8 [ppm]: 3.85 (d, 2H), 6.80 - 7.05 (m, 3H), 7.21 -7.27 (m, 1H), 7.32 - 7.42 (m, 2H), 7.58 (dd, 1H), 7.93 (d, 1H), 10.29 (s, 1H), 10.35 -10.68 (m, 1H).
Intermediate 011 5-Bromo-2-hydroxypyridine-3-sulfonamide 0=S 2 OH
BrN
Water (50 mL) was cooled to 0 C and within 1 h thionyl chloride (13.6 g, 119 mmol) was carefully added. The reaction mixture was allowed to warm to room temperature and zo stirring was continued overnight. Copper(l)chloride was added and the reaction mixture was cooled to -3 C.
In a separate flask, concentrated hydrochloric acid (27.2 mL) was carefully added under ice cooling to 3-amino-5-bromopyridin-2-ol (3.50 g, 16.9 mmol) at a speed that the temperature stayed below 30 C. After stirring for 15 min at that temperature it was cooled to -5 C and a solution of sodium nitrite (2.05 g, 29.7 mmol) in water (8 mL) was added over 45 min while the temperature was kept between -5 and 0 C. Stirring was continued for 10 min at -5 C, then this orange suspension was slowly added over 30 min at -5 to 0 C to the "thionyl chloride solution" from the beginning. Stirring was continued at 0 C for 75 min and the white precipitate was isolated by filtration, resulting in 3.5 g crude sulfonyl chloride.

This crude sulfonyl chloride was dissolved in methanol (300 mL) and ammonia in methanol (4.20 mL, 33%) was slowly added. Stirring was continued for 1 h before concentration in vacuo. The residue was stirred in n-hexane/ethyl acetate (1/1) and the precipitate was filtered off. 5-Bromo-2-hydroxypyridine-3-sulfonamide was obtained in sufficient purity by removing the solvent of the mother liquor under reduced pressure (953 mg, 5.51 mmol, 21 % yield, 95% purity) LC-MS (Method A): Rt = 0.50 min MS (ESIpos): m/z = 274 (M+H)+
1H-NMR (400 MHz, DMSO-d6) 8 [ppm]: 7.95 (s, 2H), 8.45 (d, 1H), 8.80 (d, 1H).
Intermediate 012 5-Bromo-2[3-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide ,NH.
0=S 2 I
Br F F
3-Trifluoromethylphenol (475 mg, 2.93 mmol) was added to sodium hydroxide (1.17 g, 2.93 mmol) in water (1 mL). After 30 min water was removed under reduced pressure and the resulting alcoholate was added to a solution of 5-bromo-2-hydroxypyridine-sulfonamide (795 mg, 2.93 mmol) in acetonitrile (10 mL), together with potassium carbonate (1.21 g, 8.78 mmol), cesium carbonate (954 mg, 2.93 mmol) and 3-trifluoromethylphenol (475 mg, 2.93 mmol). The reaction mixture was stirred overnight at zo 110 C, cooled to room temperature and the solvent was removed under reduced pressure. Water and dichloromethane were added for extraction, the phases were separated, the organic phase was dried and concentrated in vacuo. Column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) led to 5-bromo-2-[3-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide (290 mg, 0.73 mmol, 25% yield, 95% purity).
LC-MS (Method A): Rt = 1.22 min MS (ESIpos): m/z = 397/399 (M+H).
1H NMR (400MHz, DICHLOROMETHANE-d2) 8 [ppm]: 5.34 (s, 2H), 7.40 - 7.47 (m, 1H), 7.51 (s, 1H), 7.57 - 7.66 (m, 2H), 8.35 (d, 1H), 8.45 (d, 1H).

Intermediate 013 5-Amino-2[3-(trifluoromethyl)phenoxylpyridine-3-sulfonamide ,.NH
0=S 2 I

F F
5 5-Bromo-2[3-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide (280 mg, 0.705 mmol) was added to a solution of 1,1-dimethoxy-N,N-dimethylmethanamine (168 mg, 1.41 mmol) in dimethylformamide (5 mL), followed by stirring at room temperature for 1 h.
The solvent was removed in vacuo, it was extracted with ethyl acetate and water, the organic phase was dried and concentrated in vacuo to yield crude 5-bromo-N-10 [(dimethylamino)methylene]-243-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide.
Crude 5-bromo-N-[(dimethylamino)methylene]-243-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide from the previous step was redissolved in dioxane (5 mL), the flask was flushed with argon, followed by addition of Xantphos (38.4 mg, 0.0663 mmol), palladium(I1)acetate (7.45 mg, 0.0332 mmol), cesium carbonate (648 mg, 1.99 mmol) and 15 1,1-diphenylmethanimine (180 mg, 0.995 mmol). The reaction mixture was flushed again with argon, followed by stirring at 95 C overnight. It was cooled to room temperature, the solvent was removed under reduced pressure and the resulting residue was extracted with water and ethyl acetate. The organic phase was dried over sodium sulfate and the solvent was removed under reduced pressure to obtain crude zo N-[(dimethylamino)methylene]-5-[(diphenylmethylene)amino]-2-[3-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide.
Crude N-[(dimethylamino)methylene]-5-[(diphenylmethylene)amino]-243-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide was redissolved in ethanol (20 mL) and treated with 4N-HCI in dioxane (165 pL, 662 mmol), followed by stirring at room 25 temperature for 1 h. Solvent was removed under reduced pressure to obtain crude 5-amino-243-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide (300 mg crude material).
LC-MS (Method A): Rt = 0.97 min MS (ESIpos): m/z = 334 (M+H) Intermediate 014 N-(2,4-Dimethoxybenzy1)-5-nitro-24[2-(trifluoromethyl)pyrimidin-5-yl]oxy}benzenesulfonamide CH CH

0,0 NH
0":-S
N
0, = F

According to general procedure GP1.1 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (96.7 mg, 0.25 mmol) and 2-(trifluoromethyl)pyrimidin-5-ol (41 mg, 0.25 mmol) were converted to N-(2,4-dimethoxybenzy1)-5-nitro-24[2-(trifluoromethyppyrimidin-5-yl]oxylbenzenesulfonamide and were purified by column chromatography on a Biotage Isolera system (silica gel, gradient dichloromethane to dichloromethane/methanol 80/20) (80 mg, 0.156 mmol, 62 % yield, 98 % purity).
LC-MS (Method A): Rt = 1.27 min MS (ESIpos): m/z = 515 (M+H)+
11-I-NMR (400MHz, DMSO¨d6) ei [ppm]: 3.55 (s, 3H), 3.68 (s, 3H), 4.85 (s, 2H), 6.33 (d, 1H), 6.43 (dd, 1H), 7.11 (d, 1H), 7.19(d, 1H), 8.32 - 8.37 (m, 2H), 9.06(s, 2H).
Intermediate 015 2-(2-Chloropheny1)-N-(3-[(2,4-dimethoxybenzyl)sulfamoyl]-4-{[2-(trifluoromethyl)pyrimidin-5-yl]oxy}phenyl)acetamide ,..NH
(110 0 CI

According to general procedures GP2.2 and GP3.2 purified N-(2,4-dimethoxybenzy1)-5-nitro-24[2-(trifluoromethyppyrimidin-5-yl]oxylbenzenesulfonamide (77.2 mg, 0.15 mmol) and (2-chlorophenyl)acetic acid (38.4 mg, 0.23 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-(3-[(2,4-dimethoxybenzyl)sulfamoy1]-4-{[2-(trifluoromethyppyrimidin-5-yl]oxy}phenypacetamide and were purified by column chromatography on a Biotage lsolera system (silica gel, gradient dichloromethane/ethyl acetate) (35 mg, 0.0549 mmol, 37 % yield, 98 % purity).
LC-MS (Method A): Rt = 1.34 min MS (ESIpos): m/z = 637 (M+H)+
1H-NMR (400MHz, DMSO¨d6) o [ppm]: 3.58 (s, 3H), 3.69 (s, 3H), 3.79 (s, 2H), 4.84 (s, 2H), 6.41 - 6.45 (m, 2H), 6.96 (d, 1H), 7.13 (d, 1H), 7.26 -7.32 (m, 2H), 7.38 - 7.46 (m, 2H), 7.69 (dd, 1H), 8.05 (d, 1H), 8.91 (s, 2H), 10.25 (s, 1H), 10.78 (s, 1H).
Intermediate 016 2-(2-Chloropheny1)-N-{3-[(2,4-dimethoxybenzyl)sulfamoyl]-44(2-isopropylpyrimidin-5-yl)oxy]phenyllacetamide CH CH

0,0 0--"S

rN
CI
According to general procedures GP1.1, GP2.2 and GP3.2 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (96.7 mg, 0.25 mmol), 2-isopropylpyrimidin-5-01 (34.5 mg, 0.25 mmol) and (2-chlorophenyl)acetic acid (64.0 mg, 0.38 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{3-[(2,4-dimethoxybenzypsulfamoyl]-4-[(2-isopropylpyrimidin-5-ypoxy]phenyllacetamide and were purified at the end by column chromatography on a Biotage Isolera system (silica gel, gradient dichloromethane/ethyl acetate) (50 mg, 0.0818 mmol, 33 % yield over 3 steps, 90 % purity).
LC-MS (Method A): Rt = 1.35 min MS (ESIpos): m/z = 611 (M+H)+

Intermediate 017 2-(2-Chloropheny1)-N-{44(2-cyclopropy1-4-methylpyrimidin-5-yl)oxy]-34(2,4-dimethoxybenzyl)sulfamoyllphenyl}acetamide CH CH

0 ati NH
oS
\\

According to general procedures GP1.1, GP2.2 and GP3.2 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (96.7 mg, 0.25 mmol), 2-cyclopropy1-methylpyrimidin-5-ol (37.5 mg, 0.25 mmol) and (2-chlorophenyl)acetic acid (64.0 mg, 0.38 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{4-[(2-cyclopropy1-4-methylpyrimidin-5-yl)oxy]-3-[(2,4-dimethoxybenzypsulfamoyl]phenyl}acetamide and were purified at the end by column chromatography on a Biotage lsolera system (silica gel, gradient dichloromethane/ethyl acetate) (50 mg, 0.0802 mmol, 32 % yield over 3 steps, 90 % purity).
LC-MS (Method A): Rt = 1.35 min MS (ES1pos): m/z = 623 (M+H)+
Intermediate 018 N-{4-(4-Bromophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]pheny1}-2-(2-chlorophenyl)acetamide CH CH

0,0 0 "Li 0-r-S

Br CI
According to general procedures GP1.1, GP2.2 and GP3.2 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (2.90 g, 7.50 mmol), 4-bromophenol (1.30 g, 7.50 mmol) and (2-chlorophenyl)acetic acid (1.15 g, 6.75 mmol) were converted without purification of intermediates to N-{4-(4-bromophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]pheny11-2-(2-chlorophenypacetamide. A small amount was purified at the end by column chromatography on a Biotage lsolera system (silica gel, gradient dichloromethane/ethyl acetate) for NMR characterization, the rest was used in the next step without further purification (purity 40%).
LC-MS (Method A): Rt = 1.45 min MS (ES1neg): m/z = 645 (M-H) 11-1-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.65 (s, 3H), 3.71 (s, 3H), 3.85 (s, 2H), 4.03 (d, 2H), 6.39 - 6.43 (m, 2H), 6.89 - 6.94 (m, 2H), 6.96 (d, 1H), 7.10 - 7.14 (m, 1H), 7.29 - 7.36 (m, 2H), 7.42 - 7.49 (m, 2H), 7.52 - 7.58 (m, 2H), 7.73 (t, 1H), 7.77 (dd, 1H), 8.12 (d, 1H), 10.50 (s, 1H).
Intermediate 019 N-{4-(3-Bromophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]pheny11-2-(2-chlorophenyl)acetamide I I ' ,NH
= 0 =
CI Br According to general procedures GP1.1, GP2.2 and GP3.2 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (2.90 g, 7.50 mmol), 3-bromophenol (1.30 g, 7.50 mmol) and (2-chlorophenyl)acetic acid (1.28 g, 7.50 mmol) were converted without purification of intermediates to N-{4-(3-bromophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]pheny11-2-(2-chlorophenyl)acetamide. A small amount was purified at the end by column chromatography on a Biotage Isolera system (silica gel, gradient dichloromethane/ethyl acetate) for NMR characterization, the rest was used in the next step without further purification (purity 40%).
LC-MS (Method A): Rt = 1.43 min MS (ESIneg): m/z = 645 (M-H) 1H-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.66 (s, 3H), 3.71 (s, 3H), 3.86 (s, 2H), 4.03 (d, 2H), 6.38 - 6.42 (m, 2H), 6.92 - 6.97 (m, 1H), 7.01 (d, 1H), 7.10 - 7.13 (m, 1H), 7.14 - 7.16 (m, 1H), 7.29 - 7.37 (m, 4H), 7.42 - 7.49 (m, 2H), 7.75 (t, 1H), 7.79 (dd, 1H), 8.13 (d, 1H), 10.52 (s, 1H).
Intermediate 020 Methyl 3-{2-[(2,4-dimethoxybenzyl)sulfamoyI]-4-nitrophenoxylbenzoate CH CH, 0,0 µµ õNH

0,N==0 0 2-Chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (484 mg, 1.25 mmol) was dissolved in acetonitrile (17.5 mL), cesium carbonate (407 mg, 1.25 mmol) and methyl 3-hydroxybenzoate (190 mg, 1.25 mmol) were added. The reaction mixture was stirred in a sealed vial overnight at 110 C. After cooling to room temperature the solvent was removed under reduced pressure and the crude was treated with dichloromethane and brine solution, the organic phase was separated, dried over sodium sulfate and concentrated in vacuo. Chromatography on a Biotage lsolera System (silica gel, gradient ethyl acetate to dichloromethane/methanol) led to methyl 3-{2-[(2,4-dimethoxybenzyl)sulfamoyI]-4-nitrophenoxylbenzoate (350 mg, 0.697 mmol, 56 %
yield, 98% purity).
LC-MS (Method A): Rt = 1.32 min MS (ESIneg): m/z = 501 (M-I-1) Intermediate 021 Methyl 2-{2[(2,4-dimethoxybenzyl)sulfamoy1]-4-nitrophenoxylbenzoate CH CH.

,,INM0 0 OS 'CH3 0,N, 110 2-Chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (484 mg, 1.25 mmol) was dissolved in acetonitrile (17.5 mL), cesium carbonate (407 mg, 1.25 mmol) and methyl 3-hydroxybenzoate (190 mg, 1.25 mmol) were added. It was stirred in a sealed vial zo overnight at 110 C. After cooling to room temperature the solvent was removed under reduced pressure and the crude was treated with dichloromethane and brine solution, the organic phase was separated, dried over sodium sulfate and concentrated in vacuo.
Chromatography on a Biotage lsolera System (silica gel, gradient ethyl acetate to dichloromethane/methanol) led to methyl 2-{2-[(2,4-dimethoxybenzypsulfamoyl]-4-nitrophenoxylbenzoate (350 mg, 0.697 mmol, 56 % yield, 98% purity).
LC-MS (Method A): Rt = 1.34 min MS (ESIneg): m/z = 501 (M-1-)+

Intermediate 022 Methyl 3-(4-{[(2-chlorophenyl)acetyl]amino}-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate CH CH

0,0 ,NH

IT 0 =

CI
Methyl 3-{2-[(2,4-dimethoxybenzypsulfamoy1]-4-nitrophenoxylbenzoate (350 mg, 0.70 mmol) was dissolved in dioxane (5 mL) and treated with tin(I1)chloride dihydrate (786 mg, 3.48 mmol). The reaction mixture was stirred in a sealed vial at 70 C for 3 h, cooled to room temperature and filtered over a PTFE membrane. The filtrate was concentrated and redissolved in tetrahydrofuran (14 mL). (2-Chlorophenyl)acetic acid (179 mg, 1.05 mmol), N,N-diisopropylethylamine (1.36 g, 10.5 mmol) and HATU (399 mg, 1.05 mmol) were added and it was stirred overnight at room temperature. It was concentrated in vacuo and the crude was extracted and washed with water and dichloromethane. The organic phase was separated, dried over sodium sulfate and concentrated in vacuo.
Chromatography on a Biotage Isolera system (silica gel, gradient dichloromethane/ethyl acetate) led to methyl 3-(4-{[(2-chlorophenyl)acetyl]amino}-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate (150 mg, 0.240 mmol, 34 % yield, 98%
purity).
LC-MS (Method A): Rt = 1.34 min MS (ESIneg): m/z = 623 (M-H) Intermediate 023 Methyl 2-(4-{[(2-chlorophenyl)acetyl]amino}-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate CH CH

,NH 0 OS..

o CH3 = 00 CI
Methyl 2-{2-[(2,4-dimethoxybenzypsulfamoy1]-4-nitrophenoxylbenzoate (350 mg, 0.70 mmol) was dissolved in dioxane (5 mL) and treated with tin(I1)chloride dihydrate (786 mg, 3.48 mmol). The reaction mixture was stirred in a sealed vial at 70 C for 3 h, cooled to room temperature and filtered over a PTFE membrane. The filtrate was concentrated and redissolved in tetrahydrofuran (14 mL). (2-Chlorophenyl)acetic acid (179 mg, 1.05 mmol), N,N-diisopropylethylamine (1.36 g, 10.5 mmol) and HATU (399 mg, 1.05 mmol) were added and it was stirred overnight at room temperature. The solvent was removed in vacuo and the residue was extracted and washed with water and dichloromethane.
The organic phase was separated, dried over sodium sulfate and concentrated in vacuo.
Chromatography on a Biotage Isolera system (silica gel, gradient dichloromethane/ethyl acetate) led to methyl 2-(4-{[(2-chlorophenyl)acetyl]amino}-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate (100 mg, 0.160 mmol, 23 % yield, 98%
purity).
LC-MS (Method A): Rt = 1.36 min MS (pos): m/z = 625 (M+1-1)+
Intermediate 024 2-(2-Chloropheny1)-N-(3-[(2,4-dimethoxybenzyl)sulfamoyq-443-(2-hydroxypropan-2-yl)phenoxy]phenyllacetamide CH CH

CI
To a solution of methyl 3-(4-{[(2-chlorophenyl)acetyl]amino}-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate (125 mg, 0.20 mmol) in tetrahydrofuran (20 mL) was added at 0 C methyl magnesium bromide solution (4.29 mL of 1.4 M in THF/toluene, 6.0 mmol). Stirring was continued at room temperature for 5 days.
It was quenched with ammonium chloride solution, the solvent was removed under reduced pressure followed by extraction with water and dichloromethane. The organic phase was separated, dried over sodium sulfate and concentrated in vacuo. Chromatography on a Biotage lsolera system (silica gel, gradient dichloromethane/ethyl acetate) led to 2-(2-(45 mg, 0.0720 mmol, 36 % yield, 98% purity).
LC-MS (Method A): Rt = 1.28 min MS (ESIneg): m/z = 623 (M-1-1)' 11-I-NMR (400MHz, DMSO¨d6) [ppm]: 1.41 (s, 6H), 3.66 (s, 3H), 3.71 (s, 3H), 3.84 (s, 2H), 4.05 (d, 2H), 5.09 (s, 1H), 5.77 (s, 1H), 6.39 - 6.43 (m, 2H), 6.76 (ddd, 1H), 6.84 (d, 1H), 7.12 -7.35 (m, 5H), 7.41 - 7.48 (m, 2H), 7.64 (t, 1H), 7.74 (dd, 1H),

8.12 (d, 1H), 10.46 (s, 1H).
Intermediate 025 2-(2-Chloropheny1)-N-{3-[(2,4-dimethoxybenzyl)sulfamoyl]-442-(2-hydroxypropan-yl)phenoxy]phenyllacetamide CH CH

CI
To a solution of methyl 2-(4-{[(2-chlorophenypacetyl]aminol-2-[(2,4-dimethoxybenzypsulfamoyl]phenoxy)benzoate (68.8 mg, 0.11 mmol) in tetrahydrofuran (11 mL) was added at 0 C methyl magnesium bromide solution (2.36 mL of 1.4 M
in THF/toluene, 3.3 mmol). Stirring was continued at room temperature for 5 days.
It was quenched with ammonium chloride solution, the solvent was removed under reduced pressure followed by extraction with water and dichloromethane. The organic phase was separated, dried over sodium sulfate and concentrated under reduced pressure.
Chromatography on a Biotage Isolera system (silica gel, gradient dichloromethane/ethyl acetate) led to 2-(2-chlorophenyI)-N-(3-[(2,4-dimethoxybenzyl)sulfamoyl]-4-[2-(2-hydroxypropan-2-yl)phenoxy]phenyllacetamide (35 mg, 0.0563 mmol, 51 % yield, 98%
purity).
LC-MS (Method A): Rt = 1.32 min MS (ESIneg): m/z = 623 (M-H) 11-I-NMR (400MHz, DMSO¨d6) 5 [ppm]: 1.48 (s, 6H), 3.59 (s, 3H), 3.73 (s, 3H), 3.85 (s, 2H), 4.00 - 4.08 (m, 2H), 5.18 (s, 1H), 5.77 (s, 1H), 6.41 - 6.46 (m, 2H), 6.61 (dd, 1H), 6.74 (d, 1H), 7.12 - 7.23 (m, 3H), 7.29 - 7.36 (m, 2H), 7.45 (s, 2H), 7.65 (t, 1H), 7.69 - 7.75 (m, 2H), 8.18 (d, 1H), 10.47 (s, 1H).
Intermediate 026 2-(4-Chlorophenoxy)-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide CH CH

0,0 ,NH
¨S
0,N, 1:1101 1.
CI

2-Chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (6.0 g, 16 mmol) was dissolved in acetonitrile (60 mL) and cesium carbonate (7.6 g, 23 mmol) and 4-chlorophenol (3.0 g, 23 mmol, 1.5 eq) were added. Stirring was continued at 110 C until TLC showed consumption of starting material. After cooling to room temperature, the reaction mixture was filtered and the solvent was removed under reduced pressure.
Afterwards water and ethyl acetate were added and the phases were separated.
The organic phase was dried and the solvent was removed under reduced pressure.
The crude was used without further purification.
Intermediate 027 5-Amino-2-(4-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide yE13 yH3 µµ õNH
01;

According to GP2.2 2-(4-chlorophenoxy)-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (8.4 g, 5.2 mmol) was converted to 5-amino-2-(4-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide and purified via column chromatography on a Biotage Isolera system (silica gel, gradient n-hexane/ethyl acetate)(2.8 g, 8.3 mmol, 40% yield).

Intermediate 028 2-Chloro-5-nitrobenzenesulfonamide 0. õNH
:S 2 0"
CI
0õN+

2-Chloro-5-nitrobenzenesulfonyl chloride (5.0 g, 20 mmol) was dissolved in dioxane (100 mL). Pyridine (7.0 g, 98 mmol, 7.9 mL) and ammonia (33% solution in dioxane, 39 mmol, 2.3 mL) were added. The reaction was stirred at 50 C until completion of the reaction.
After cooling to room temperature, the solvents were removed under reduced pressure and water was added. The suspension was filtered and the solid was dried and used without further purification.(3.6 g, 15 mmol, 78 % yield) Intermediate 029 2-(Cyclobutyloxy)-5-nitrobenzenesulfonamide 0, _NH
:S 2 0,N.
SO
According to GP1.2 2-chloro-5-nitrobenzenesulfonamide (500 mg, 2.1 mmol) was reacted with cyclobutanol (229 mg, 3.2 mmol) and sodium hydride (0.6 g, 15 mmol, 60 %
purity).
The crude was purified by column chromatography on a Biotage lsolera (silica gel, gradient n-hexane/ethyl acetate) to yield pure 2-(cyclohexyloxy)-5-nitrobenzenesulfonamide (670 mg, 2.5 mmol, 116 % yield).
Intermediate 030 5-Amino-2-(cyclobutyloxy)benzenesulfonamide 0".
Oc\

According to GP 2.1 2-(cyclohexyloxy)-5-nitrobenzenesulfonamide (670 mg, 2.5 mmol) was converted to 5-amino-2-(cyclobutyloxy)benzenesulfonamide (470 mg, 1.9 mmol, 79 % yield) and used in the next step without further purification.
Intermediate 031 2-(Cyclohexyloxy)-5-nitrobenzenesulfonamide ;-**S
0, N+ 101 010 According to GP1.2 2-chloro-5-nitrobenzenesulfonamide (500 mg, 2.1 mmol) was reacted with cyclohexanol (254 mg, 2.5 mmol) and sodium hydride (0.3 g, 7.4 mmol, 60 %
purity).
The crude was purified by column chromatography on a Biotage lsolera (silica gel, gradient n-hexane/ethyl acetate) to yield pure 2-(cyclohexyloxy)-5-nitrobenzenesulfonamide (430 mg, 1.43 mmol, 68 % yield).
Intermediate 032 5-Amino-2-(cyclohexyloxy)benzenesulfonamide O
,NH
S S
, 2 -0.õ.0 According to GP2.1 2-(cyclohexyloxy)-5-nitrobenzenesulfonamide (430 mg, 1.43 mmol) was converted to 5-amino-2-(cyclohexyloxy)benzenesulfonamide (360 mg, 1.3 mmol, 93 % yield) and used in the next step without further purification.
Intermediate 033 5-Nitro-2-(tetrahydro-2H-pyran-4-yloxy)benzenesulfonamide ,NH, ,S
0' According to GP1.2 2-chloro-5-nitrobenzenesulfonamide (500 mg, 2.1 mmol) was reacted with tetrahydro-2H-pyran-4-ol (324 mg, 3.2 mmol) and sodium hydride (0.6g, 15 mmol, 60 % purity). The crude was purified by column chromatography on a Biotage lsolera (silica gel, gradient n-hexane/ethyl acetate) to yield pure 2-(cyclohexyloxy)-nitrobenzenesulfonamide (420 mg, 1.4 mmol, 66 % yield).
Intermediate 034 5-Amino-2-(tetrahydro-2H-pyran-4-yloxy)benzenesulfonamide NH
0=S 2 si According to GP2.1 2-(cyclohexyloxy)-5-nitrobenzenesulfonamide (420 mg, 1.4 mmol) was converted to 5-amino-2-(tetrahydro-2H-pyran-4-yloxy)benzenesulfonamide (420 mg, 1.5 mmol, quant. yield) and used in the next step without further purification.
Intermediate 035 tert-Butyl 3-{24(2,4-dimethoxybenzyl)sulfamoy1]-4-nitrophenoxy}azetidine-1-carboxylate ?H3 0 el 0%CH3 \\ ,NH
0=S
0 Oc....1 \---'NO
0. +
N
H3CH3.. r o1 According to GP1.2 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.3 mmol) was reacted with tert-butyl 3-hydroxyazetidine-1-carboxylate (336 mg, 1.9 mmol) and sodium hydride (217 mg, 9 mmol). The crude was purified by column chromatography on a Biotage !soSera (silica gel, gradient n-hexane/ethyl acetate) to yield pure tert-butyl 342-[(2,4-dimethoxybenzyl)sulfamoy1]-4-nitrophenoxy}azetidine-1-carboxylate (510 mg, 1.0 mmol, 75% yield).
Intermediate 036 tert-Butyl 3-{4-amino-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy}azetidine-1-carboxylate ?H3 0 0%
0 cH3 \\ ,NH
0=S
0 Ors..n O
H2N H3C r H3C.)0 cH3 According to GP2.1 tert-butyl 342-[(2,4-dimethoxybenzyl)sulfamoy1]-4-nitrophenoxy)azetidine-1-carboxylate (510 mg, 1.0 mmol) was converted to tert-butyl 3-{4-amino-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxylazetidine-1-carboxylate (490 mg, 1.0 mmol, 100 % yield) and used in the next step without further purification.

Intermediate 037 2-(Cyclopentyloxy)-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide CH

,NH
0=
0'.N. c)).
oI
According to GP1.2 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.3 mmol) was reacted with cyclopentanol (334 mg, 3.9 mmol) and sodium hydride (310 mg, 13 mmol). The crude was purified by column chromatography on a Biotage lsolera (silica gel, gradient n-hexane/ethyl acetate) to yield pure 2-(cyclopentyloxy)-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (470 mg, 1.0 mmol, 83 % yield).
Intermediate 038 5-Amino-2-(cyclopentyloxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide CH
I

o,CH3 0 mu 0=S

According to GP1.2 2-(cyclopentyloxy)-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (470 mg, 1.0 mmol) was converted to 5-amino-2-(cyclopentyloxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (470 mg, 1.2 mmol, quant.
yield) and used in the next step without further purification.

Intermediate 039 N-(2,4-DimethoxybenzyI)-5-nitro-2-[(3S)-tetrahydrothiophen-3-yloxy]benzenesulfonamide CH, I -0 0, 40) CH3 ,NH
0=S

140:1 oi According to GP1.2 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1.6 g, 4.2 mmol) was reacted with tetrahydrothiophene-3-ol (650 mg, 6.2 mmol) and sodium hydride (699 mg, 29 mmol). The crude was purified by column chromatography on a Biotage Isolera (silica gel, gradient n-hexane/ethyl acetate) to yield pure 2-(cyclopentyloxy)-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1.2 g, 2.6 mmol, 63 % yield).
Intermediate 040 2-(2-Chloropheny1)-N-{34(2,4-dimethoxybenzyl)sulfamoy11-4-[(3S)-tetrahydrothiophen-3-yloxy]phenyllacetamide yH3 0 o,cH3 czµ..NH
0=S

L'Sf CI
According to GP2.3 and GP3.2 2-(cyclopentyloxy)-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1.2 g, 2.6 mmol) was converted with (2-chlorophenyl)acetic acid (550 mg, 3.2 mmol) to 2-(2-chloropheny1)-N-{3-[(2,4-dimethoxybenzypsulfamoyl]-4-[(3S)-tetrahydrothiophen-3-yloxy]phenyllacetamide and purified by column chromatography on a Biotage Isolera (silica gel, gradient n-hexane/ethyl acetate) (1.7 g, 3.0 mmol, 110 % yield).
Intermediate 041 2-(2-Chlorophenyl)-N-(34(2,4-dimethoxybenzyl)sulfamoyl]-4-{[(3S)-1,1-dioxidotetrahydrothiophen-3-yl]oxylphenyl)acetamide CH

0 0, cH3 µN õNH
0=S
0' '01 Cl 2-(2-Chloropheny1)-N-{3-[(2,4-dimethoxybenzypsulfamoyl]-4-[(3S)-tetrahydrothiophen-3-yloxy]phenyllacetamide (100 mg, 0.2 mmol) was dissolved in dichloromethane (2 mL) and 10 3-chlorobenzenecarboperoxoic acid (119 mg, 0.52 mmol, 75 1% purity) were added at room temperature. Stirring was continued for 16 h, afterwards, sat. aq. sodium bicarbonate and ethyl acetate were added. The phases were separated and the organic phase was dried. After removal of the solvent under reduced pressure, the crude was purified by preparative HPLC (Chromatorex 0-18 10pm, 125x30mm, acetonitrile/water +
15 0.1% formic acid) to yield 2-(2-chloropheny1)-N-(3-[(2,4-dimethoxybenzypsulfamoyl]-4-{[(35)-1,1-dioxidotetrahydrothiophen-3-yl]oxylphenypacetamide (18 mg, 0.030 mmol, 17% yield).
LC-MS (Method A): Rt = min 1.17 MS (ESIpos): m/z = 609 (M+H).
Intermediate 042 N-(2,4-DimethoxybenzyI)-2-{[(3R)-1-methylpyrrolidin-3-yl]oxy}-5-nitrobenzenesulfonamide CH

1 3el 0,CH3 µµ IAFI
0=

101 tN¨CH3 ... .
(3% N
1 _ According to GP1.2 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.3 mmol) was reacted with 1-methylpyrrolidin-3-ol (196 mg, 1.9 mmol) and sodium hydride (217 mg, 9.0 mmol). The crude was purified by column chromatography on a Biotage lsolera (silica gel, 2 c/o gradient of ethanol in dichloromethane) to yield N-(2,4-d imethoxybenzy1)-2-{[(3R)-1-methylpyrrolid in-3-yl]oxy}-5-n itrobenzenesulfona m ide (480 mg, 1.0 mmol, 82 % yield).
Intermediate 043 5-Amino-N-(2,4-dimethoxybenzy1)-2-{[(3R)-1-methylpyrrolidin-3-yi]oxy}benzenesulfonamide yit o o, ...pan ki Li \\ .
0=S
OP O¨CF13 According to GP2.1 N-(2,4-dimethoxybenzy1)-2-{[(3R)-1-methylpyrrolidin-3-yl]oxy}-5-nitrobenzenesulfonamide (480 mg, 1.0 mmol) was converted to 5-amino-2-(cyclopentyloxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (450 mg, 1.1 mmol, 100 ''/0 yield) and used in the next step without further purification.

Intermediate 044 5-Amino-N-(2,4-dimethoxybenzyI)-2-[(1-methylpiperidin-4-yl)oxy]benzenesulfonamide CH

0 0' C
o \\ NH
0=S

0,CH3 According to GP1.2 and GP2.1 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.3 mmol) was reacted with 1-methylpiperidin-4-ol (223 mg, 1.9 mmol) to yield 5-amino-N-(2,4-dimethoxybenzy1)-2-[(1-methylpiperidin-4-yl)oxy]benzenesulfonamide (780 mg, 1.8 mmol, 31 % yield over 2 steps).
io Intermediate 045 N-(2,4-Dimethoxybenzy1)-2-{[(3R)-1-methylpiperidin-3-yl]oxy}-5-nitrobenzenesulfonamide CH

0 0, 0 mu 0=S

o+Si oI
According to GP1.2 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.3 mmol) was reacted with 1-methylpiperidin-3-ol (223 mg, 1.9 mmol) and sodium hydride (217 mg, 9.0 mmol). The crude was purified by column chromatography on a Biotage Isolera (silica gel, 2 % gradient of ethanol in dichloromethane) to yield N-(2,4-dimethoxybenzyI)-2-{[(3R)-1-methylpiperidin-3-yl]oxy}-5-nitrobenzenesulfonamide (470 mg, 1.0 mmol, 78 % yield).

Intermediate 046 5-Amino-N-(2,4-dimethoxybenzy1)-2-{[(3R)-1-methylpiperidin-3-yl]oxy}benzenesulfonamide CH

0 0, (:)µµ õNH
0=
0N,CH3 According to GP2.1 N-(2,4-dimethoxybenzyI)-2-{[(3R)-1-methylpiperidin-3-yl]oxy}-5-nitrobenzenesulfonamide (470 mg, 1.0 mmol) was converted to 5-amino-N-(2,4-dimethoxybenzy1)-2-{[(3R)-1-methylpiperidin-3-yl]oxylbenzenesulfonamide (480 mg, 1.1 mmol, quant. yield) and used in the next step without further purification.
io Intermediate 047 N-14-(3-Chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]phenyll-2-phenylacetamide yH3 o o.CH3 ,NH
0=S
o 0=

CI
5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (500 mg, 1.14 mmol) was converted according to GP3.2 to N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]phenyll-2-phenylacetamide. The crude was purified by column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) (550mg, 631mmol, 87 % yield, 99% purity).
LC-MS (Method A): Rt = min 1.39 MS (ESIpos): m/z = 567 (M+H)+

11-1-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.54 - 3.73 (m, 8H), 4.01 (d, 2H), 6.30 -6.42 (m, 2H), 6.80 - 6.92 (m, 1H), 6.92 - 7.03 (m, 2H), 7.04 - 7.15 (m, 1H), 7.15 -7.23 (m, 1H), 7.23 - 7.31 (m, 1H), 7.31 - 7.39 (m, 5H), 7.63 - 7.75 (m, 1H), 7.75 - 7.85 (m, 1H), 8.08 (d, 1H), 10.44 (s, 1H).
Intermediate 048 N-{4-(3-Chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]phenyll-2-(pyridin-2-yl)acetamide yH3 o o.CH3 NH
0=S-N N
CI
5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (200 mg, 0.446 mmol) was converted according to GP3.2 to N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]phenyll-2-(pyridin-2-ypacetamide (quantitative yield).
Intermediate 049 N-{4-(3-Chlorophenoxy)-34(2,4-dimethoxybenzypsulfamoyliphenyll-2-(pyridin-3-y1)acetamide cH3 o 0.CH3 qs NH
0=

n 0 NN
CI
5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (150 mg, 0.267 mmol) was converted according to GP3.2 to N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]pheny11-2-(pyridin-3-ypacetamide (quantitative yield).

Intermediate 050 N-{443-Chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]phenyll-2-(3-chlorophenyl)acetamide o 0-0=b' Si 0 CI
CI
5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (170 mg, 0.284 mmol) was converted according to GP3.2 to N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]pheny11-2-(3-chlorophenypacetannide. The crude was purified by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.2%
io aqueous ammonia (32%)).
LC-MS (Method B): Rt = min 1.45 MS (ESIneg): m/z = 599 (M-H) Intermediate 051 N-{4-(3-Chlorophenoxy)-34(2,4-dimethoxybenzyl)sulfamoyl]pheny11-2-(2-chlorophenyl)acetamide cH3 o o'cH3 ,NH
0=S
o CI CI
5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (170 mg, 0.284 mmol) were converted according to GP3.2 to N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]pheny11-2-(2-chlorophenypacetamide. The crude was purified by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.2%

aqueous ammonia (32%)) (70 mg, 0.120 mmol, 42 % yield).
LC-MS (Method E): Rt = 1.29 min MS (ESIneg): m/z = 580 (M-H) Intermediate 052 N44-(3-Chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]pheny1}-2-(4-methoxyphenyl)acetamide 0 . 0.CH3 0q NH
0=S
0 . 1, 4 0 ot N
H CI
5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (175 mg, 0.292 mmol) was converted according to GP3.2 to N-(4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]pheny1)-2-(4-methoxyphenyl)acetamide. The crude was purified by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water +
0.2% aqueous ammonia (32%)) (70 mg, 0.120 mmol, 40 % yield).
LC-MS (Method E): Rt = 1.34 min MS (ESIneg): m/z = 595 (M-H)+
Intermediate 053 N-{4-(3-Chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]pheny1}-2-(3-zo methoxyphenyl)acetamide y1-13 0 0 0scH3 C:40 ,NH
0=
H3C.0 0 0 0 Oki lei N
H CI

According to GP 3.1 5-am ino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (175 mg, 0.29 mmol) was reacted with (3-methoxyphenyl)acetic acid (53 mg, 0.32 mmol). The crude was purified by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.2% aqueous ammonia (32%)) to yield pure N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]phenyl}-2-(3-methoxyphenypacetamide (70 mg, 0.12 mmol, 40 % yield).
LC-MS (Method E): Rt = 1.34 min MS (ESIneg): m/z = 595 (M-H) Intermediate 054 N-{4-(3-Chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]pheny11-2-(2-methoxyphenyl)acetamide 0 O.CH3 Q, NH

H3C,0 CI
According to GP 3.1 5-am ino-2-(3-chlorophenoxy)-N-(2 ,4-dimethoxybenzyl)benzenesulfonamide (175 mg, 0.29 mmol) was reacted with (2-methoxyphenyl)acetic acid (53 mg, 0.32 mmol). The crude was purified by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.2% aqueous ammonia (32%)) to yield pure N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]pheny11-2-(3-methoxyphenypacetamide (70 mg, 0.12 mmol, 40 % yield).
zo LC-MS (Method E): Rt = 1.36 min MS (ESIneg): m/z = 595 (M-H)t Intermediate 055 N-{4-(3-Chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]pheny11-2-(5-methylpyridin-2-yl)acetamide cH3 o o.CH3 Q, NH
0=S-H3Cr 0 )L0 CI
According to GP3.2 5-amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (150 mg, 0.334 mmol) and (5-methylpyridin-2-yl)acetic acid (121 mg, 0.401 mmol) were reacted to N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]pheny11-2-(5-methylpyridin-2-ypacetamide. The crude was purified by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water +
0.2% aqueous ammonia (32%)) (75 mg, 0.130 mmol, 45 % yield).
LC-MS (Method E): Rt = 1.29 min MS (ESIneg): m/z = 580 (M-1-1) Intermediate 056 N-{4-(3-Chlorophenoxy)-3-[(2,4-dimethoxybenzyl)sulfamoyl]pheny11-2-(pyridin-4-yl)acetamide yH3 o o.CH3 qs NH
0=S-0 0 i CI
40) j=,)LN
According to GP3.2 5-amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (170 mg, 0.284 mmol) and (pyridin-4-ylacetic acid (42 mg, 0.312 mmol) were reacted to N-{4-(3-chlorophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]phenyll-2-(5-methylpyridin-2-ypacetamide. The crude was purified by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water +
zo 0.2% aqueous ammonia (32%)) (70 mg, 0.120 mmol, 43 % yield).
LC-MS (Method B): Rt = min 1.22 MS (ESIneg): m/z = 566 (M-1-1)*

Intermediate 057 N-(2,4-Dimethoxybenzy1)-2-fluoro-4-methy1-5-nitrobenzenesulfonamide ?H3 CH

NH
0.1.0 0, +

To a solution of 2-fluoro-4-methyl-5-nitrobenzenesulfonyl chloride (1 g, 3.9 mmol) in dichloromethane (20 mL) was added sodium bicarbonate (1.0 g, 4.3 mmol) and 1-(2,4-dimethoxyphenyl)methanamine (0.7 g, 4.3 mmol) at 0 C. The mixture was stirred at room temperature overnight. Then all volatile components were removed in vacuo, followed by addition of water and ethyl acetate. After stirring for 10 min the resulting precipitate was separated by filtration and it was dried at 40 C over night in vacuo to obtain N-(2,4-dimethoxybenzy1)-2-fluoro-4-methy1-5-nitrobenzenesulfonamide (1.5 g, 4.0 mmol, 100 %
yield). The intermediate was used in the next steps without further purification.
LC-MS (Method A): Rt = 1.16 min MS (ES1neg): m/z = 383 (M-H)+
Intermediate 058 [2-(2-Methoxyethoxy)phenyl]acetic acid Olt 0 OH

(2-Hydroxyphenyl)acetic acid (10 g, 66 mmol) was dissolved in dimethylformamide (100 zo mL) and bicarbonate (8.2 g, 98 mmol) was added. (Bromomethyl)benzene (12.4 g, 72 mmol) in dimethylformamide (5 mL) was added dopwise and stirring was continued for 18 h at room temperature. Water and ethyl acetate were added and the phases were separated. The organic phase was dried and the solvent removed under reduced pressure. The crude was recrystallized from n-hexane/methyl tert-butyl ether to yield benzyl (2-hydroxyphenyl)acetate (12.7 g, 52 mmol, 80 % yield).
LC-MS (Method A): Rt = 1.14 min MS (ESIpos): m/z = 243 (M+H)+
In the next step, benzyl (2-hydroxyphenyl)acetate (1 g, 4.1 mmol) and 2-methoxyethyl 4-methylbenzenesulfonate (2.4 g, 8.2 mmol, 80 % purity) were dissolved in dimethylformamide (14 mL). Cesium carbonate (2.7 g, 8.3 mmol) was added and the reaction mixture was stirred for 2 days at 50 C. After cooling to room temperature, water and dichloromethane were added and the phases separated. The organic phase was dried and solvent was removed under reduced pressure. The crude was purified by column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) to yield benzyl [2-(2-methoxyethoxy)phenyl]acetate (621 mg, 1.3 mmol, 50 %
yield, 65 % purity).
LC-MS (Method A): Rt = 1.32 min MS (ESIpos): m/z = 301 (M+1-1)+
Benzyl [2-(2-methoxyethoxy)phenyl]acetate (621 mg, 1.3 mmol) was converted to [2-(2-methoxyethoxy)phenyl]acetic acid by GP2.1 and the crude was used without further zo purification in the next step.
LC-MS (Method A): Rt = 0.79 min MS (ESIpos): m/z = 211 (M+H)+
Intermediate 059 {3-[(2-Methoxyethyl)(methyl)carbamoyl]phenyl}acetic acid yH3 0 OH

(3-Bromophenyl)acetic acid (5.0 g, 23 mmol) was dissolved in tetrahydrofurane (63 mL) and trifluoroacetic anhydride (12 g, 58 mmol) was added at 0 C. After 1 h, tert-butanol (22 g, 302 mmol) was added dropwise and the reaction was stirred at room temperature until TLC showed disappearance of starting material. The reaction was cooled to 0 C and quenched by addition of saturated aqeous bicarbonate solution (100 mL). Ethyl acetate was added and the phases were separated. The organic phase was dried and concentrated in vacuo. The crude was used without further purification in the next step.
tert-Butyl (3-bromophenyl)acetate (1 g, 3.7 mmol), 2-methoxy-N-methylethanamine (1 g, 11 mmol), tri-tert-butylphosphonium tetrafluoroborate (53 mg, 0.184 mmol) ), tri-tert-butylphosphonium tetrafluoroborate (106 mg, 0.369 mmol), palladium(II) acetate (83 mg, 0.367 mmol), carbon monooxide - molybdenum (6:1) (1 g, 3.7 mmol) and sodium carbonate (1.2 g, 1.1 mmol) were dissolved in dioxane (29 mL) under argon atmosphere.
Drops of water were added and the reaction was stirred at 100 C for 18h.
After cooling to room temperature, the reaction mixture was filtered and concentrated. The crude was io purified by column chromatography on silica gel on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) to yield tert-butyl {3-[(2-methoxyethyl)(methyl)carbamoyl]phenyllacetate (100 mg, 0.325 mmol, 9 % yield).
LC-MS (Method A): Rt = 1.14 min MS (ESIpos): m/z = 308 (M+H)+
tert-Butyl {3-[(2-methoxyethyl)(methyl)carbamoyl]phenyllacetate (100 mg, 0.325 mmol) was converted according to GP4 to {3-[(2-methoxyethyl)(methyl)carbamoyl]phenyllacetic acid (100 mg, 0.400 mmol). The crude was co-distilled twice with toluene and used without further purification in the next step.
zo LC-MS (Method A): Rt = 1.14 min MS (ESIpos): m/z = 252 (M+H) Intermediate 060 [3-(2-tert-Butoxyethoxy)phenyl]acetic acid H3C¨y 0 OH

Benzyl (3-hydroxyphenyl)acetate (0.7 g, 2.9 mmol), 2-tert-butoxyethyl 4-methylbenzenesulfonate (1.6 g, 5.8 mmol) and cesium carbonate (1.9 g, 5.8 mmol) were dissolved in dimethylformamide (9 mL) under argon atmosphere and stirred for 72 h at 50 C. After cooling to room temperature, dichloromethane and water were added. The organic phase was separated, dried and concentrated. The crude was purified by column chromatography (silica gel, gradient n-hexane/ethyl acetate) to yield benzyl [3-(2-tert-butoxyethoxy)phenyl]acetate (1.6 g, 2.3 mmol, 50 % purity).

Benzyl [3-(2-tert-butoxyethoxy)phenyl]acetate (1.6 g, 2.3 mmol) was converted according to GP 2.1 to [3-(2-tert-butoxyethoxy)phenyl]acetic acid. Purification was done by column chromatography on a Biotage lsolera (silica gel, gradient n-hexane/ethyl acetate) to yield 1.32 g (2.6 mmol, 50% purity). The compound was used in the next step without further purification.
LC-MS (Method A): Rt = 1.09 min MS (ESIneg): m/z = 251 (M-1-1)+
Intermediate 061 [2-(2-tert-Butoxyethoxy)phenyl]acetic acid = 0 OH

1-13COC) ((2-Hydroxyphenyl)acetic acid (10 g, 66 mmol) was dissolved in dimethylformamide (100 mL) and bicarbonate (8.2 g, 98 mmol) were added. (Bromomethyl)benzene (12.4 g, mmol) in dimethylformamide (5 mL) was added dopwise and stirring was continued for 18 h at room temperature. Water and ethyl acetate were added and the phases were separated. The organic phase was dried and the solvent removed under reduced pressure. The crude was recrystallized from n-hexane/methyl tert-butyl ether to yield benzyl (2-hydroxyphenyl)acetate (12.7 g, 52 mmol, 80 % yield).
LC-MS (Method A): Rt = 1.14 min MS (ESIpos): m/z = 243 (M-f-H) In the next step, benzyl (2-hydroxyphenyl)acetate (1 g, 2.9 mmol, 70 % purity) and 2-tert-butoxyethyl 4-methylbenzenesulfonate (1.6 g, 5.8 mmol) were dissolved in dimethylformamide (9 mL). Cesium carbonate (1.9 g, 5.8 mmol) was added and the reaction mixture was stirred for 2 days at 50 C. After cooling to room temperature, water and dichloromethane were added and the phases separated. The organic phase was dried and the solvent was removed under reduced pressure. The crude was purified by column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) to yield benzyl [2-(2-tert-butoxyethoxy)phenyl]acetate (1 g, 1.5 mmol, 50 %
purity).

Benzyl [2-(2-tert-butoxyethoxy)phenyl]acetate (1 g, 1.5 mmol,) was converted to [2-(2-tert-butoxyethoxy)phenyl]acetic acid by GP2.1 and the crude was used without further purification in the next step (726 mg, 1.4 mmol, 50 % purity).
Intermediate 062 [3-(2-Methoxyethoxy)phenyl]acetic acid Benzyl (3-hydroxyphenyl)acetate (500 mg, 2.1 mmol) and 2-methoxyethyl 4-methylbenzenesulfonate (1.1 g, 4.1 mmol) were dissolved in dimethylformamide (7 mL).
io Cesium carbonate (1.4 g, 4.1 mmol) was added and the reaction mixture was stirred for 2 days at 50 C. After cooling to room temperature, water and dichloromethane were added and the phases separated. The organic phase was dried and the solvent was removed under reduced pressure. The crude was purified by column chromatography (silica gel, gradient n-hexane/ethyl acetate) to yield benzyl [3-(2-methoxyethoxy)phenyl]acetate (360 mg, 1.2 mmol, 60 % yield, 80 % purity).
Benzyl [3-(2-methoxyethoxy)phenyl]acetate (360 mg, 1.2 mmol) was converted to [3-(2-methoxyethoxy)phenyl]acetic acid by GP2.1 and the crude was used without further purification in the next step (117 mg, 0.6 mmol, 47 c/o yield).
1H-NMR (CDCI3) o [ppm]: 3.46 (s, 3H), 3.61 (s, 2H), 3.73 - 3.78 (m, 2H), 4.08 -4.15 (m, zo 2H), 6.82 - 6.91 (m, 3H), 7.24 (t, 1H).
Intermediate 063 {2[(2-Methoxyethyl)(methyl)carbamoyliphenyllacetic acid OH
H 3C, 0 N 0 (2-Bromophenyl)acetic acid (15.0 g, 70 mmol) was dissolved in tetrahydrofurane (45 mL) and trifluoroacetic anhydride (25 mL, 36 g, 174 mmol) was added at 0 C. After 1 h, tert-butanol (103 g, 1.4 mol) was added dropwise and the reaction was stirred at room temperature until TLC showed disappearance of starting material. The reaction was cooled to 0 C and quenched by addition of saturated aq. bicarbonate solution (100 mL).
Ethyl acetate was added and the phases were separated. The organic phase was dried and the solvent was removed under reduced pressure. The crude was used without further purification in the next step.
tert-Butyl (2-bromophenyl)acetate (500 mg, 1.8 mmol), 2-methoxy-N-methylethanamine (493 mg, 5.5 mmol), tri-tert-butylphosphonium tetrafluoroborate (53 mg, 0.184 mmol), palladium(II) acetate (41 mg, 0.184 mmol), carbon monooxide - molybdenum (6:1) (486 mg, 1.8 mmol) and sodium carbonate (586 mg, 5.5 mmol) were dissolved in dioxane (29 mL) under argon atmosphere. Drops of water were added and the reaction was heated for min at 140 C in the microwave (100 W, 4 bar). After cooling to room temperature, the reaction mixture was filtered and concentrated. The crude was purified by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.2% aqueous ammonia (32%)) to yield {2-[(2-methoxyethyl)(methyl)carbamoyl]phenyllacetic acid (60 mg, 0.191 15 MMOI, 10 % yield).
LC-MS (Method A): Rt = 1.12 min MS (ESIpos): m/z = 308 (M+H)+
{2-[(2-Methoxyethyl)(methyl)carbamoyl]phenyl}acetic acid (54 mg, 0.175 mmol) was zo converted according to GP4 to {2-[(2-methoxyethyl)(methyl)carbamoyl]phenyllacetic acid (45 mg, 0.179 mmol, quant). The crude was co-distilled twice with toluene and used without further purification in the next step.
LC-MS (Method A): Rt = 0.59 min MS (ESIpos): m/z = 252 (M+H) Intermediate 064 [3-(Dimethylcarbamoyl)phenyl]acetic acid ,,NF13 tert-Butyl (3-bromophenyl)acetate (500 mg, 1.8 mmol), N-methylmethanamine (2.8 mL, 250 mg, 5.5 mmol), tri-tert-butylphosphonium tetrafluoroborate (53 mg, 0.184 mmol), trans-Bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (173 mg, 0.184 mmol), carbon monooxide - molybdenum (6:1) (486 mg, 1.8 mmol) and 1,8-diazabicyclo(5.4.0)undec-7-en (842 mg, 5.5 mmol) were dissolved in tetrahydrofurane (14 mL) under argon atmosphere. Drops of water were added and the reaction was heated for 20 min at 125 C in the microwave (100 W, 7 bar). After cooling to room temperature, the reaction mixture was filtered and concentrated. The crude was purified by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.2% aqueous ammonia (32%)) to yield tert-butyl [3-(dimethylcarbamoyl)phenyl]acetate (39 mg, 0.148 mmol, 8 %
yield).
LC-MS (Method A): Rt = 1. 07 min MS (ESIneg): m/z = 262 (M-H) tert-Butyl [3-(dimethylcarbamoyl)phenyl]acetate (39 mg, 0.148 mmol) was converted according to GP4 to [3-(dimethylcarbamoyl)phenyl]acetic acid (60 mg, 0.289 mmol, quant). The crude was co-distilled twice with toluene and used without further purification in the next step.
Intermediate 065 [2-(Dimethylcarbamoyl)phenyl]acetic acid (00 0 OH
H C
3N o cH3 tert-Butyl (3-bromophenyl)acetate (500 mg, 1.8 mmol), N-methylmethanamine (2.8 mL, zo 250 mg, 5.5 mmol), tri-tert-butylphosphonium tetrafluoroborate (53 mg, 0.184 mmol), trans-Bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (173 mg, 0.184 mmol), carbon monooxide - molybdenum (6:1) (486 mg, 1.8 mmol) and sodium carbonate (586 mg, 5.5 mmol) were dissolved in dioxane (10 mL) under argon atmosphere. Drops of water were added and the reaction was heated for 20 min at 140 C in the microwave (100 W, 7 bar). After cooling to room temperature, the reaction mixture was filtered and concentrated. The crude was purified by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.2% aqueous ammonia (32%)) to yield tert-butyl [2-(dimethylcarbamoyl)phenyl]acetate (127 mg, 0.48 mmol, 26 % yield).
LC-MS (Method A): Rt = 1. 08 min MS (ESIpos): m/z = 264 (M+H)+

tert-Butyl [2-(dimethylcarbamoyl)phenyl]acetate (127 mg, 0.48 mmol) was converted according to GP4 to [2-(dimethylcarbamoyl)phenyl]acetic acid (100 mg, 0.482 mmol, quant). The crude was co-distilled twice with toluene and used without further purification in the next step.
Intermediate 066 {3[(2-Methoxyethyl)carbamoyliphenyllacetic acid H3C,0 tert-Butyl (3-bromophenyl)acetate (250 mg, 0.9 mmol), 2-methoxyethanamine (0.3 mL, 207 mg, 2.8 mmol), tri-tert-butylphosphonium tetrafluoroborate (28 mg, 0.092 mmol), trans-Bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (86 mg, 0.092 mmol), carbon monooxide - molybdenum (6:1) (243 mg, 0.9 mmol) and 1,8-diazabicyclo(5.4.0)undec-7-en (421 mg, 2.7 mmol) were dissolved in tetrahydrofurane (6 mL) under argon atmosphere. Drops of water were added and the reaction was heated for 20 min at 125 C in the microwave (100 W, 7 bar). After cooling to room temperature, the reaction mixture was filtered and concentrated. The crude was purified by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.2% aqueous ammonia (32%)) to yield tert-butyl 13-[(2-methoxyethyl)carbamoyl]phenyllacetate (70 mg, 0.239 mmol, 26 % yield).
tert-Butyl {3-[(2-methoxyethyl)carbamoyl]phenyllacetate (70 mg, 0.239 mmol) was converted according to GP4 to {3-[(2-methoxyethyl)carbamoyl]phenyllacetic acid (65 mg, 0.274 mmol, quant). The crude was co-distilled twice with toluene and used without further purification in the next step.
Intermediate 067 [3-(Methylcarbamoyl)phenyl]acetic acid õN

tert-Butyl (3-bromophenyl)acetate (500 mg, 1.8 mmol), methylmethanamine (2.8 mL, 172 mg, 5.5 mmol), tri-tert-butylphosphonium tetrafluoroborate (53 mg, 0.184 mmol), trans-Bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (173 mg, 0.184 mmol) and carbon monooxide - molybdenum (6:1) (486 mg, 1.8 mmol) and 1,8-diazabicyclo(5.4.0)undec-7-en (842 mg, 5.5 mmol) were dissolved in tetrahydrofurane (14 mL) under argon atmosphere. Drops of water were added and the reaction was heated for 20 min at 125 C in the microwave (100 W, 7 bar). After cooling to room temperature, the reaction mixture was filtered and concentrated. The crude was purified by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.2% aqueous ammonia (32%)) to yield tert-butyl [3-(methylcarbamoyl)phenyl]acetate (30 mg, 0.120 mmol, 7 %
yield).
LC-MS (Method A): Rt = 1. 00 min MS (ESIneg): m/z = 248 (M-I-1) tert-Butyl [3-(methylcarbamoyl)phenyl]acetate (30 mg, 0.120 mmol) was converted according to GP4 to [3-(methylcarbamoyl)phenyl]acetic acid (60 mg, 0.310 mmol, quant).
The crude was co-distilled twice with toluene and used without further purification in the next step.
Intermediate 068 N-(2,4-Dimethoxybenzy1)-2-fluoro-3-methy1-5-nitrobenzenesulfonamide 0 0, 0 ""
0=S

2-Fluoro-3-methyl-5-nitrobenzenesulfonyl chloride (1.00 g, 3.94 mmol) was dissolved in dichloromethane (500 mL) and sodium bicarbonate (662 mg, 7.89 mmol) was added.
It was cooled to 0 C and slowly a solution of 1-(2,4-dimethoxyphenyl)methanamine (659 mg, 3.94 mmol) in dichloromethane (250 mL) was added. The reaction mixture was stirred and allowed to warm to room temperature overnight. Water was added, the phases were separated and the organic phase was dried over sodium sulfate and concentrated in vacuo to yield crude N-(2,4-dimethoxybenzy1)-2-fluoro-3-methy1-5-nitrobenzenesulfonamide (1.51 g, quant.).
LC-MS (Method A): Rt = 1.16 min MS (ESIneg): m/z = 383 (M-1-1)+
Intermediate 069 5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyI)-3-methylbenzenesulfonamide CH

,,NH
0=S

CI
Cesium carbonate (1.27 g, 3.90 mmol) was added to a solution of crude N-(2,4-dimethoxybenzy1)-2-fluoro-3-methy1-5-nitrobenzenesulfonamide (1.50 g, 3.90 mmol) in acetonitrile (20 mL). It was cooled to 0 C and 3-chlorophenol (502 mg, 3.90 mmol) was added. The reaction mixture was stirred and allowed to warm to room temperature overnight. The solvent was removed in vacuo, water and dichloromethane were added, the phases were separated and the organic phase was dried over sodium sulfate and concentrated in vacuo.
The crude product was redissolved in dioxane (30 mL) and tin(I1)chloride dihydrate (4.58 g, 20.2 mmol) was added. The reaction mixture was stirred for 2h at 70 C.
After cooling to zo room temperature the reaction mixture was filtered and concentrated in vacuo to yield crude 5-amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyI)-3-methylbenzenesulfonamide that was used without further purification in the next step.
LC-MS (Method A): Rt = 1.26 min MS (ESIneg): m/z = 461 (M-H) Intermediate 070 2,2-Dimethyltetrahydro-2H-pyran-4-carboxylic acid Ox0H

2,2-Dimethyltetrahydro-2H-pyran-4-carbonitrile (900 mg, 6.47 mmol) was refluxed overnight in aqueous 2N KOH solution. It was diluted with water, extracted with ethyl acetate and this organic phase was discarded. The aqueous phase was acidified with 2N
HCI solution and extracted twice with ethyl acetate. These organic phases were combined, dried over sodium sulfate and concentrated in vacuo to yield crude 2,2-dimethyltetrahydro-2H-pyran-4-carboxylic acid (889 mg, 5.62 mmol, 87 % yield).
1H-NMR (400MHz, DMSO-d6) ei [ppm]: 1.13 (s, 3H), 1.14 (s, 3H), 1.26 - 1.45 (m, 2H), 1.65 -1.73 (m, 2H), 2.59 (tt, 1H), 3.54 (td, 1H), 3.60 (ddd, 1H), 12.20 (s, 1H).
Intermediate 071 (2,2-Dimethyltetrahydro-2H-pyran-4-yl)methanol OH

2,2-Dimethyltetrahydro-2H-pyran-4-carboxylic acid (820 mg, 5.18 mmol) was dissolved in tetrahydrofuran (16 mL). At 0 C BH3-tetrahydrofuran-complex (668 mg, 7.78 mmol) was added and stirred for another 2 hours at 0 C. It was quenched with saturated ammonium chloride solution, the organic solvent was removed in vacuo, water was added and it was extracted twice with ethyl acetate. The combined organic phases were dried over sodium sulfate and concentrated in vacuo.
As GC-MS showed only 50% conversion the same procedure was repeated leading to crude (2,2-dimethyltetrahydro-2H-pyran-4-yl)methanol (491 mg) which was used in the next step without further purification.
Intermediate 072 N-(2,4-dimethoxybenzy1)-2-[(2,2-dimethyltetrahydro-2H-pyran-4-y1)methoxy]-5-nitrobenzenesulfonamide CH

0 0, OCC)k¨CH3 0 +

(2,2-Dimethyltetrahydro-2H-pyran-4-yl)methanol (200 mg, 1.39 mmol) and 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (536 mg, 1.39 mmol) were dissolved in acetonitrile (10 mL) and treated with cesium carbonate (452 mg, 1.39 mmol).
The reaction mixture was stirred at 110 C overnight. The solvent was removed in vacuo, water and dichloromethane were added. The organic phase was washed with brine, dried over sodium sulfate and concentrated in vaco. The crude material was purified by column chromatography on a Biotage lsolera system (silica gel, dichloromethane/ethyl acetate) to yield N-(2,4-dimethoxybenzyl)-2-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-5-(154 mg, 0.311 mmol, 22% yield).
Intermediate 073 Methyl 2-(4-{[(2-chlorophenyl)acetyl]amino}-24(2,4-dimethoxybenzyl)sulfamoyliphenoxypaenzoate CH

0 0, cH3 0..1,..NH 0 0, Cl According to general procedures GP1.1, GP2.1 (with methanol as solvent) and GP3.2 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (1.00 g mg, 2.59 mmol), methyl 2-hydroxybenzoate (393 mg, 2.59 mmol) and (2-chlorophenyl)acetic acid (486 mg, 2.85 mmol) were converted without purification of intermediates to methyl 2-(4-{[(2-chlorophenyl)acetyl]amino}-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate and were purified at the end twice by column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate and dichloromethane/ethyl acetate) (354 mg, 0.566 mmol, 221%, yield over 3 steps).
Intermediate 074 Methyl 444-{[(2-chlorophenyl)acetyl]amino}-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate CH

0 0, 04\ õNH

CI
H3C,0 According to general procedures GP1.1, GP2.1 (with methanol as solvent) and GP3.2 2-(1.00 g mg, 2.59 mmol), methyl 4-hydroxybenzoate (393 mg, 2.59 mmol) and (2-chlorophenyl)acetic acid (527 mg, 3.09 mmol) were converted without purification of intermediates to methyl 4-(4-{[(2-chlorophenyl)acetyl]amino}-2-[(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate and were purified at the end by column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) (441 mg, 0.705 mmol, 27 % yield over 3 steps).
Intermediate 075 Methyl 3-(4-{[(2-chlorophenyl)acetyl]amino}-24(2,4-dimethoxybenzyl)sulfamoyl]phenoxy)benzoate CH

'C H3 ,NH

CI
According to general procedures GP1.1, GP2.1 (with methanol as solvent) and GP3.2 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1.00 g mg, 2.59 mmol), methyl 3-hydroxybenzoate (393 mg, 2.59 mmol) and (2-chlorophenyl)acetic acid (324 mg, 1.90 mmol) were converted without purification of intermediates to methyl 3-(4-{[(2-chlorophenypacetyl]amino}-2-[(2,4-dimethoxybenzypsulfamoyl]phenoxy)benzoate and were purified at the end by column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) (497 mg, 0.795 mmol, 31 % yield over 3 steps).
Intermediate 076 Methyl 3-(4-{[(2-chlorophenyl)acetyl]amino}-2-sulfamoylphenoxy)benzoate 1µ' NH
0=S 2 0 el 0 0 40 CI
According to GP4 methyl 3-(4-{[(2-chlorophenypacetyl]amino}-2-[(2,4-dimethoxybenzypsulfamoyl]phenoxy)benzoate (281 mg, 0.45 mmol) was converted to methyl 3-(4-{[(2-chlorophenyl)acetyl]amino}-2-sulfamoylphenoxy)benzoate and was used without further purification in the next step (226 mg).
LC-MS (Method A): Rt = 1.11 min MS (ESIpos): m/z = 475 (M+I-1)+
Intermediate 077 N-(2,4-DimethoxybenzyI)-5-nitro-2-(tetrahydro-2H-pyran-4-ylmethoxy)benzenesulfonamide CH

0 0,CH3 ,NH
0=S 0 0 101...
2-Ohloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (2.00 g, 5.17 mmol) was dissolved in dimethylformamide (10 mL), treated with tetrahydro-2H-pyran-4-ylmethanol (901 mg, 7.76 mmol) and sodium hydride (1.58 g, 36.2 mmoL) and was stirred for 2 hours at room temperature. It was quenched under ice cooling with water/ethyl acetate. The phases were separated, the aqueous phase was three times reextracted with ethyl acetate and all organic phases were combined, dried and concentrated in vacuo.
It was tehn stirres with ethyl acetate/methyl tert.-butyl ether (1/2) until a white solid precipitated.
Filtration led to N-(2,4-dimethoxybenzyI)-5-nitro-2-(tetrahydro-2H-pyran-4-ylmethoxy)benzenesulfonamide (2.20 g, 4.75 mmol, 91% yield, 95% purity) LC-MS (Method A): Rt = 1.16 min MS (ESIneg): m/z = 465 (M-H) 1H-NMR (400MHz, DM50¨d6) ei [ppm]: 1.23 - 1.36 (m, 2H), 1.70 - 1.77 (m, 2H), 2.09 -2.23 (m, 1H), 3.29 - 3.39 (m, 2H), 3.59 (s, 3H), 3.65 (s, 3H), 3.89 (dd, 2H), 3.99 (d, 2H), 4.08 (s, 2H), 6.21 (d, 1H), 6.30 (dd, 1H), 7.01 (d, 1H), 7.25 (d, 1H), 7.42 (s, 1H), 8.23 (d, 1H), 8.31 (dd, 1H).
Intermediate 078 5-Amino-N-(2,4-dimethoxybenzyI)-2-(tetrahydro-2H-pyran-4-ylmethoxy)benzenesulfonamide 40) CH3 %1 iN1H
0=S
OOD

N-(2,4-dimethoxybenzyI)-5-n itro-2-(tetra hyd ro-2H-pyra n-4-ylmethoxy)benzenesulfon a m ide (2.20 g, 4.75 mmol) was dissolved in methanol, treated with Pd/C (10% loading) and stirred under a hydrogen atmosphere for 3 days at room temperature. After filtration, the filtrate was concentrated in vacuo to give 5-amino-N-(2,4-dimethoxybenzyI)-2-(tetrahydro-2H-pyran-4-ylmethoxy)benzenesulfonamide (1.55 g, 3.54 mmol, 75% yield), which was used without further purification in the following steps.
LC-MS (Method A): Rt = 0.92 min MS (ESIpos): m/z = 437 (M+H)*
11-1-NMR (400MHz, DMSO¨d6) 43 [ppm]: 1.25 (ddd, 2H), 1.63 - 1.70 (m, 2H), 1.90 - 2.03 (m, 1H), 3.25 - 3.33 (m, 2H), 3.68 - 3.74 (m, 8H), 3.85 (dd, 2H), 3.94 (d, 2H), 5.10 (s, 2H), 6.40 (dd, 1H), 6.46 (d, 1H), 6.54 (t, 1H), 6.72 (dd, 1H), 6.84 (d, 1H), 7.01 (d, 1H), 7.05 (d, 1H).
Intermediate 079 5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide H3C-o 140 H N
i 0=S=0 00 *

CI
2-Chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (62.4 g, 161 mmol) was dissolved in acetonitrile (620 mL), cesium carbonate (52.6 g, 161 mmol) and 3-chlorophenol (20.7 g, 161 mmol) were added. The reaction mixture was stirred overnight at 110 C (bath temperature). Dichloromethane (620 mL) was added and it was stirred for 30 min. The precipitate was discarded. The filtrate was concentrated in vacuo, suspended in dichloromethane (500 mL) and purified over a silica bed (dichloromethane as eluent).
After concentration in vacuo the material (53 g) was suspendend in a mixture of acetonitrile (530 mL) and dichloromethane (530 mL) and stirred for 30 min. The precipitate was collected and dried to provide 2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyI)-nitrobenzenesulfonamide (30.0 g) LC-MS (Method B): Rt = 1.39 min MS (ESIneg): m/z = 477 (M-H)-The material from the previous step was suspended in toluene (390 mL). Water (390 mL), phosphoric acid (40 pL to reach pH 3) and platinum/vanadium (1%/2%) on charcoal (10 g) were added. The reaction mixture was stirred for 4h at 100 C under hydrogen atmosphere (6.25 bar) in an autoclave. The catalyst was filtered off and the filtrate was extracted with ethylacetate/water. The aqueous phase was reextracted three times with ethyl acetate The organic phases were combined, washed with brine, dried over sodium sulfate and were concentrated in vacuo. Purification on a Biotage lsolera system (hexane/ethyl acetate 1/1) provided 5-amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide (28.8 g,64.2 mnnol, 401% yield over 2 steps).
LC-MS (Method B): Rt = 1.26 min MS (ESIpos): m/z = 449 (M-f-H) 11-I-NMR (400MHz, DMSO¨d6) ei [ppm]: 3.71 (d, 3H), 3.72 (d, 3H), 3.98 (d, 2H), 5.46 (s, 2H), 6.40 - 6.47 (m, 2H), 6.75 (dd, 1H), 6.79 - 6.85 (m, 2H), 6.90 (t, 1H), 7.04 - 7.10 (m, 2H), 7.13 (d, 1H), 7.31 (t, 1H), 7.44 (t, 1H).
Intermediate 080 5-Amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzyI)-3-fluorobenzenesulfonamide CF-1,4 0".
H 3C,0 H N
0=S=0 CI
N-(2,4-DimethoxybenzyI)-2,3-difluoro-5-nitrobenzenesulfonamide (1.51 g, 3.88 mmol) was dissolved in acetonitrile (50 mL). Under ice cooling, cesium carbonate (1.26 g, 3.88 mmol) and 3-chlorophenol (499 mg, 3.88 mmol) in acetonitrile (20 mL) were slowly added. The reaction mixture was stirred and allowed to warm to room temperature overnight. After concentration in vacuo it was extracted with ethyl acetate/water, the organic phase was dried over sodium sulfate and concentrated again in vacuo to give crude 2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzy1)-3-fluoro-5-nitrobenzenesulfonamide.
The material from the previous step was dissolved in dioxane (15 mL) and treated with tin(II) chloride dihydrate for 2h at 70 C. After cooling to room temperature the reaction mixture was filtered and the filtrate was concentrated in vacuo to give crude 5-amino-2-(3-chlorophenoxy)-N-(2,4-dimethoxybenzy1)-3-fluorobenzenesulfonamide that was used in the next step without further purification.
Intermediate 081 5-Amino-2-(3-chlorophenoxy)pyridine-3-sulfonamide 0=S=0 CI
3-Chlorophenol (1.89 g, 14.7 mmol) was stirred for 30 min in aqueous 10%
sodium hydroxide solution (5.36 mL, 14.7 mmol), followed by concentration in vacuo to generate the corresponding alcoholate.

A suspension of this alcoholate, further 3-chlorophenol (946 mg, 7.37 mmol), 5-bromo-2-chloropyridine-3-sulfonamide (2.00 g, 7.37 mmol), cesium carbonate (4.8 g, 14.7 mmol) and potassium carbonate (4.07 g, 29.4 mmol) in acetonitrile (30 mL) was irradiated in the microwave (150 C, 1h). Afterwards the reaction mixture was concentrated in vacuo, extracted with ethyl acetate/water and the organic phase was dried over sodium sulfate, concentrated in vacuo and purified with a Biotage Isolera system providing 5-bromo-2-(3-chlorophenoxy)pyridine-3-sulfonamide (2.67 g).
LC-MS (Method A): Rt = 1.11 min MS (ESIpos): m/z = 363/365 (M+H)+
The material from the previous step was added to a solution of 1,1-dimethoxy-N,N-dimethylnnethanamine (1.70 g, 14.3 mmol) in DMF (30 mL) and was stirred for 1h at room temperature. The reaction mixture was concentrated in vacuo and extracted with ethyl acetate/water. The organic phase was dried over sodium sulfate and concentrated in vacuo.
LC-MS (Method A): Rt = 1.18 min MS (ESIpos): m/z = 418/420 (M+H)+
11-I-NMR (400MHz, DMSO-d6) 5 [ppm]: 2.91 (s, 3H), 3.04 (s, 3H), 7.07 (ddd, 1H), 7.23 (t, 1H), 7.34 (ddd, 1H), 7.47 (t, 1H), 8.25 (s, 1H), 8.37 (d, 1H), 8.51 (d, 1H).
The material from the previous step was dissolved in dioxane (10 mL) and flushed with zo argon. Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) (138 mg, 0.239 mmol) and palladium(II) acetate (26.8 mg, 0.118 mmol) were added, followed by a second argon flushing. Then, cesium carbonate (2.33 g, 7.16 mmol) and 1,1-diphenylmethanimine (649 mg, 3.58 mmol) were added and the reaction mixture was stirred overnight at 95 C.
After concentration in vacuo it was extracted with ethyl acetate/water and the organic phase was dried over sodium sulfate and concentrated again in vacuo to give crude 2-(3-chlorophenoxy)-N-[(dimethylamino)methylene]-5-[(diphenylmethylene)amino]pyridine-3-sulfonamide (1.20 g) that was used without further purification in the next step.
LC-MS (Method A): Rt = 1.39 min MS (ESIpos): m/z = 519 (M+H)+
The material from the previous step was dissolved in ethanol (150 mL), 4N HCI
in dioxane (5.78 mL) was added and it was stirred at room temperature until complete conversion.
Concentration in vacuo was followed by purification on a Biotage lsolera system to yield 5-amino-2-(3-chlorophenoxy)pyridine-3-sulfonamide (450 mg, 1.50 mmol, 20 % yield over 4 steps, 85 % purity) LC-MS (Method A): Rt = 0.82 min MS (ESIpos): m/z = 300 (M+H)+

1H-NMR (400MHz, DMSO¨d6) 6 [ppm]: 5.59 (s, 2H), 7.03 (ddd, 1H), 7.12 (t, 1H), 7.20 (ddd, 1H), 7.39 (t, 1H), 7.44 (s, 2H), 7.54 (d, 1H), 7.67 (d, 1H).
Synthesis of Examples Example 001 N-[4-(3-Chloro-5-cyanophenoxy)-3-sulfamoylphenyI]-2-(2-chlorophenyl)acetamide Os,I1õNH, 0 =0 Cl CI INI
Example 1 was synthesized according to general procedures GP1.1, GP2.2, GP3 and GP4 without purification of intermediates as following:
2-Chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol) was dissolved in acetonitrile (10 mL) and cesium carbonate (421 mg, 1.29 mmol) and 3-chloro-5-hydroxybenzonitrile (199 mg, 1.29 mmol) were added. Stirring was continued overnight.
Afterwards, all volatile components were removed in vacuo, followed by addition of water and dichloromethane. The phases were separated, the organic phase was removed and dried over sodium sulfate and concentrated in vacuo to obtain crude 2-(3-chloro-5-cyanophenoxy)-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide.
LC-MS (Method A): Rt = 1.33 min MS (ESIneg): m/z = 502 (M-H) To a solution of crude 2-(3-chloro-5-cyanophenoxy)-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide from the previous step in dioxane (6 mL) was added tin(II) chloride hydrate (1.46 g, 6.46 mmol). The reaction mixture was stirred for 2h at 70 C.
Then the reaction mixture was cooled to room temperature and the resulting precipitate was removed by filtration. The filtrate was concentrated in vacuo to obtain crude 5-amino-2-(3-chloro-5-cyanophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide.
LC-MS (Method A): Rt = 1.17 min MS (ESIpos): m/z = 474 (M+H)+

To a solution of crude 5-amino-2-(3-chloro-5-cyanophenoxy)-N-(2,4-dimethoxybenzyl)benzenesulfonamide from the previous step in tetrahydrofuran (10 mL) was added (2-chlorophenyl)acetic acid (330 mg, 1.94 mmol), N,N-diisopropylethylamine (1.67 g, 12.9 mmol) and HATU (736 mg, 1.94 mmol). The reaction mixture was stirred overnight at room temperature. Then it was concentrated in vacuo, followed by extraction from ethyl acetate/water. The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to obtain crude N-{4-(3-chloro-5-cyanophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]phenyll-2-(2-chlorophenypacetamide.
LC-MS (Method A): Rt = 1.34 min MS (ESIneg): m/z = 624 (M-H) To a solution of crude N-{4-(3-chloro-5-cyanophenoxy)-3-[(2,4-dimethoxybenzypsulfamoyl]pheny11-2-(2-chlorophenypacetamide from the previous step in dichloromethane (10 mL) was added trifluoroacetic acid (7.36 g, 64.6 mmol) and the reaction mixrture was stirred for 1 h at room temperature. All volatile components were removed in vacuo and the resulting residue was purified by preparative HPLC
(Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) to obtain N-[4-(3-chloro-5-cyanophenoxy)-3-sulfamoylpheny1]-2-(2-chlorophenyl)acetamide (97 mg, 95%
purity, 0.204 mmol, 16% yield over 4 steps).
zo LC-MS (Method A): Rt = 1.16 min MS (ESIpos): m/z = 476 (M+H)+
1H-NMR (400MHz, DMSO-d6) o [ppm]: 3.78 (s, 2H), 6.88 (d, 1H), 7.24 - 7.34 (m, 2H), 7.34 -7.47 (m, 4H), 7.56 - 7.66 (m, 2H), 8.06 (d, 1H), 10.23 (s, 1H), 10.75 (s, 2H).
Example 002 2-(2-Chloropheny1)-N-{40-(dimethylamino)phenoxy]-3-sulfamoylphenyllacetamide =

Cl ,N, According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (1.06 g, 2.73 mmol), 3-(dimethylamino)phenol (374 mg, 2.73 mmol) and (2-chlorophenyl)acetic acid (545 mg, 3.19 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[3-(dimethylamino)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end by column chromatography on a Biotage Isolera system (silica gel, gradient n-hexane/ethyl acetate), followed by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (30 mg, 0.0652 mmol, 2% yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.15 min MS (ESIpos): m/z = 460 (M+H).
1H-NMR (400MHz, DICHLOROMETHANE¨d2) o [ppm]: 2.96 (s, 6H), 3.88 (s, 2H), 5.20 (s, 2H), 6.37 (dd, 1H), 6.47 (t, 1H), 6.59 (dd, 1H), 6.95 (d, 1H), 7.24 (t, 1H), 7.31 -7.38 (m, 2H), 7.40 - 7.52 (m, 3H), 7.78 (dd, 1H), 7.88 (d, 1 H).
Example 003 2-(2-Chloropheny1)-N-{4-[(2-chloropyridin-4-y1)oxy]-3-sulfamoylphenyllacetamide Os, õ.NH

o o yN
Cl CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (1.03 mg, 2.66 mmol), 2-chloropyridin-4-ol (344 mg, 2.63 mmol) and (2-chlorophenyl)acetic acid (681 mg, 3.99 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[(2-chloropyridin-4-yl)oxy]-3-sulfamoylphenyllacetamide and were purified at the end by column chromatography on a Biotage Isolera system (silica gel, gradient n-hexane/ethyl acetate/methanol), followed by preparative HPLC (Chromatorex 0-18 10pm, 125x30mm, acetonitrile/water + 0.1% formic acid) (45 mg, 0.0995 mmol, 4% yield over 4 steps, 98 %
purity).
LC-MS (Method A): Rt = 1.06 min MS (ESIpos): m/z = 452 (M+H).
1H-NMR (400MHz, DM50¨d6) ei [ppm]: 3.82 (s, 2H), 6.91 (d, 1H), 7.01 (d, 1H), 7.05 (s, 1H), 7.27 - 7.37 (m, 2H), 7.40 - 7.48 (m, 2H), 7.64 (dd, 1H), 8.13 (d, 1H), 8.18 (d, 1H), 10.29 (s, 1H), 10.71 -11.27 (m, 2H).

Example 004 2-(2-Chloropheny1)-N-[4-(3-isopropylphenoxy)-3-sulfamoylphenyl]acetamide Oss õNH.

o CI

According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1025 mg, 2.65 mmol), 3-isopropylphenol (361 mg, 2.65 mmol) and (2-chlorophenyl)acetic acid (499 mg, 2.93 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(3-isopropylphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by column chromatography on a Biotage Isolera system (silica gel, gradient n-hexane/ethyl acetate) (251 mg, 0.547 mmol, 21 % yield over 4 steps, 95 % purity).
LC-MS (Method A): Rt = 1.33 min MS (ESIpos): m/z = 459 (M+H)+
1H-NMR (400MHz, DICHLOROMETHANE¨d2) [ppm]: 1.26 (d, 6H), 2.93 (sep, 1H), 3.86 (s, 2H), 5.22 (s, 2H), 6.86 - 6.90 (m, 2H), 7.00 (t, 1H), 7.12 (d, 1H), 7.29-7.36 (m, 3H), 7.39 - 7.49 (m, 2H), 7.52 (s, 1H), 7.78 (dd, 1H), 7.88 (d, 1H).
Example 005 2-(2-Chloropheny1)-N-{3-sulfamoy1-443-(trifluoromethyl)phenoxy]phenyl}acetamide 0µ. t\JH

o 0 CI
F. F
zo According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (998 mg, 2.58 mmol), 3-(trifluoromethyl)phenol (418 mg, 2.58 mmol) and (2-chlorophenyl)acetic acid (509 mg, 2.98 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{3-sulfamoy1-4-[3-(trifluoromethyl)phenoxy]phenyllacetamide and were purified at the end by column chromatography on a Biotage Isolera (silica gel, gradient n-hexane/ethyl acetate) (405 mg, 0.835 mmol, 32 % yield over 4 steps, 95 % purity).
LC-MS (Method A): Rt = 1.26 min MS (ESIpos): m/z = 485 (M+H)+
1H-NMR (400MHz, DICHLOROMETHANE¨d2) o [ppm]: 3.87 (s, 2H), 5.26 (s, 2H), 6.93 (d, 1H), 7.24 -7.28 (m, 1H), 7.29 - 7.35 (m, 2H), 7.37 (s, 1H), 7.39 - 7.57 (m, 4H), 7.68 (s, 1H), 7.84 (dd, 1H), 7.95 (d, 1H).
Example 006 2-(2-Chloropheny1)-N-{3-sulfamoy1-443-(trifluoromethoxy)phenoxy]phenyl}acetamide O
=

Cl According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (1.03 g, 2.66 mmol), (trifluoromethoxy)phenol (473 mg, 2.66 mmol) and (2-chlorophenyl)acetic acid (516 mg, 3.02 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{3-sulfamoy1-4-[3-(trifluoromethoxy)phenoxy]phenyl}acetamide and were purified at the end by column chromatography on a Biotage lsolera system (silica gel, gradient n-hexane/ethyl acetate) (227 mg, 0.453 mmol, 17 c/o yield over 4 steps, 97 %
purity).
LC-MS (Method A): Rt = 1.29 min MS (ESIpos): m/z = 501 (M+1-1)' 1H-NMR (400MHz, DICHLOROMETHANE¨d2) ô [ppm]: 3.88 (s, 2H), 5.18 (s, 2H), 6.97 (d, 1H), 6.99 - 7.01 (m, 1H), 7.03 (ddd, 1H), 7.07 - 7.12 (m, 1H), 7.30 - 7.37 (m, 2H), 7.40 -7.52 (m, 4H), 7.85 (dd, 1H), 7.93 (d, 1H).
Example 007 N44-(3-Acetylphenoxy)-3-sulfamoylpheny1]-2-(2-chlorophenyl)acetamide 0 :SõNH, 0' (10 0 CI

According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 1-(3-hydroxyphenyl)ethanone (176 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to N44-(3-acetylphenoxy)-3-sulfamoylpheny1]-2-(2-chlorophenyl)acetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x30mm, acetonitrile/water +
0.1%
formic acid) (15 mg, 0.0327 mmol, 3 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.08 min MS (ESIpos): m/z = 459 (MI-H) 1H-NMR (400MHz, DMSO¨d6) 6 [ppm]: 2.58 (s, 3H), 3.86 (s, 2H), 7.04 (d, 1H), 7.27 - 7.36 (m, 3H), 7.40 (s, 2H), 7.42 - 7.48 (m, 2H), 7.52 - 7.58 (m, 2H), 7.74 -7.78 (m, 1H), 7.80 (dd, 1H), 8.23 (d, 1H), 10.53 (s, 1H).
Example 008 N44-(1,3-Benzodioxo1-5-yloxy)-3-sulfamoylpheny1]-2-(2-chlorophenyl)acetamide ,NH2 According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (1.03 g, 2.66 mmol), 1,3-benzodioxo1-5-ol zo (367 mg, 2.66 mmol) and (2-chlorophenyl)acetic acid (577 mg, 3.38 mmol) were converted without purification of intermediates to N44-(1,3-benzodioxo1-5-yloxy)-3-sulfamoylpheny1]-2-(2-chlorophenypacetamide and were purified at the end by column chromatography on a Biotage Isolera system (silica gel, gradient n-hexane/ethyl acetate) followed by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water +
0.1% formic acid) (65 mg, 0.141 mmol, 5% yield over 4 steps, 98% purity).
LC-MS (Method A): Rt = 1.10 min MS (ESIpos): m/z = 461 (M+1-1)+
1H-NMR (400MHz, DICHLOROMETHANE¨d2) 6 [ppm]: 3.88 (s, 2H), 5.21 (s, 2H), 6.04 (s, 2H), 6.60 (dd, 1H), 6.66 (d, 1H), 6.83 (d, 1H), 6.90 (d, 1H), 7.31 - 7.39 (m, 2H), 7.39 - 7.51 (m, 3H), 7.79 (dd, 1H), 7.87 (d, 1H).
Example 009 N14-(3-Acetamidophenoxy)-3-sulfamoylpheny1]-2-(2-chlorophenyl)acetamide :S 2 (-21 CI HC NH

According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), N-(3-hydroxyphenyl)acetamide (195 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to N-[4-(3-acetamidophenoxy)-3-sulfamoylpheny1]-2-(2-chlorophenyl)acetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water +
0.1% formic acid) (15 mg, 0.0317 mmol, 2% yield over 4 steps, 94% purity).
LC-MS (Method A): Rt = 0.99 min MS (ESIpos): m/z = 474 (M+1-1)*
1H-NMR (400MHz, DMSO¨c16) 8 [ppm]: 2.02 (s, 3H), 3.85 (s, 2H), 6.71 - 6.77 (m, 1H), 6.96 (d, 1H), 7.26 - 7.40 (m, 7H), 7.41 -7.48 (m, 2H), 7.75 (dd, 1H), 8.19 (d, 1H), 10.00 (s, 1H), zo 10.48 (s, 1H).
Example 010 2-(2-Chloropheny1)-N44-(2-fluorophenoxy)-3-sulfamoylphenyl]acetamide 'S F

CI

According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 2-fluorophenol (145 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (239 mg, 1.40 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N44-(2-fluorophenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC
(Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (65 mg, 0.0149 mmol, 12 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.12 min MS (ES1pos): m/z = 435 (M+H) 1H-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.82 (s, 2H), 6.80 (d, 1H), 7.12 - 7.34 (m, 5H), 7.35 -7.47 (m, 5H), 7.71 (dd, 1H), 8.18 (d, 1H), 10.43 (s, 1H).
Example 011 2-(2-Chloropheny1)-N4443-fluorophenoxy)-3-sulfamoylphenyliacetamide CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-fluorophenol (145 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (239 mg, 1.40 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N44-(3-fluorophenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC
(Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (66 mg, 0.0152 mmol, 121% yield over 4 steps, 981% purity).
LC-MS (Method A): Rt = 1.14 min MS (ES1pos): m/z = 435 (M+H)+
1H-NMR (400MHz, DMSO¨d6) o [ppm]: 3.84 (s, 2H), 6.81 -6.91 (m, 2H), 6.96 (tdd, 1H), 7.07 (d, 1H), 7.26 - 7.47 (m, 7H), 7.78 (dd, 1H), 8.20 (d, 1H), 10.50 (s, 1H).
Example 012 2-(2-chlorophenyI)-N-[4-(4-fluorophenoxy)-3-sulfamoylphenyl]acetamide 0.11õNH2 NSSF
CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 4-fluorophenol (145 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (239 mg, 1.40 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(4-fluorophenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC
(Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (44 mg, 0.101 mmol, 8 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.14 min MS (ESIpos): m/z = 435 (M+H)+
11-I-NMR (400MHz, DMSO¨d6) ei [ppm]: 3.82 (s, 2H), 6.92 (d, 1H), 7.04 - 7.12 (m, 2H), 7.18 - 7.26 (m, 2H), 7.27 - 7.37 (m, 4H), 7.38 - 7.46 (m, 2H), 7.74 (dd, 1H), 8.18 (d, 1H), 10.45 (s, 1H).
Example 013 2-(2-Chloropheny1)-N44-(pyridin-2-yloxy)-3-sulfamoylphenyliacetamide oS

o 0 N
Cl According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), pyridin-2-ol (123 mg, zo 1.29 mmol) and (2-chlorophenyl)acetic acid (239 mg, 1.40 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(pyridin-2-yloxy)-3-sulfamoylphenyl]acetamide (among other isomers) and were purified at the end twice by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid), (27 mg, 0.646 mmol, 5 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 0.99 min MS (ESIpos): m/z = 418 (M+H)f 1H-NMR (400MHz, DMSO¨c16) 6 [ppm]: 3.85 (s, 2H), 7.11 (ddd, 1H), 7.15 (d, 1H), 7.23 (d, 1H), 7.26 - 7.34 (m, 4H), 7.39 - 7.47 (m, 2H), 7.79 (dd, 1H), 7.83 (ddd, 1H), 8.07 (ddd, 1H), 8.17 (d, 1H), 10.49 (s, 1H).
Example 014 2-(2-ChlorophenyI)-N-(4-phenoxy-3-sulfamoylphenyl)acetamide 0õNH
'S 2 o CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), phenol (127 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (240 mg, 1.41 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-(4-phenoxy-3-sulfamoylphenyl)acetamide and were purified at the end by preparative HPLC
(Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (67 mg, 0.161 mmol, 12% yield over 4 steps, 98% purity).
LC-MS (Method A): Rt = 1.12 min MS (ESIpos): m/z = 417 (M+H)+
11-I-NMR (400MHz, DM50¨c16) 8 [ppm]: 3.83 (s, 2H), 6.92 (d, 1H), 7.02 - 7.08 (m, 2H), 7.14 (tt, 1H), 7.26 - 7.35 (m, 4H), 7.35 - 7.47 (m, 4H), 7.74 (dd, 1H), 8.18 (d, 1H), 10.45 (s, 1H).
Example 015 2-(2-Chloropheny1)-N44-(3-cyanophenoxy)-3-sulfamoylphenyllacetamide .N H2 o 0 0 CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1.00 g, 2.59 mmol), 3-hydroxybenzonitrile (308 mg, 2.59 mmol) and (2-chlorophenyl)acetic acid (485 mg, 2.84 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(3-cyanophenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Chromatorex 0-18 10pm, 125x30mm, acetonitrile/water + 0.1% formic acid) (112 mg, 0.253 mmol, 10% yield over 4 steps, 98% purity).
LC-MS (Method A): Rt = 1.09 min MS (ESIpos): m/z = 442 (M+H)+
1H-NMR (400MHz, DMSO¨d6) ei [ppm]: 3.85 (s, 2H), 7.11 (d, 1H), 7.27 - 7.35 (m, 3H), 7.37 - 7.48 (m, 5H), 7.53 - 7.60 (m, 2H), 7.81 (dd, 1H), 8.22 (d, 1H), 10.53 (s, 1H).
Example 016 2-(2-Chloropheny1)-N-{443-(methylsulfonyl)phenoxy]-3-sulfamoylphenyllacetamide II
0 0 sz-cH3 Cl According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1.00 g, 2.59 mmol), 3-(methylsulfonyl)phenol (445 mg, 2.59 mmol) and (2-chlorophenyl)acetic acid (485 mg, 2.84 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[3-(methylsulfonyl)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Chromatorex 0-18 10pm, 125x30mm, acetonitrile/water +
0.1%
zo formic acid) (50 mg, 0.101 mmol, 4 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.02 min MS (ESIpos): m/z = 495 (M+H) 1H-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.21 (s, 3H), 3.85 (s, 2H), 7.13 (d, 1H), 7.26 - 7.35 (m, 3H), 7.40 - 7.47 (m, 4H), 7.52 - 7.55 (m, 1H), 7.61 -7.68 (m, 2H), 7.82 (dd, 1H), 8.23 (d, 1H), 10.53 (s, 1H).
Example 017 3-(4-{[(2-Chlorophenyl)acetyl]amino}-2-sulfamoylphenoxy)benzamide = 0 CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-hydroxybenzamide (177 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (240 mg, 1.41 mmol) were converted without purification of intermediates to 3-(4-{[(2-chlorophenyl)acetyl]amino}-2-sulfamoylphenoxy)benzamide and were purified at the end by preparative HPLC
(Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (47 mg, 0.102 mmol, 8 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 0.92 min MS (ESIpos): m/z = 460 (M-1-1-1)*
11-I-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.84 (s, 2H), 6.98 (d, 1H), 7.18 (ddd, 1H), 7.26 -7.37 (m, 4H), 7.38 - 7.49 (m, 4H), 7.51 -7.56 (m, 1H), 7.63- 7-67 (m, 1H), 7.76 (dd, 1H), 7.98 (s, 1H), 8.21 (d, 1H), 10.48 (s, 1H).
Example 018 2-(2-Chloropheny1)-N44-(3-methylphenoxy)-3-sulfamoylphenyl]acetamide O, NH2 CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), m-cresol (140 mg, zo 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N44-(3-methylphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC
(Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (41 mg, 0.095 mmol, 7 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.19 min MS (ES1pos): m/z = 431 (M+H)+

1H-NMR (400MHz, DMSO¨d6) 8 [ppm]: 2.28 (s, 3H), 3.83 (s, 2H), 6.81 - 6.89 (m, 2H), 6.92 (d, 1H), 6.96 (d, 1H), 7.23 - 7.34 (m, 5H), 7.39 - 7.46 (m, 2H), 7.73 (dd, 1H), 8.17 (d, 1H), 10.44 (s, 1H).
Example 019 2-(2-ChlorophenyI)-N-[4-(pyrimidin-5-yloxy)-3-sulfamoylphenyl]acetamide 0.1I,NH
%S 2 = o 0 orN
) N N
H
CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), pyrimidin-5-ol (124 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N44-(pyrimidin-5-yloxy)-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC
(Chromatorex C-18 10pm, 125x30mm, acetonitrile/water + 0.1% formic acid) followed by another preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water +
0.1%
formic acid) (2 mg, 0.00477 mmol, 0.4 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 0.89 min MS (ESIpos): m/z = 419 (M+H)*
11-1-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.85 (m, 2H), 7.24 (d, 1H), 7.28 - 7.34 (m, 2H), 7.39 - 7.46 (m, 2H), 7.49 (s, 2H), 7.82 (dd, 1H), 8.23 (d, 1H), 8.52 (s, 2H), 8.95 (s, 1H), 10.56 (s, 1H).
Example 020 2-(2-Chloropheny1)-N-{3-sulfamoy1-4-(3-(4H-1,2,4-triazol-4-y1)phenoxy]phenyl}acetamide o 40 CI
N¨N
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(4H-1,2,4-triazol-4-yl)phenol (208 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-(3-sulfamoy1-4-[3-(4H-1,2,4-triazol-4-yl)phenoxy]phenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omnn, acetonitrile/water + 0.1%
formic acid) (17 mg, 0.0351 mmol, 3% yield over 4 steps, 98% purity).
LC-MS (Method A): Rt = 0.92 min MS (ES1pos): m/z = 484 (M+H)*
1H-NMR (400MHz, DMSO¨c16) 8 [ppm]: 3.84 (s, 2H), 6.99 (ddd, 1H), 7.09 (d, 1H), 7.27 -7.34 (m, 2H), 7.36 (s, 2H), 7.40 - 7.46 (m, 2H), 7.46 - 7.50 (m, 1H), 7.51 -7.57 (m, 2H), 7.79 (dd, 1H), 8.22 (d, 1H), 9.13 (s, 2H), 10.50 (s, 1H).
Example 021 2-(2-Chloropheny1)-N-{3-sulfamoy1-443-(1H-tetrazol-5-yl)phenoxy]phenyllacetamide CI
HN N N
N=N
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(1H-tetrazol-yl)phenol (210 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without punfication of intermediates to 2-(2-chloropheny1)-N-{3-sulfamoy1-443-(1H-tetrazol-5-yl)phenoxy]phenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (20 mg, 0.0412 mmol, 3% yield over 4 steps, 95% purity).
LC-MS (Method A): Rt = 0.98 min MS (ESIpos): m/z = 485 (MI-H) 1H-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.85 (s, 2H), 7.09 (d, 1H), 7.23 (ddd, 1H), 7.27 -7.35 (m, 2H), 7.37 - 7.47 (m, 4H), 7.60 (t, 1H), 7.69 (t, 1H), 7.78 - 7.82 (m, 2H), 8.23 (d, 1H), 10.51 (s, 1H).
Example 022 2-(2-Chloropheny1)-N44-(3-methoxyphenoxy)-3-sulfamoylphenyllacetamide 00,11,NH, CH
i CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-methoxyphenol (160 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(3-methoxyphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (42 mg, 0.0940 mmol, 7 ck yield over 4 steps, 97 % purity).
LC-MS (Method A): Rt = 1.13 min zo MS (ESIpos): m/z = 447 (M+H) 1H-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.75 (s, 3H), 3.85 (s, 2H), 6.60 (ddd, 1H), 6.67 (t, 1H), 6.74 (ddd, 1H), 6.99 (d, 1H), 7.25 - 7.36 (m, 5H), 7.41 -7.49 (m, 2H), 7.76 (dd, 1H), 8.20 (d, 1H), 10.48 (s, 1H).
Example 023 2-(2-Chloropheny1)-N44-(4-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 0NH, 0' I-13 CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 4-methoxyphenol (160 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N44-(4-methoxyphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (38 mg, 0.0850 mmol, 7 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.12 min MS (ESIpos): m/z = 447 (M+H) 1H-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.76 (s, 3H), 3.83 (s, 2H), 6.83 (d, 1H), 6.95 - 7.07 (m, 4H), 7.28 - 7.35 (m, 4H), 7.39 - 7.48 (m, 2H), 7.71 (dd, 1H), 8.17 (d, 1H), 10.43 (s, 1H).
Example 024 2-(2-Chloropheny1)-N-{443-(difluoromethoxy)phenoxy]-3-sulfamoylphenyllacetamide 0, ,NH
iS 2 CI F,T,0 According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(difluoromethoxy)phenol (207 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[3-(difluoromethoxy)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end twice by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water +
0.1% formic acid) (29 mg, 0.0601 mmol, 5% yield over 4 steps, 97% purity).

LC-MS (Method A): Rt = 1.18 min MS (ESIneg): m/z = 481 (M-1-1)+
11-1-NMR (400MHz, DMSO¨c16) 6 [ppm]: 3.85 (s, 2H), 6.87 (dd, 1H), 6.90 (t, 1H), 6.93 -6.96 (dd, 1H), 7.07 (d, 1H), 7.27 (t, 1H), 7.29 - 7.35 (m, 2H), 7.38 (s, 2H), 7.40 -7.48 (m, 3H), 7.80 (dd, 1H), 8.22 (d, 1H), 10.52 (s, 1H).
Example 025 2-(2-Chloropheny1)-N44-(3,4-dicyanophenoxy)-3-sulfamoylphenyl]acetamide 0*

0 o 40) 0 N
H N
CI INI
lo According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesuffonamide (500 mg, 1.29 mmol), 4-hydroxyphthalonitrile (186 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N44-(3,4-dicyanophenoxy)-3-suffamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (18 mg, 0.0386 mmol, 3 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.09 min MS (ESIneg): m/z = 465 (M-1-1)+
11-1-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.81 (s, 2H), 6.89 (d, 1H), 7.28 - 7.35 (m, 2H), 7.40 -7.48 (m, 3H), 7.55 (s, 1H), 7.63 (dd, 1H), 7.94 (d, 1H), 8.15 (s, 1H), 10.27 (s, 1H), 11.05 (s, 2H).
Example 026 2-(2-Chloropheny1)-N-{4-(3-(morpholin-4-yl)phenoxy]-3-sulfamoylphenyl}acetamide :S
0' CI
Co) According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(morpholin-4-yl)phenol (232 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{4-[3-(morpholin-4-yl)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end twice by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (18 mg, 0.0386 mmol, 3% yield over 4 steps, 98% purity).
LC-MS (Method A): Rt = 1.11 min MS (ES1pos): m/z = 502 (M+H)+
1H-NMR (400MHz, DMS0-4:16) 6 [ppm]: 3.07 - 3.13 (m, 4H), 3.69 - 3.75 (m, 4H), 3.84 (s, 2H), 6.46 (dd, 1H), 6.69 (t, 1H), 6.76 (dd, 1H), 6.94 (d, 1H), 7.22 (t, 1H), 7.26 - 7.35 (m, 4H), 7.41 -7.47 (m, 2H), 7.73 (dd, 1H), 8.18 (d, 1H), 10.45 (s, 1H).
Example 027 2-(2-Chloropheny1)-N-[4-(3-{4-[(2-chlorophenyl)acetyl]piperazin-1-yllphenoxy)-sulfamoylphenyliacetamide CI

CI

According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(piperazin-1-yl)phenol (230 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(3-{4-[(2-chlorophenyl)acetyl]piperazin-1-yllphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (16 mg, 0.0245 mmol, 2% yield over 4 steps, 95%
purity). The monoacylated compound could not be isolated.
LC-MS (Method A): Rt = 1.26 min MS (ESIneg): m/z = 651 (M-H) 11-I-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.11 -3.22 (m, 4H), 3.59 - 3.72 (m, 4H), 3.84 (s, 2H), 3.86 (s, 2H), 6.47 (dd, 1H), 6.71 (t, 1H), 6.76 (dd, 1H), 6.95 (d, 1H), 7.23 (t, 1H), 7.26 -7.35 (m, 7H), 7.41 -7.48 (m, 3H), 7.74 (dd, 1H), 8.18 (d, 1H), 10.46 (s, 1H).
Example 028 2-(2-Chloropheny1)-N44-(pyridin-3-yloxy)-3-sulfamoylphenyl]acetamide 0,11,NH, o t Cl According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), pyridin-3-ol (123 mg, zo 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(pyridin-3-yloxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC
(Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (45 mg, 0.108 mmol, 8 % yield over 4 steps, 95 % purity).
LC-MS (Method A): Rt = 0.89 min MS (ESIneg): m/z = 416 (M-H) 1H-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.85 (s, 2H), 7.07 (d, 1H), 7.26 - 7.46 (m, 8H), 7.80 (dd, 1H), 8.22 (d, 1H), 8.35 (dd, 1H), 8.38 (d, 1H), 10.52 (s, 1H).

Example 029 2-(2-Chloropheny1)-N44-[(5-chloropyridin-3-y0oxy]-3-sulfamoylphenyllacetamide CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 5-chloropyridin-3-ol (167 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[(5-chloropyridin-3-yl)oxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) followed by another preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.2% aqueous ammonia (32%)) (11.2 mg, 0.0248 mmol, 2 c/o yield over 4 steps, 95 % purity).
LC-MS (Method B): Rt = 0.99 min MS (ESIpos): m/z = 452 (M+H)+
11-I-NMR (400MHz, METHANOL¨d4) S [ppm]: 3.90 (s, 2H), 7.14 (d, 1H), 7.25 -7.33 (m, 2H), 7.41 (s, 2H), 7.51 (t, 1H), 7.87 (dd, 1H), 8.25 (d, 1H), 8.29 (d, 1H), 8.32 (d, 1H).
Example 030 2-(2-Chloropheny1)-N44-(4-cyanophenoxy)-3-sulfamoylphenyl]acetamide CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 4-hydroxybenzonitrile (154 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(4-cyanophenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (10.6 mg, 0.0240 mmol, 2 c/o yield over 4 steps, 97 % purity).
LC-MS (Method A): Rt = 1.06 min MS (ESIpos): m/z = 442 (M+H)+
1H-NMR (400MHz, DMSO¨d6) [ppm]: 3.80 (s, 2H), 6.87 (d, 1H), 7.19 (d, 2H), 7.28 - 7.35 (m, 2H), 7.40 - 7.48 (m, 2H), 7.60 (dd, 1H), 7.65(d, 2H), 8.11 (d, 1H), 10.24(s, 1H), 10.80 (s, 2H).
Example 031 2-(2-Chloropheny1)-N-{443-(difluoromethyl)phenoxy]-3-sulfamoylphenyl}acetamide CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(difluoromethyl)phenol (186 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[3-(difluoromethyl)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%

formic acid) (22.5 mg, 0.0482 mmol, 4 c/o yield over 4 steps, 97 % purity).
LC-MS (Method A): Rt = 1.17 min MS (ESIpos): m/z = 467 (M+H)+
1H-NMR (400MHz, DICHLOROMETHANE¨d2) 8 [ppm]: 3.89 (s, 2H), 5.20 (s, 2H), 6.69 (t, 1H), 6.96 (d, 1H), 7.20 - 7.61 (m, 8H), 7.86 (dd, 1 H ) , 7.95 (d, 1H).
Example 032 2-(2-Chloropheny1)-N44-(2-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 0=¨N H2 =,CH3 la 0 0 .
CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 2-methoxyphenol (160 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (331 mg, 1.94 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(2-methoxyphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (140 mg, 0.0313 mmol, 24% yield over 4 steps, 99% purity).
LC-MS (Method A): Rt = 1.13 min MS (ESIpos): m/z = 447 (M+H)+
1H-NMR (400MHz, DICHLOROMETHANE¨d2) 5 [ppm]: 3.79 (s, 3H), 3.85 (s, 2H), 5.39 (s, 2H), 6.79 (d, 1H), 7.04 (td, 1H), 7.08 (dd, 1H), 7.21 (dd, 1H), 7.25 -7.38 (m, 4H), 7.40 -7.50 (m, 2H), 7.73 (dd, 1H), 7.84 (d, 1H).
Example 033 242-Chloropheny1)-N44-(3,5-dicyanophenoxy)-3-sulfamoylphenyliacetamide 0=S¨NH2 Cl I I
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 5-hydroxyisophthalonitrile (186 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (330 mg, 1.94 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(3,5-dicyanophenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (65 mg, 0.139 mmol, 11 % yield over 4 steps, 97% purity).
LC-MS (Method A): Rt = 1.08 min MS (ESIpos): m/z = 467 (M+H) 11-I-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.78 (s, 2H), 6.88 (d, 1H), 7.26 - 7.33 (m, 2H), 7.38 - 7.45 (m, 2H), 7.62 (dd, 1H), 7.67 (d, 2H), 8.02 (s, 1H), 8.08 (d, 1H), 10.23 (s, 1H), 10.85 (s, 2H).
Example 034 2-(2-Chloropheny1)-N44-(5-cyano-2-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 0=S¨NH2 õ.= N

0is According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-10 dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-hydroxy-4-methoxybenzonitrile (92 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (330 mg, 1.94 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(5-cyano-2-methoxyphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (132 mg, 0.280 mmol, 22 % yield over 4 steps, 99 % purity).
LC-MS (Method A): Rt = 1.07 min MS (ESIpos): m/z = 472 (M+H) 1H-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.82 (s, 2H), 3.84 (s, 3H), 6.75 (d, 1H), 7.25 (s, 2H), 7.28 - 7.32 (m, 2H), 7.34 (d, 1H), 7.39 - 7.46 (m, 2H), 7.48 (d, 1H), 7.68 (dd, 1H), zo 7.72 (dd, 1H), 8.16 (d, 1H), 10.42 (s, 1H).
Example 035 2-(2-Chloropheny1)-N-{4-[(2,5-dichloropyridin-3-yl)oxy]-3-sulfamoylphenyllacetamide 0=S¨NH2 CI
o o CI CI

According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 2,5-dichloropyridin-3-ol (212 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (330 mg, 1.94 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[(2,5-dichloropyridin-3-yl)oxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (32 mg, 0.0657 mmol, 5 % yield over 4 steps, 90 % purity).
LC-MS (Method A): Rt = 1.16 min MS (ESIpos): m/z = 487/488 (M+H)+
1H-NMR (400MHz, DMSO¨c16) ei [ppm]: 3.77 (s, 2H), 6.91 (d, 1H), 7.25 - 7.33 (m, 2H), 7.36 - 7.46 (m, 2H), 7.63 (dd, 1H), 7.84 (d, 1H), 7.96 (d, 1H), 8.24 (s, 1H),

9.92 (s, 1H),

10.19 (s, 1H), 10.71 (s, 1H).
Example 036 2-(2-ChlorophenyI)-N-{44(5,6-dichloropyridin-3-yl)oxy]-3-sulfamoylphenyl}acetamide 0=S¨NH2 o 0 CI
CI CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 5,6-dichloropyridin-3-ol (212 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (330 mg, 1.94 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[(5,6-dichloropyridin-3-yl)oxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (98 mg, 0.154 mmol, 12% yield over 4 steps, 93% purity).
LC-MS (Method A): Rt = 1.24 min MS (ESIpos): m/z = 487/488 (M+H)+
1H-NMR (400MHz, DMSO¨d6) 6 [ppm]: 3.83 (s, 2H), 6.89 (d, 1H), 7.06 (d, 1H), 7.25 - 7.47 (m, 6 H), 7.63 (d, 1H), 7.75 (dd, 1H), 8.22 (d, 1H), 10.50 (s, 1H).

Example 037 3-(4-{[(2-Chlorophenyl)acetyl]amino}-2-sulfamoylphenoxy)-N-cyclopropylbenzamide li 0=S¨NH2 N
H
CI

H
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), N-cyclopropy1-hydroxybenzamide (229 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (121 mg, 0.707 mmol) were converted without purification of intermediates to 3-(4-{[(2-chlorophenyl)acetyl]amino}-2-sulfamoylphenoxy)-N-cyclopropylbenzamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (9 mg, 0.0180 mmol, 1 % yield over 4 steps, 97 %
purity).
LC-MS (Method A): Rt = 1.02 min MS (ESIpos): m/z = 500 (M+H)+
1H-NMR (400MHz, DMSO¨d6) 6 [ppm]: 0.53 - 0.59 (m, 2H), 0.66 - 0.72 (m, 2H), 2.79 -2.87 (m, 1H), 3.85 (s, 2H), 6.98 (d, 1H), 7.17 (ddd, 1H), 7.28 - 7.35 (m, 2H), 7.38 (s, 2H), 7.41 - 7.48 (m, 3H), 7.52 (t, 1H), 7.59 - 7.63 (m, 1H), 7.77 (dd, 1H), 8.22 (d, 1H), 8.50 (d, 1H), 10.52 (s, 1H).
Example 038 zo 2-(2-chloropheny1)-N-(4-[(3-chloropyridin-2-yl)oxy]-3-sulfamoylphenyl}acetamide 0 = 0 O)z)N
N CI
H
CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (1500 mg, 3.88 mmol), 3-chloropyridin-2-ol (502 mg, 3.88 mmol) and (2-chlorophenyl)acetic acid (646 mg, 3.79 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[(3-chloropyridin-2-yl)oxy]-3-sulfamoylphenyllacetamide (among other isomers) and were purified at the end by preparative HPLC (YMC - Triart 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) followed by another preparative HPLC
(Phenomenex Kinetex 018 5p 100x3Omm, acetonitrile/water + 0.1% trifluoroacetic acid) (1.8 mg, 0.00398 mmol, 0.1 % yield over 4 steps, 97% purity).
LC-MS (Method D): Rt = 2.12 min MS (ESIpos): m/z = 452 (M+H)*

11-I-NMR (500MHz, DMSO¨d6) 8 [ppm]: 3.87 (s, 2H), 7.14 - 7.21 (m, 3H), 7.25 (d, 1H), 7.29 - 7.35 (m, 2H), 7.41 -7.48 (m, 2H), 7.82 (dd, 1H), 8.00 - 8.03 (m, 2H), 8.21 (d, 1H), 10.55 (s, 1H).
Example 039 2-(2-chloropheny1)-N-{4-[(4-chloropyridin-2-y1)oxy]-3-sulfamoylphenyl}acetamide o 0 N
Cl Cl According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (1500 mg, 3.88 mmol), 4-chloropyridin-2-ol (502 mg, 3.88 mmol) and (2-chlorophenyl)acetic acid (634 mg, 3.72 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[(3-chloropyridin-2-yl)oxy]-3-sulfamoylphenyllacetamide (among other isomers) and were purified at the end by preparative HPLC (YMC - Triart 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) followed by another preparative HPLC (:

Phenomenex Kinetex 018 5p 100x3Omm, acetonitrile/water + 0.1% trifluoroacetic acid) (2.8 mg, 0.00619 mmol, 0.2% yield over 4 steps, 90% purity).
LC-MS (Method D): Rt = 2.17 min MS (ESIpos): m/z = 452 (M+H) 1H-NMR (500MHz, DMSO¨d6) 8 [ppm]: 3.87 (s, 2H), 7.24 (dd, 1H), 7.29 - 7.38 (m, 6H), 7.40 -7.49 (m, 2H), 7.82 (dd, 1H), 8.07 (d, 1H), 8.18 (d, 1H), 10.53 (s, 1H).

Example 040 2-(2-Chloropheny1)-N-{4-[(6-chloropyridin-2-y1)oxy]-3-sulfamoylphenyllacetamide 0=S¨NH2 I
CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide (1500 mg, 3.88 mmol), 6-chloropyridin-2-ol (502 mg, 3.88 mmol) and (2-chlorophenyl)acetic acid (413 mg, 2.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{4-[(6-chloropyridin-2-ypoxy]-3-sulfamoylphenyllacetamide (among other isomers) and were purified at the end by preparative HPLC (YMC - Triart 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (11.2 mg, 0.0248 mmol, 0.6 % yield over 4 steps, 95 % purity).
LC-MS (Method D): Rt = 2.20 min MS (ESIpos): m/z = 452 (M+H)+
1H-NMR (500MHz, DM50¨d6) 8 [ppm]: 3.86 (s, 2H), 7.12 (d, 1H), 7.22 (d, 1H), 7.28 - 7.35 (r111, 3H), 7.38 (s, 2H), 7.42 - 7.48 (m, 2H), 7.84 (dd, 1H), 7.89 (t, 1H), 8.20 (d, 1H), 10.55 (s, 1H).
Example 041 2-(2-Chloropheny1)-N-{443-(1 -methyl-4, 5-dihydro-1H-imidazol-2-yOphenoxy]-3-sulfamoylphenyllacetamide 0=S¨NH2 lei 0 =
CI

According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(1-methy1-4,5-dihydro-1H-imidazol-2-yl)phenol (228 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (241 mg, 1.41 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{4-[3-(1-methy1-4,5-dihydro-1H-imidazol-2-y1)phenoxy]-3-sulfamoylphenyl}acetamide and were purified at the end by preparative HPLC
(Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (5 mg, 0.100 mmol, 1 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 0.83 min MS (ESIpos): m/z = 499 (M+H) 11-I-NMR (400MHz, METHANOL¨d4) [ppm]: 3.10 (s, 3H), 3.92 (s, 2H), 3.94 - 4.12 (m, 4H), 7.12 (d, 1H), 7.23 -7.27 (m, 1H), 7.28 - 7.35 (m, 2H), 7.39 - 7.48 (m, 4H), 7.65 (t, 1H), 7.91 (dd, 1H), 8.23 (d, 1H).
Example 042 2-(2-Chloropheny1)-N-{4-[4-(1H-imidazol-1-yflphenoxy1-3-sulfamoylphenyllacetamide 0=S¨NH2 o Cl H Li According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 4-(1H-imidazol-yl)phenol (207 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (197 mg, 1.15 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{444-(1H-imidazol-1-yl)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 Si 100x3Omm, acetonitrile/water + 0.1% formic acid) (6 mg, 0.0124 mmol, 1 % yield over 4 steps, 97% purity).
LC-MS (Method A): Rt = 0.82 min MS (ESIpos): m/z = 483 (M+H).
1H-NMR (400MHz, METHANOL¨d4) 6 [ppm]: 3.91 (s, 2H), 7.06 (d, 1H), 7.24 - 7.34 (m, 5H), 7.40 - 7.45 (m, 2H), 7.61 - 7.65 (m, 2H), 7.69 (t, 1H), 7.85 (dd, 1H), 8.23 (d, 1H), 8.46 (s, 1H).

Example 043 2-(2-Chloropheny1)-N-{444-(2-oxopyrrolidin-1-yl)phenoxy]-3-sulfamoylphenyllacetamide 0=S¨NH2 = 0 CI

According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 1-(4-hydroxyphenyl)pyrrolidin-2-one (229 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (213 mg, 1.25 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{444-(1H-imidazol-1-yl)phenoxy]-3-sulfamoylphenyllacetamide and were io purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (15 mg, 0.0300 mmol, 2% yield over 4 steps, 95%
purity).
LC-MS (Method A): Rt = 1.03 min MS (ESIpos): m/z = 500 (M+H)+
11-I-NMR (400MHz, METHANOL¨d4) zi [ppm]: 2.19 (quin, 2H), 2.60 (t, 2H), 3.88 (s, 2H), 3.92 (t, 2H), 6.91 (d, 1H), 7.12 - 7.16 (m, 2H), 7.25 - 7.32 (m, 2H), 7.36 -7.43 (m, 2H), 7.60 -7.64 (m, 2H), 7.75 (dd, 1H), 8.18 (d, 1H).
Example 044 2-(2-Chloropheny1)-N-{444-(morpholin-4-yl)phenoxy]-3-sulfamoylphenyl}acetamide 0=S¨NH2 = 0 Cl According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 4-(morpholin-4-yl)phenol (231 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (224 mg, 1.31 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[4-(morpholin-4-yl)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1% formic acid) (33 mg, 0.0657 mmol, 5 % yield over 4 steps, 98 % purity).
LC-MS (Method A): Rt = 1.07 min MS (ESIpos): m/z = 502 (M+H)+
1H-NMR (400MHz, METHANOL¨d4) ei [ppm]: 3.09- 3.16 (m, 4H), 3.81 - 3.85 (m, 4H), 3.87 (s, 2H), 6.82 (d, 1H), 7.00 -7.08 (m, 4H), 7.25 -7.32 (m, 2H), 7.37 - 7.43 (m, 2H), 7.69 (dd, 1H), 8.14(d, 1H).
Example 045 2-(2-Chloropheny1)-N44-(5-cyano-2-methylphenoxy)-3-sulfamoylphenyl]acetamide I. 0505 Cl INI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-hydroxy-4-methylbenzonitrile (172 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(5-cyano-2-methylphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (53 mg, 0.116 mmol, 9 % yield over 4 steps, 95 % purity).
zo LC-MS (Method A): Rt = 1.13 min MS (ESIpos): m/z = 456 (M+H) 11-I-NMR (400MHz, DMSO¨d6) 8 [ppm]: 2.31 (s, 3H), 3.85 (s, 2H), 6.82 (d, 1H), 7.27 (d, 1H), 7.28 - 7.35 (m, 2H), 7.40 - 7.48 (m, 4H), 7.54 (d, 1H), 7.60 (dd, 1H), 7.74 (dd, 1H), 8.23 (d, 1H), 10.50 (s, 1H).
Example 046 2-(2-Chloropheny1)-N44-(3-cyano-2-methylphenoxy)-3-sulfamoylphenyliacetamide 0.II,NH7 =o ao1 According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-hydroxy-2-methylbenzonitrile (172 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-[4-(3-cyano-2-methylphenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (29 mg, 0.0636 mmol, 5 % yield over 4 steps, 95 % purity).
LC-MS (Method A): Rt = 1.13 min MS (ESIpos): m/z = 456 (M+H)+
11-I-NMR (400MHz, DMSO¨d6) 8 [ppm]: 2.42 (s, 3H), 3.84 (s, 2H), 6.81 (d, 1H), 7.18 (dd, 1H), 7.28- 7.35 (m, 2H), 7.39 - 7.48 (m, 5H), 7.64 (dd, 1H), 7.73 (dd, 1H), 8.22 (d, 1H), 10.48 (s, 1H).
Example 047 2-(2-Chloropheny1)-N44-(3-cyano-4-fluorophenoxy)-3-sulfamoylphenyl]acetamide 0.11õN H, = 0 CI IN' According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 2-fluoro-5-hydroxybenzonitrile (177 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (251 mg, 1.47 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N44-(3-cyano-4-fluorophenoxy)-3-sulfamoylphenyl]acetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water + 0.1%
formic acid) (46 mg, 0.100 mmol, 8 % yield over 4 steps, 95 % purity).
LC-MS (Method A): Rt = 1.12 min MS (ESIpos): m/z = 460 (M+H) 1H-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.86 (s, 2H), 7.12 (d, 1H), 7.30 - 7.35 (m, 2H), 7.39 - 7.48 (m, 5H), 7.55 (t, 1H), 7.60 (dd, 1H), 7.82 (dd, 1H), 8.22 (d, 1H), 10.55 (s, 1H).
Example 048 N-{41(5-Chloro-2-cyanopyridin-3-yl)oxy]-3-sulfamoylphenyI}-2-(2-chlorophenyl)acetamide 0 ()N
CI CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 5-chloro-3-hydroxypyridine-2-carbonitrile (200 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to N-{4-[(5-chloro-2-cyanopyridin-3-yl)oxy]-3-sulfamoylphenyI}-2-(2-chlorophenyl)acetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water +
0.1% formic acid) (23 mg, 0.0482 mmol, 4% yield over 4 steps, 90% purity).
LC-MS (Method A): Rt = 1.12 min zo MS (ESIpos): m/z = 477 (M+H)+
1H-NMR (400MHz, DMSO¨d6) 8 [ppm]: 3.81 (s, 2H), 6.92 (d, 1H), 7.28 - 7.35 (m, 2H), 7.39 - 7.48 (m, 2H), 7.64 (dd, 1H), 7.69 (d, 1H), 8.19 (d, 1H), 8.39 (d, 1H), 10.30 (s, 1H), 10.92 (s, 1H), 11.40 (s, 1H).
Example 049 2-(2-Chloropheny1)-N-{443-(piperidin-1-yl)phenoxy]-3-sulfamoylphenyl}acetamide 0.11,NH
=-ss 2 = 0 CI
According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(piperidin-1-yl)phenol (229 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{443-(piperidin-1-yl)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde C18 Si 100x3Omm, acetonitrile/water + 0.1% formic acid) (64 mg, 0.128 mmol, 10% yield over 4 steps, 98% purity).
LC-MS (Method A): Rt = 1.15 min MS (ESIpos): m/z = 500 (M+H)+
11-I-NMR (400MHz, DMSO¨d6) zi [ppm]: 1.49- 1.65 (m, 6H), 3.09 -3.18 (m, 4H), 3.84 (s, 2H), 6.39 (dd, 1H), 6.66 (t, 1H), 6.73 (dd, 1H), 6.93 (d, 1H), 7.18 (t, 1H), 7.25 -7.35 (s, 4H), 7.41 -7.48 (m, 2H), 7.72 (dd, 1H), 8.17 (d, 1H), 10.44 (s, 1H).
Example 050 2-(2-Chloropheny1)-N-{443-(2-oxopyrrolidin-1-yl)phenoxy]-3-sulfamoylphenyllacetamide 0,I1, NH, = 0 Cl Cy0 According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 1-(3-hydroxyphenyl)pyrrolidin-2-one (229 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chloropheny1)-N-{443-(2-oxopyrrolidin-1-yl)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water +
0.1% formic acid) (15 mg, 0.0300 mmol, 2% yield over 4 steps, 99% purity).
LC-MS (Method A): Rt = 1.06 min MS (ESIpos): m/z = 500 (M+H)+
1H-NMR (400MHz, DMSO¨d6) ei [ppm]: 2.00 - 2.11 (m, 2H), one signal overlapped by solvent peak, 3.82 (t, 2H), 3.85 (s, 2H), 6.75 - 6.82 (m, 1H), 6.96 (d, 1H), 7.28 - 7.40 (m, 6H), 7.42 - 7.48 (m, 2H), 7.57 - 7.58 (m, 1H), 7.76 (dd, 1H), 8.20 (d, 1H), 10.49 (s, 1H).
Example 051 2-(2-Chloropheny1)-N-{443-(2-oxo-1,3-oxazolidin-3-yl)phenoxy]-3-sulfamoylphenyllacetamide 'S 2 NSS
CI
( Nr0 \-0 According to general procedures GP1.1, GP2.2, GP3.2 and GP4, 2-chloro-N-(2,4-dimethoxybenzy1)-5-nitrobenzenesulfonamide (500 mg, 1.29 mmol), 3-(3-hydroxyphenyI)-1,3-oxazolidin-2-one (231 mg, 1.29 mmol) and (2-chlorophenyl)acetic acid (242 mg, 1.42 mmol) were converted without purification of intermediates to 2-(2-chlorophenyI)-N-{4-[3-(2-oxo-1,3-oxazolidin-3-yl)phenoxy]-3-sulfamoylphenyllacetamide and were purified at the end by preparative HPLC (Waters XBrigde 018 5p 100x3Omm, acetonitrile/water +
0.1%
formic acid) (42 mg, 0.0837 mmol, 6 % yield over 4 steps, 95 % purity).
LC-MS (Method A): Rt = 1.04 min MS (ESIpos): m/z = 502 (M+H) 1H-NMR (400MHz, DMSO¨d6) 5 [ppm]: 3.85 (s, 2H), 4.05 (dd, 2H), 4.44 (dd, 2H), 6.77 (ddd, 1H), 6.98(d, 1H), 7.26 - 7.48 (m, 9H), 7.77 (dd, 1H), 8.20(d, 1H), 10.49(s, 1H).
Example 052 2-(2-ChlorophenyI)-N-{4-[3-(morpholin-4-ylcarbonyl)phenoxy]-3-sulfamoylphenyllacetamide DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:

Claims (29)

344

1. A compound of formula (I) <1MG>
in which:
A represents CR5 or N;
R1 represents a group selected from:
or wherein * indicates the point of attachment of said group with the rest of the molecule;
represents C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-C1-C4-alkyl, phenyl, phenyl-C1-C4-alkyl, heteroaryl or heteroaryl-C1-C4-alkyl, wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring or substituted with one to five deuterium atoms and optionally one to two times with R11 being, independently from each other, the same or different, or R2 represents branched (C1-C4-alkyl)-C1-C4-alkyl;
R3 represents hydrogen, deuterium, fluoro or methyl;
R4 represents hydrogen, deuterium or fluoro;
R5, R5a and R5b are the same or different and represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy;
R6, R6a, R6b and R6c are the same or different and represent, independently from each other, respectively R6 hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)- or F3C-S-;
R6a hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-; or R6a and R6b adjacent to each other together represent a group selected from -O-CH2-CH2-, -O-CH2-O- or -O-CH2-CH2-O-;
R6c hydrogen or halogen;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, hydroxy, halogen, C1-C4-alkyl or C1-C4-haloalkyl;
R8 represents, independently from each respective occurence, C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl;
R9 and R10 are the same or different and represent, independently from each other, hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, (C1-C4-alkoxy)-(C2-C4-alkyl), phenyl or heteroaryl, wherein said phenyl and heteroaryl groups are optionally substituted one to three times, independently from each other, with hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy, R9a and R10a together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from O, NH, NR a in which R a represents a C1-C6-alkyl- or C1-C6-haloalkyl- group, or S and being optionally substituted, one to three times, independently from each other, with halogen or C1-C4-alkyl;
R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R11a represents a group selected from C3-C6-cycloalkyl, morpholino, R9a R10a N-;
R9a R10a N-C(O)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl, or represents:
wherein * indicates the point of attachment of said group with the rest of the molecule.; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

2. A compound of formula (la) according to claim 1 characterized in that R1 represents a group selected from:
or , wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-C1-C4-alkyl, phenyl, phenyl-C1-C4-alkyl, heteroaryl or heteroaryl-C1-C4-alkyl, wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring or substituted with one to five deuterium atoms and optionally one to two times with R11 or R11a being, independently from each other, the same or different;or R2 represents branched (C1-C4-alkyl)-C1-C4-alkyl;
R3 represents hydrogen, deuterium, fluoro or methyl;

R4 represents hydrogen, deuterium or fluoro;
R6, R6a, R6b and R6c are the same or different and represent, independently from each other, respectively R6 hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)- or F3C-S-;
R6a hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-; or R6a and R6b adjacent to each other together represent a group selected from -O-CH2-CH2-, -O-CH2-O- or -O-CH2-CH2-O-;
R6c hydrogen or halogen;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, hydroxy, halogen, C1-C4-alkyl or C1-C4-haloalkyl;
R8 represents, independently from each respective occurence, C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl;
R9 and R10 are the same or different and represent, independently from each other, hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, (C1-C4-alkoxy)-(C2-C4-alkyl), phenyl or heteroaryl, wherein said phenyl and heteroaryl groups are optionally substituted one to three times, independently from each other, with hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy;
R9a and R10a together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from O, NH, NR a in which R a represents a C1-C6-alkyl- or C1-C6-haloalkyl- group, or S and being optionally substituted, one to three times, independently from each other, with halogen or C1-C4-alkyl;

R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R11a represents a group selected from C3-C6-cycloalkyl, morpholino, R9a R10a N-;
R9a R10a N-C(O)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents:
or wherein * indicates the point of attachment of said group with the rest of the molecule; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

3. A compound of formula (lb) according to claim 1 characterized in that R1 represents a group selected from:

wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-C1-C4-alkyl, phenyl, phenyl-C1-C4-alkyl, heteroaryl or heteroaryl-C1-C4-alkyl, wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring or substituted with one to five deuterium atoms and optionally one to two times with R11 being, independently from each other, the same or different;
or R2 represents branched (C1-C4-alkyl)-C1-C4-alkyl;
R3 represents hydrogen, fluoro or methyl;
R4 represents hydrogen or fluoro;
R5a and R5b are the same or different and represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy;
R6, R6a, R6b and R6c are the same or different and represent, independently from each other, respectively R6 hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)- or F3C-S-;
R6a hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;

R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-; or R6a and R6b adjacent to each other together represent a group selected from -O-CH2-CH2-, -O-CH2-O- or -O-CH2-CH2-O-;
R6c hydrogen or halogen;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, hydroxy, halogen, C1-C4-alkyl or C1-C4-haloalkyl;
R8 represents, independently from each respective occurence, C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl;
R9 and R10 are the same or different and represent, independently from each other, hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, (C1-C4-alkoxy)-(C2-C4-alkyl), phenyl or heteroaryl, wherein said phenyl and heteroaryl groups are optionally substituted one to three times, independently from each other, with hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy;
R9a and R10a together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from O, NH, NR a in which R a represents a C1-C6-alkyl- or C1-C6-haloalkyl- group, or S and being optionally substituted, one to three times, independently from each other, with halogen or C1-C4-alkyl;
R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R11a represents a group selected from C3-C6-cycloalkyl, morpholino, R9a R10a N-;
R9a R10a N-C(O)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents:

or wherein * indicates the point of attachment of said group with the rest of the molecule; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

4. A compound of formula (la) according to claim 2 characterized in that R1 represents a group selected from:
or wherein * indicates the point of attachment of said group with the rest of the molecule;
R2 represents C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-C1-C4-alkyl, phenyl, phenyl-C1-C4-alkyl, heteroaryl or heteroaryl-C1-C4-alkyl, wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring or substituted with one to five deuterium atoms and optionally one to two times with R11 being, independently from each other, the same or different;
R3 represents hydrogen, fluoro or methyl;
R4 represents hydrogen or fluoro;

R6, R6a, R6b and R6c are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, C1-C4-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or F3C-S-;
R6a hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or R9R10N-C(O)-;
R6b hydrogen, fluoro, chloro or bromo; or R6a and R6b adjacent to each other together represent a group selected from ¨O-CH2-CH2- or ¨O-CH2-CH2-O-;
R6b hydrogen or halogen;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, chloro, methyl, difluoromethyl or trifluoromethyl;
represents methyl;
R9 and R10 are the same or different and represent, independently from each other, hydrogen, methyl, cyclopropyl or 2-methoxy-ethyl, or R9a and R10a together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from O, NH, NCH3 or S and being optionally substituted, one to three times, independently from each other, with halogen or methyl R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R11a represents a group selected from C3-C6-cycloalkyl, morpholino, R9aR10aN-;
R9a R10aN-C(O)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents a group selected from:

or wherein * indicates the point of attachment of said group with the rest of the molecule; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

5. A compound of formula (la) according to claim 2 characterized in that R1 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule;

R2 represents C4-C6-cycloalkyl, C3-C6-cycloalkyl-methyl, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl-methylõ phenyl, phenyl-C1-C2-alkyl, heteroaryl, heteroaryl-methyl wherein said groups are optionally substituted one to four times with R11, being, independently from each other, the same or different, or substituted one time with R11a and optionally one to two times with R11 being independently from each other, the same or different, or substituted with two adjacent substituents R11 which together represent a methylendioxy group to form a 5-membered ring;
R3 represents hydrogenor methyl;
R4 represents a hydrogen;
R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, C1-C4-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-rnethoxy-ethoxy or F3C-S-;
R6a hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or R9R10N-C(O)-;
R6b hydrogen, fluoro, chloro or bromo; or R6a and R6b adjacent to each other together represent a group selected from ¨O-CH2-CH2- or ¨O-CH2-CH2-O-;
R6c represents hydrogen or halogen;
R9 and R10 are the same or different and represent, independently from each other, hydrogen, methyl, cyclopropyl or 2-methoxy-ethyl, or R9a and R10a together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, said ring optionally containing one additional heteroatom selected from O, NH, NR a in which R a represents a C1-C6-alkyl- or C1-C6-haloalkyl- group, or S and being optionally substituted, one to three times, independently from each other, with halogen or methyl;
R11 represents, independently from each other, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R11a represents a group selected from C3-C6-cycloalkyl, morpholino, R9a R10a N;
R9a R10a N-C(O)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule; or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

6. A compound according to any one of the claims 1 to 5 characterized in that R1 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule;
R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)- ;

R6a hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R8R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R6c represents hydrogen.

7. A compound according to any one of the claims 1 to 5 characterized in that R1 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule; and R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 hydrogen, fluoro, chloro, bromo, cyano, C1-C4-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy or F3C-S-;
R6a hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-R6c represents hydrogen.

8. A compound according to any one of the claims 1 to 5 characterized in that R1 represents a group selected from:

wherein * indicates the point of attachment of said group with the rest of the molecule; and R6, R6a and R6b are the same or different and represent, independently from each other, respectively R6 fluoro, chloro, bromo, cyano, C1-C4-alkyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy or F3C-S-;
R6a hydrogen, fluoro, chloro, bromo, hydroxy, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy;
R6b hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, R9R10N, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-R6c represents hydrogen.

9. A compound according to claim 1 to 5 characterized in that R1 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule; and R6 represents hydrogen or halogen and R6a and R6b adjacent to each other together represent a group selected from -O-CH2-CH2- or -O-CH2-CH2-O-R6c represents hydrogen.

10. A compound according to claim 1 to 4 characterized in that R1 represents a group selected from:

wherein * indicates the point of attachment of said group with the rest of the molecule;
R7a and R7b are the same or different and represent, independently from each other, hydrogen, fluoro, chloro, C1-C4-alkyl, difluoromethyl or trifluoromethyl.

11. A compound according to claim 1 to 10 characterized in that R2 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule and in which, R11 represents independently from each other, hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-.

12. A compound according to claim 1 to 11 characterized in that R2 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule and in which R11 and R11a are respectively R11 represents, hydrogen, halogen, hydroxy, nitro, cyano, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, HO-(C2-C4-alkoxy)-, (C1-C4-alkoxy)-(C2-C4-alkoxy)-, (C1-C4-haloalkyl)-S-, R9R10N-, R8-C(O)-NH-, R8-C(O)-, R8-O-C(O)-, R9R10N-C(O)- or (C1-C4-alkyl)-SO2-;
R11a represents a group selected from hydrogen, C3-C6-cycloalkyl, morpholino, R9a R10a N-;
R9a R10a N-C(O)-; a 5- to 6-membered heteroaryl, which is optionally substituted with methyl or represents:

13. A compound according to claim 1 to 12 characterized in that R2 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule R12 represents hydrogen, halogen, C1-C4-alkyl, C3-C6-cycloalkyl, methoxy, difluoromethyl or trifluoromethyl;

R12a and R12b represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C3-C6-cycloalkyl, methoxy, difluoromethyl or trifluoromethyl.

14. A compound according to claim 1 to 13 characterized in that R2 represents a group selected from:
or wherein * indicates the point of attachment of said group with the rest of the molecule;
R13 represents hydrogen, halogen, cyano or C1-C4-alkyl.

15. A compound according to claim 1 characterized in that R5, R5a and R5b are the same or different and represent, independently from each other, hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy.

16. A compound according to claim 1 to 15 characterized in that R5 represents C1-C4-alkyl, C3-C6-cycloalkyl or C1-C4-haloalkyl.

17. A compound according to claim 1 to 15 characterized in that R9 represents, independently from each other, C1-C4-alkyl or C3-C6-cycloalkyl;
R10 represents, independently from each other, hydrogen or C1-C4-alkyl.

18. A compound according to claim 1 to 15 characterized in that R9a and R10a together with the nitrogen atom to which they are attached form a 4- to 6-membered nitrogen containing heterocyclic ring, optionally containing one additional heteroatom selected from O, NMe or NH.

19. A compound according to claim 1 to 16 of the following formula:
N-[4-(3-chloro-5-cyanophenoxy)-3-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide 2-(2-chlorophenyl)-N-4-[3-(dimethylamino)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(2-chloropyridin-4-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-[4-(3-isopropylphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-3-sulfamoyl-4-[3-(trifluoromethyl)phenoxylphenylacetamide 2-(2-chlorophenyl)-N-3-sulfamoyl-4-[3-(trifluoromethoxy)phenoxy]phenylacetamide N-[4-(3-acetylphenoxy)-3-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide N-[4-(1,3-benzodioxol-5-yloxy)-3-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide N-[4-(3-acetamidophenoxy)-3-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide 2-(2-chlorophenyl)-N-[4-(2-fluorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(3-fluorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(4-fluorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(pyridin-2-yloxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-(4-phenoxy-3-sulfamoylphenyl)acetamide 2-(2-chlorophenyl)-N-[4-(3-cyanophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-4-[3-(methylsulfonyl)phenoxy]-3-sulfamoylphenylacetamide 3-(4-[(2-chlorophenyl)acetyl]amino-2-sulfamoylphenoxy)benzamide 2-(2-chlorophenyI)-N-[4-(3-methylphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(pyrimidin-5-yloxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-3-sulfamoyl-4-[3-(4H-1,2,4-triazol-4-yl)phenoxy]phenylacetamide 2-(2-chlorophenyl)-N-3-sulfamoyl-4-[3-(1H-tetrazol-5-yl)phenoxy]phenylacetamide 2-(2-chlorophenyl)-N-[4-(3-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(4-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-4-[3-(difluoromethoxy)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-[4-(3,4-dicyanophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-4-[3-(morpholin-4-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-[4-(3-4-[(2-chlorophenyl)acetyl]piperazin-1-ylphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(pyridin-3-yloxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-4-[(5-chloropyridin-3-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-[4-(4-cyanophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-4-[3-(difluoromethyl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-[4-(2-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(3,5-dicyanophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(5-cyano-2-methoxyphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-4-[(2,5-dichloropyridin-3-yl)oxyl-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(5,6-dichloropyridin-3-yl)oxy]-3-sulfamoylphenylacetamide 3-(4-[(2-chlorophenyl)acetyl]amino-2-sulfamoylphenoxy)-N-cyclopropylbenzamide 2-(2-chlorophenyl)-N-4-[(3-chloropyridin-2-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(4-chloropyridin-2-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(6-chloropyridin-2-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[3-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[4-(1H-imidazol-1-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[4-(2-oxopyrrolidin-1-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[4-(morpholin-4-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-[4-(5-cyano-2-methylphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(3-cyano-2-methylphenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(3-cyano-4-fluorophenoxy)-3-sulfamoylphenyl]acetamide N-4-[(5-chloro-2-cyanopyridin-3-yl)oxy]-3-sulfamoylphenyl-2-(2-chlorophenyl)acetamide 2-(2-chlorophenyl)-N-4-[3-(piperidin-1-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[3-(2-oxopyrrolidin-1-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[3-(2-oxo-1,3-oxazolidin-3-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[3-(morpholin-4-ylcarbonyl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(4-methyltetrahydro-2H-pyran-4-yl)methoxyl-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[(4-cyanotetrahydro-2H-pyran-4-yl)methoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-(3-sulfamoyl-4-[2-(trifluoromethyl)pyrimidin-5-yI]oxyphenyl)acetamide 2-(2-chlorophenyl)-N-4-[(2-isopropylpyrimidin-5-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(2-cyclopropyl-4-methylpyrimidin-5-yl)oxyl-3-sulfamoylphenylacetamide N-[4-(3-bromophenoxy)-3-sulfamoylphenyI]-2-(2-chlorophenyl)acetamide N-[4-(4-bromophenoxy)-3-sulfamoylphenyI]-2-(2-chlorophenyl)acetamide 2-(2-chlorophenyl)-N-4-[3-(2-methyl-1,3-thiazol-4-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[4-(5-oxopyrrolidin-2-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[4-(2-oxo-1,3-oxazolidin-3-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-3-sulfamoyl-4-[4-(1,3-thiazol-2-yI)phenoxy]phenylacetamide N-[4-(2-chlorophenoxy)-3-sulfamoylphenyI]-2-(2-chlorophenyl)acetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyI]-2-(2-chlorophenyl)acetamide 2-(2-chlorophenyl)-N-4-[3-(piperidin-1-ylcarbonyl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-3-sulfamoyl-4-[4-(tetrahydrofuran-3-yI)phenoxy]phenylacetamide 2-(2-chlorophenyI)-N-[4-(3-cyano-5-fluorophenoxy)-3-sulfamoylphenyl]acetamide N-[4-(2-methoxyphenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(2-methoxyphenoxy)-3-sulfamoylphenyl]-2-[4-(trifluoromethyl)phenyl]acetamide N-3-suIfamoyl-4-[2-(trifIuoromethoxy)phenoxy]phenyl-2-[4-(trifluoromethyl)phenyl]acetamide N-[4-(2-chlorophenoxy)-3-sulfamoylphenyI]-2-[4-(trifluoromethyl)phenyl]acetamide 2-phenyl-N-3-sulfamoyl-4-[2-(trifluoromethoxy)phenoxy]phenylacetamide 2-(2-chlorophenyl)-N-4-[(2-oxo-1,2-dihydropyridin-3-yl)oxy]-3-sulfamoylphenylacetamide N-[4-(2-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-4-[(5-chloropyridin-3-yl)oxy]-3-sulfamoylphenyl-2-phenylacetamide 2-(2-chlorophenyI)-N-4-[(2-chloropyrimidin-5-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(5-fluoropyridin-3-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(6-chloropyridin-3-yl)oxy]-3-sulfamoylphenylacetamide N-[2-chloro-4-(3-chlorophenoxy)-5-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide N-[2-chloro-4-(3-chlorophenoxy)-5-sulfamoylphenyl]-2-(2-chloro-3-fluorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(3-fluorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(4-fluorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-(trifluoromethyl)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2-isopropylphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2-ethoxyphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-(difluoromethyl)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-2-[(trifluoromethyl)sulfanyl]phenylacetamide 2-(2-bromophenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(4-methylpyridin-3-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2-chloropyridin-3-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2-chlorophenyl)-2,2-difluoroacetamide 2-(2-chloro-4-methylphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-6-methylphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-5-methylphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-3-fluorophenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-5-fluorophenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-6-fluorophenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-6-methoxyphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-5-methoxyphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2,3-dichlorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2,6-dichlorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-(trifluoromethoxy)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2,2-difluoro-2-phenylacetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-chloro-3-(trifluoromethyl)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-chloro-6-(trifluoromethyl)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-chloro-5-(trifluoromethyl)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2,4-dichlorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(4,6-dichloropyridin-3-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(3-chloropyridin-2-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-(difluoromethoxy)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2,5-dichlorophenyl)acetamide 2-[6-chloro-2,3-difluoro-4-(trifluoromethyl)phenyl]-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[4-(trifluoromethyl)phenyl]acetamide 2-(5-bromo-2-chlorophenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(4-bromo-2-chloro-5-methylphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(3-chloropyridin-4-yl)acetamide 2-(2-chloro-6-fluoro-3-methylphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(6-chloro-2-fluoro-3-methylphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-3,6-difluorophenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-4,5-difluorophenyI)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2,3-dichloro-6-fluorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2,3,6-trichlorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2,6-dichloro-4-methylphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-[2,3-dichloro-6-(trifluoromethyl)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2,6-dichloro-3-methylphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2,6-dichloro-3-cyclopropylphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2,6-dichloro-3-(trifluoromethyl)phenyl]acetamide 2-(3-bromo-2,6-dichlorophenyl)-N-[4-(3-chIorophenoxy)-3-sulfamoylphenyl]acetamide 2-(3-bromo-2-chloro-6-methylphenyI)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(3-bromo-6-chloro-2-methylphenyI)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-chloro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]acetamide 2-(2-chlorophenyI)-N-(4-[3-(methylsulfonyl)benzyl]oxy-3-sulfamoylphenyl)acetamide 2-(2-chlorophenyl)-N-4-[(2-fluorobenzyl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(4-cyanobenzyl)oxy]-3-sulfamoylphenylacetamide N-4-[(3-chlorobenzyl)oxy]-3-sulfamoylphenyl-2-(2-chlorophenyl)acetamide 2-(2-chlorophenyl)-N-4-[(3-methoxybenzyl)oxy]-3-sulfamoylphenylacetamide N-[4-(benzyloxy)-3-sulfamoylphenyI]-2-(2-chlorophenyl)acetamide 2-(2-chIorophenyI)-N-4-[(3-cyanobenzyl)oxy[-3-suIfamoyIphenyIacetamide 2-(2-chlorophenyl)-N-4-[(4-fluorobenzyl)oxy]-3-sulfamoylphenylacetamide N-4-[(2-chlorobenzyl)oxy]-3-sulfamoylphenyl-2-(2-chlorophenyl)acetamide 2-(2-chlorophenyl)-N-4-[(2-cyanobenzyl)oxy]-3-sulfamoylphenylacetamide N-[4-(benzyloxy)-3-sulfamoylphenyI]-2-phenylacetamide 2-(2-chlorophenyI)-N-(4-[4-(methylsulfonyl)benzyl]oxy-3-sulfamoylphenyl)acetamide 2-(2-chlorophenyI)-N-[4-(1-phenylethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(1-phenylethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(pyridin-3-ylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(pyridin-2-ylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(pyridin-4-ylmethoxy)-3-sulfamoylphenyl]acetamide N-[4-(pyridin-2-ylmethoxy)-3-sulfamoylphenyI]-2-[4-(trifluoromethyl)phenyl]acetamide 2-(2-chlorophenyI)-N-[4-(pyrimidin-4-ylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(pyrimidin-2-ylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(2-phenylethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-4-[2-(3-chIorophenyl)ethoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-[4-(cyclobutylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(oxetan-2-ylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[4-(oxetan-3-ylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyI)-N-[4-(cyclopentylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-[3-sulfamoyl-4-(tetrahydrofuran-2-ylmethoxy)phenyl]acetamide 2-(2-chlorophenyl)-N-[3-sulfamoyl-4-(tetrahydrofuran-3-ylmethoxy)phenyl]acetamide 2-(2-chloro-5-fluorophenyl)-N-[3-suIfamoyl-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide 2-(2-chlorophenyl)-N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide 2-(2-chlorophenyl)-N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-3-ylmethoxy)phenyl]acetamide 2-(2-chloro-6-fluorophenyl)-N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide 2-(2-chloro-3-fluorophenyl)-N-[3-suIfamoyl-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide 2-(2-chlorophenyl)-N-5-sulfamoyl-6-[3-(trifluoromethyl)phenoxy]pyridin-3-ylacetamide 2-phenyl-N-5-sulfamoyl-6-[3-(trifluoromethyl)phenoxy]pyridin-3-ylacetamide N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoylphenyI]-2-phenylacetamide N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoylphenyI]-2-(2-methylphenyl)acetamide N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoylphenyI]-2-(3-methylphenyl)acetamide 2-(2-chlorophenyI)-N-4-[3-(3-oxomorpholin-4-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[4-(3-oxomorpholin-4-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[4-(2-oxopiperidin-1-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[3-(2-oxopiperidin-1-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[3-(prop-1-en-2-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-4-[2-(prop-1-en-2-yl)phenoxy]-3-sulfamoylphenylacetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(4-methylphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(4-chlorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(pyridin-3-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2-methylphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(3-methylphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-phenylpropanamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(pyridin-2-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(3-chlorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2-chlorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(pyridin-4-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(6-methylpyridin-2-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(4-methoxyphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(3-methoxyphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(2-methoxyphenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyI]-2-(5-methylpyridin-2-yl)acetamide (2S)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylpropanamide (2R)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylpropanamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2-chlorophenyl)propanamide 2-(2-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]amino-2-oxoethyl)-N-(2-methoxyethyl)-N-methylbenzamide 2-(2-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]amino-2-oxoethyl)-N,N-dimethylbenzamide N-[4-(cyclohexyloxy)-3-sulfamoylphenyl]-2-phenylacetamide 2-(2-chlorophenyl)-N-[4-(cyclohexyloxy)-3-sulfamoylphenyl]acetamide 3-(2-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]amino-2-oxoethyl)-N-(2-methoxyethyl)benzamide 3-(2-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]amino-2-oxoethyl)-N,N-dimethylbenzamide 3-(2-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]amino-2-oxoethyl)-N-methylbenzamide N-[4-(cyclobutyloxy)-3-sulfamoylphenyl]-2-phenylacetamide 2-(2-chlorophenyl)-N-[4-(cyclobutyloxy)-3-sulfamoylphenyl]acetamide 2-phenyl-N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-4-yloxy)phenyl]acetamide 2-(2-chlorophenyl)-N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-4-yloxy)phenyl]acetamide 3-(2-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]amino-2-oxoethyl)-N-(2-methoxyethyl)-N-methylbenzamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(5-chloropyridin-2-yl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[3-(2-methoxyethoxy)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-(2-methoxyethoxy)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[3-(2-hydroxyethoxy)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-[2-(2-hydroxyethoxy)phenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2-fluorophenyl)acetamide N-[4-(oxetan-3-yloxy)-3-sulfamoylphenyl]-2-phenylacetamide 2-(2-chlorophenyl)-N-[4-(oxetan-3-yloxy)-3-sulfamoylphenyl]acetamide N-[4-(cyclopentyloxy)-3-sulfamoylphenyl]-2-phenylacetamide 2-(2-chlorophenyl)-N-[4-(cyclopentyloxy)-3-sulfamoylphenyl]acetamide N-4-[(1-methylpiperidin-3-yl)oxy]-3-sulfamoylphenyl-2-phenylacetamide 2-(2-chlorophenyl)-N-4-[(1-methylpiperidin-3-yl)oxy]-3-sulfamoylphenylacetamide N-4-[(1-methylpyrrolidin-3-yl)oxy]-3-sulfamoylphenyl-2-phenylacetamide 2-(2-chlorophenyl)-N-4-[(1-methylpyrrolidin-3-yl)oxy]-3-sulfamoylphenylacetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-(4-fluorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(4-cyanophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2-cyanophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(3-cyanophenyl)acetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-[4-(trifluoromethyl)phenyl]acetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-(4-chlorophenyl)acetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-(4-methoxyphenyl)acetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-(2-fluorophenyl)acetamide 2-(2-chloro-4-fluorophenyl)-N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N--[4(1,1-dioxidotetrahydrothiophen-3-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(1-methyl-1H-pyrazol-4-yl)oxy]-3-sulfamoylphenylacetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-[4-(difluoromethyl)phenyl]acetamide 2-(2-chloro-4-methoxyphenyl)-N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-4-[(1-methyl-1H-pyrazol-3-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(1-methyl-1H-pyrazol-5-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(1-methylpiperidin-4-yl)oxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-(4-[5-methyl-2-(pyridin-3-yl)-1,3-thiazol-4-yl]oxy-3-sulfamoylphenyl)acetamide N-[4-(3-chlorophenoxy)-2-methyl-5-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide 2-(2-chlorophenyl)-N-{4-[(1-oxidotetrahydrothiophen-3-yl)oxy]-3-sulfamoylphenyl}acetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-[2,6-dichloro-4-(trifluoromethyl)phenyl]acetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-(2,5-dichloro-4-cyanophenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(cyclopropylmethoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(3,5-dimethylphenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(2,4-difluorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(4-fluorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(3-fluorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(3-methoxyphenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(2-fluoro-5-methylphenoxy)-3-sulfamoylphenyl]-2-phenylacetamide 2-phenyl-N-3-sulfamoyl-4-[4-(trifluoromethoxy)phenoxy]phenylacetamide 2-phenyl-N-3-sulfamoyl-4-[3-(trifluoromethyl)phenoxy]phenylacetamide N-[4-(3,5-dimethoxyphenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(3-cyanophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(4-hydroxyphenyl)acetamide 2-(2-chloro-6-methoxy-4-methylphenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-chloro-6-fluorophenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]propanamide 2-(2-chloro-4,6-difluorophenyl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-(2,6-dichlorophenyl)propanamide 2-(2-chlorophenyl)-N-4-[(2H5)phenyloxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-(4-{[4-chloro(2H4)phenyl]oxy}-3-sulfamoylphenyl)acetamide 2-(2-chlorophenyl)-N-(4-{[2-chloro(2H4)phenyl]oxy}-3-sulfamoylphenyl)acetamide 2-(2-chlorophenyl)-N-4-[4-(2-hydroxypropan-2-yl)phenoxyl-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-{4-[(1R,5S,60-3-oxabicyclo[3.1.0]hex-6-ylmethoxy]-3-sulfamoylphenyl}acetamide 2-(2-chlorophenyl)-N-4-[(4-chlorotetrahydro-2H-pyran-4-yl)methoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyI)-N-[4-(1,4-dioxan-2-ylmethoxy)-3-sulfamoylphenyl]acetamide 2-(2-chlorophenyl)-N-3-sulfamoyl-4-[(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)oxy]phenylacetamide N-[4-(3-chlorophenoxy)-3-methyl-5-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-methyl-5-sulfamoylphenyl]-2-phenylacetamide methyl 2-(4-[(2-chlorophenyl)acetyl]amino-2-sulfamoylphenoxy)benzoate methyl 4-(4-[(2-chlorophenyl)acetyl]amino-2-sulfamoylphenoxy)benzoate 2-(2-chlorophenyl)-N-4-[3-(2-hydroxypropan-2-yl)phenoxy]-3-sulfamoylphenylacetamide 2-(2-chlorophenyl)-N-4-[2-(2-hydroxypropan-2-yl)phenoxy]-3-sulfamoylphenylacetamide N-[4-(4-chlorophenoxy)-3-sulfamoylphenyl]-2-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide 2-(7-chloro-2,3-dihydro-1,4-benzodioxin-6-yl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(5-chloro-2,3-dihydro-1-benzofuran-4-yl)-N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]acetamide 2-(2-fluorophenyl)-N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]-2-[2-(trifluoromethyl)phenyl]acetamide 2-[2-(difluoromethyl)phenyl]-N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide 2-(2-chloro-4-fluorophenyl)-N-[3-sulfamoyl-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]acetamide 2-(2-Chlorophenyl)-N-(3-sulfamoyl-4-{[6-(trifluoromethyl)pyridin-3-yl]oxy}-phenyl)-acetamide 2-(2-Chlorophenyl)-N-(4-{[5-chloro-4-(trifluoromethyl)pyridin-2-yl]oxy}-3-sulfamoyl-phenyl)acetamide N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenyl(2H2)acetamide N-{4-[(6-Chloro-5-fluoropyridin-3-yl)oxy]-3-sulfamoylphenyl}-2-(2-chlorophenyI)-acetamide 2-(2-Chlorophenyl)-N-{4-[(4,4-difluoro-1-hydroxycyclohexyl)methoxy]-3-sulfamoyl-phenyl}acetamide 2-(2-Chlorophenyl)-N-{4-[(1-hydroxycyclohexyl)methoxy]-3-sulfamoylphenyl}-acetamide N-[4-(3-Chlorophenoxy)-3-fluoro-5-sulfamoylphenyl]-2-(2-fluorophenyl)acetamide N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoylphenyl]-2-[2-(difluoromethyl)-phenyl]acetamide N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoylphenyl]-2-(2-chlorophenyl)acetamide 2-(2-chloro-5-fluorophenyl)-N-[4-(3-chlorophenoxy)-3-fluoro-5-sulfamoyl-phenyl]acetamide N-[6-(3-Chlorophenoxy)-5-sulfamoylpyridin-3-yl]-2-(2-fluorophenyl)acetamide N-[6-(3-Chlorophenoxy)-5-sulfamoylpyridin-3-yl]-2-[2-(trifluoromethyl)phenyl]-acetamide N-[6-(3-Chlorophenoxy)-5-sulfamoylpyridin-3-yl]-2-[2-(difluoromethyl)phenyl]-acetamide 2-(2-Chloro-5-fluorophenyl)-N-[6-(3-chlorophenoxy)-5-sulfamoylpyridin-3-yl]-acetamide

20. A compound according to any one of claims 1 to 19 for the manufacture of a medicament.

21. A compound according to any one of claims 1 to 19 for use in the treatment or prophylaxis of a disease wherein said disease is a genitourinary, gastrointestinal, proliferative or pain-related disease, condition or disorder; cancer;
amyotrophic lateral sclerosis (ALS); fibrotic diseases including lung fibrosis, heart fibrosis, kidney fibrosis and fibrosis of other organs; gynaecological diseases including dysmenorrhea, dyspareunia, endometriosis and adenomyosis; endometriosis-associated pain; endometriosis-associated symptoms, wherein said symptoms are in particular endometriosis-associated proliferation, dysmenorrhea, dyspareunia, dysuria, or dyschezia; endometriosis-associated proliferation; pelvic hypersensitivity; urethritis; prostatitis; prostatodynia; cystitis; idiopathic bladder hypersensitivity; gastrointestinal disorders including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, gastroesophageal reflux, gastrointestinal distension, Crohn's disease and the like; atherosclerosis; lipid disorders; and pain-associated diseases selected from the group consisting of hyperalgesia, allodynia, functional bowel disorders (such as irritable bowel syndrome), arthritis (such as osteoarthritis and rheumatoid arthritis), burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer, traumatic nerve-injury, post-traumatic injuries (including fractures and sport injuries), trigeminal neuralgia, small fiber neuropathy, diabetic neuropathy, chronic arthritis and related neuralgias, HIV and HIV treatment-induced neuropathy, pruritus;
impaired wound healing and disease of the skeleton like degeneration of the joints, ankylosing spondylitis.

22. A compound according to any one of the claims 1 to 19 for use in the treatment of pain syndromes (including acute, chronic, inflammatory and neuropathic pain), inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, endometriosis-associated pain, pain associated with fibrotic diseases, central pain, pain due to burning mouth syndrome, pain due to burns, pain due to migraine, cluster headaches, pain due to nerve injury, pain due to neuritis, neuralgias, pain due to poisoning, pain due to ischemic injury, pain due to interstitial cystitis, cancer pain, pain due to viral, parasitic or bacterial infections, pain due to traumatic nerve-injury, pain due to post-traumatic injuries (including fractures and sport injuries), pain due to trigeminal neuralgia, pain associated with small fiber neuropathy, pain associated with diabetic neuropathy, chronic lower back pain, phantom limb pain, pelvic pain syndrome, chronic pelvic pain, neuroma pain, complex regional pain syndrome, pain associated with gastrointestinal distension, chronic arthritic pain and related neuralgias, and pain associated with cancer, pain associated with chemotherapy, HIV and HIV treatment-induced neuropathy; and pain associated with diseases or disorders selected from the group consisting of hyperalgesia, allodynia, functional bowel disorders (such as irritable bowel syndrome) and arthritis (such as osteoarthritis and rheumatoid arthritis).

23. A compound according to any one of the claims 1 to 19 for use in the treatment of a gynecological disease, preferably dysmenorrhea, dyspareunia or endometriosis, adenomyosis, endometriosis-associated pain, or other endometriosis-associated symptoms, wherein said symptoms are in particular endometriosis-associated proliferation, dysmenorrhea, dyspareunia, dysuria or dyschezia.

24. A pharmaceutical composition comprising at least one compound according to any one of the claims 1 to 19, together with at least one pharmaceutically acceptable auxiliary.

25. Use of a compound according to any one of claims 1 to 19 for the prophylaxis or treatment of a disease.

26. Use of a compound according to any one of claims 1 to 19 for the preparation of a medicament for the prophylaxis or treatment of a disease as listed in claims 21 to 23.

27 An intermediate of formula 9 whereby R1, R3, R4, R5, R5a and R5b are defined according to claims 1 to 18 and W
corresponds to either a hydrogen atom or a protecting group.

28 An intermediate of formula 13 or 14 13:Y = -N=CAr2 14:Y = -NH2 whereby R2, R3, R4, R5a and R5b are defined according to claims 1 to 18 and W
corresponds to either a hydrogen atom or a protecting group.

29. An intermediate of the following formula:
N-(2,4-Dimethoxybenzyl)-2-fluoro-5-nitrobenzenesulfonamide 2,4-Dichloro-N-(2,4-dimethoxybenzyI)-5-nitrobenzenesulfonamide N-(2,4-Dimethoxybenzyl)-2,3-difluoro-5-nitrobenzenesulfonamide 2-(2-Chlorophenyl)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide 2-(2-Chloro-3-fluorophenyl)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide 2-(2-Chloro-6-fluorophenyl)-N-(4-hydroxy-3-sulfamoylphenyl)acetamide 5-Bromo-2-hydroxypyridine-3-sulfonamide 5-Amino-2-[3-(trifluoromethyl)phenoxy]pyridine-3-sulfonamide N-(2,4-Dimethoxybenzyl)-2-fluoro-4-methyl-5-nitrobenzenesulfonamide N-(2,4-Dimethoxybenzyl)-2-fluoro-3-methyl-5-nitrobenzenesulfonamide